AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 1 CLINICAL STUDY PROTO COL  
Protocol Title:  A Phase 2, Multicenter, Randomized, 3 -Arm, Open -
Label Study to Investigate the Preliminary Efficacy 
and Safety of the Anti -TIGIT Monoclonal Antibody 
Ociperlimab (BGB -A1217) Plus Tislelizumab Plus 
Concurrent Chemoradiotherapy in Patients With 
Untreated Limited -Stage Small Cell Lung Cancer  
Protocol Identifier:  AdvanTIG -204 
Phase:  2 
Investigational Products:  Ociperlimab (BGB -A1217) and t islelizumab 
(BGB -A317)  
Indication:  Untreated limited -stage small cell lung cancer 
(LS-SCLC)  
Sponsor:  BeiGene, Ltd.  
c/o BeiGene [LOCATION_003], Inc.  
[ADDRESS_731132]  
San Mateo, [LOCATION_004] [ZIP_CODE]  
[LOCATION_003]  
Sponsor Medical Monitor:   
Telephone:  
Email:  
Original Protocol Version 0.0:  25 February  2021  
Protocol A mendment Version 1.0:  18 June 2021  
Protocol A mendment Version 2.0:  23 September 2021  
Protocol A mendment Version 3.0: 08 October  2021  
 
 
Confidentiality Statement  
This Document Is Not for Distribution – Do Not Copy  
This document contains confidential information and is the proprietary property of BeiGene, 
Ltd., and its subsidiaries. This document is for use by [CONTACT_8335] a nd their designated 
representatives for their confidential review, consideration, and/or participation in investigational 
trial(s). This document may not be copi[INVESTIGATOR_556671], Ltd., or one of its subsidiaries. 
Your acceptance of this document constitutes agreement that you will not disclose the 
information contained herein to others without the prior written authorization from BeiGene, 
Ltd., or one of its subsi diaries.  
Version .0 VV-CLIN-048167 9

AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 3 INVESTIGATOR SIGNATU RE PAGE  
Protocol Title:  A Phase 2, Multicenter, Randomized, 3 -Arm, Open -Label Study to 
Investigate the Preliminary Efficacy and Safety of the Anti -TIGIT 
Monoclonal Antibody Ociperlimab (BGB -A1217) Plus Tislelizumab Plus 
Concurrent Chemoradiotherapy in Patients With Untreat ed Limited -Stage 
Small Cell Lung Cancer  
Protocol Identifier:  AdvanTIG -[ADDRESS_731133] their origin in the Declaration of Helsinki and that are consistent with 
good clinical practices and the applicable  laws and regulations. Acceptance of this document 
constitutes my agreement that no unpublished information contained herein will be published or 
disclosed without prior written approval from BeiGene, Ltd., or one of its subsidiaries.  
Instructions for Inve stigator:  Please SIGN and DATE this signature [CONTACT_69900] -approved protocol. PRINT your name, title, and the name [CONTACT_338582].   
I have read this protocol in its entirety and agree to conduct the study accordingly:  
Signature [CONTACT_7919]:  _______________________________  Date:  _____________  
Printed Name:  _______________________________  
Investigator Title:  _______________________________  
Name/Address of Center:  ___________ ____________________  
 _______________________________  
 _______________________________  
 _______________________________   
Version .[ADDRESS_731134] -Line Therapy for Limited -Stage Small Cell Lung Cancer  .......... 24 
1.2.2.  Anti-PD-1/PD -L1 Therapy for Limited -Stage Small Cell Lung Cancer  .................... 25 
1.3. Background Information on Ociperlimab (BGB -A1217)  ................................ ........... 29 
1.3.1.  Nonclinical Summary  ................................ ................................ ................................ .29 
1.3.1. 1. Pharmacology  ................................ ................................ ................................ ............. 29 
[IP_ADDRESS].  Toxicology  ................................ ................................ ................................ .................. 29 
1.3.2.  Prior Clinical Experience With Ociperlimab  ................................ .............................. 30 
1.3.3.  Ociperlimab Clinical Pharmacology and Pharmacodynamics  ................................ ...33 
1.4. Background Information on Tislelizumab  ................................ ................................ ..34 
1.4.1.  Pharmacology  ................................ ................................ ................................ ............. 34 
1.4.2.  Toxicology  ................................ ................................ ................................ .................. 34 
1.4.3.  Clinical Pharmacology  ................................ ................................ ................................ 34 
1.4.4.  Prior Clinical Experience With Tislelizumab  ................................ ............................. 35 
[IP_ADDRESS].  Treatment -Emergent Adverse Events Assessed as Related to Tislelizumab  .............. 35 
[IP_ADDRESS].  Treatment -Emergent Serious Adverse Events  ................................ ............................ 35 
[IP_ADDRESS].  Immune -Mediated Adverse Events  ................................ ................................ ............ 36 
[IP_ADDRESS].  Infusion -Related Reactions  ................................ ................................ ......................... 36 
[IP_ADDRESS].  Liver Laboratory Abnormalities  ................................ ................................ ................. 36 
[IP_ADDRESS].  Fatal Adverse Events  ................................ ................................ ................................ ..37 
1.4.5.  Efficacy Assessment of Tislelizumab  ................................ ................................ ......... 37 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 5 1.5. Study Rationales  ................................ ................................ ................................ ......... 38 
1.5.1.  Rationale for Combination of Ociperlimab and Tislelizumab in the 
Treatment of Limited -Stage Small Cell Lung Cancer  ................................ ................ 38 
1.5.2.  Rationale for the Selection of Ociperlimab Dose  ................................ ....................... 39 
1.5.3.  Rationale for Selection of Tislelizumab Dose  ................................ ............................ 39 
1.5.4.  Rationale for Chemoradiotherapy as the Component of the Combination 
Treatment  ................................ ................................ ................................ .................... 40 
1.5.5.  Rationale  for Combination of Concurrent Chemoradiotherapy  and 
Immunotherapy  ................................ ................................ ................................ ........... 40 
1.5.6.  Rationale for Chemotherapy Regimens  ................................ ................................ ......41 
1.5.7.  Rationale for Radiation Therapy Dose  ................................ ................................ .......42 
1.5.8.  Rationale for Biomarker Strategy  ................................ ................................ ............... 42 
1.6. Benefit -Risk Assessment  ................................ ................................ ............................ 43 
2. STUDY OBJECTIVES AND  ENDPOINTS  ................................ .............................. 45 
2.1. Study Objectives  ................................ ................................ ................................ ......... 45 
2.1.1.  Primary Objective  ................................ ................................ ................................ .......45 
2.1.2.  Secondary Objectives  ................................ ................................ ................................ .45 
2.1.3.  Exploratory Objectives  ................................ ................................ ............................... 45 
2.2. Study Endpoints  ................................ ................................ ................................ .......... 45 
2.2.1.  Primary Endpoint  ................................ ................................ ................................ ........ 45 
2.2.2.  Secondary Endpoints  ................................ ................................ ................................ ..46 
2.2.3.  Exploratory Endpoints  ................................ ................................ ................................ 46 
3. STUDY DESIGN  ................................ ................................ ................................ .......47 
3.1. Summary of Study Design  ................................ ................................ .......................... 47 
3.2. Screening Period  ................................ ................................ ................................ ......... 50 
3.3. Treatment Period  ................................ ................................ ................................ ........ 50 
3.4. End of Treatment/Safety Follow -up ................................ ................................ ........... 51 
3.5. Survival Follow -up ................................ ................................ ................................ .....52 
3.6. Disco ntinuation From the Study Treatment or From the Study  ................................ .52 
3.6.1.  Patient Discontinuation From Study Treatment  ................................ ......................... 52 
3.6.2.  Patient Discontinuation From Study (End of Study for an Individual Patient)  .......... 53 
3.7. End of Study  ................................ ................................ ................................ ............... 53 
4. STUDY POPULATION  ................................ ................................ ............................. 54 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 6 4.1. Inclusion Criteria  ................................ ................................ ................................ ........ 54 
4.2. Exclusion Criteria  ................................ ................................ ................................ .......55 
5. STUDY TREATMENT  ................................ ................................ .............................. 58 
5.1. Formulation, Packaging, and Handling  ................................ ................................ ......58 
5.1.1.  Ociperlimab  ................................ ................................ ................................ ................ 58 
5.1.2.  Tislelizumab  ................................ ................................ ................................ ............... 58 
5.1.3.  Chemotherapy  ................................ ................................ ................................ ............. 58 
5.2. Dosage, Administration, and Compliance  ................................ ................................ ..58 
5.2.1.  Ociperlimab and Tislelizumab  ................................ ................................ .................... 60 
5.2.2.  Chemotherapy  ................................ ................................ ................................ ............. 61 
[IP_ADDRESS].  Cispl atin + Etoposide  ................................ ................................ ................................ ..61 
[IP_ADDRESS].  Carboplatin + Etoposide  ................................ ................................ ............................. 62 
5.2.3.  Thoracic Radiation Therapy  ................................ ................................ ....................... 62 
[IP_ADDRESS].  Radiation Dose Specifications  ................................ ................................ .................... 62 
[IP_ADDRESS].  Variations of Dose Prescription  ................................ ................................ .................. 63 
[IP_ADDRESS].  Localization, Simulation, and Immobilization  ................................ ........................... 64 
[IP_ADDRESS].  Radiation Treatment Planning  ................................ ................................ .................... 65 
5.2.4.  Prophylactic cranial irradiation (PCI)  ................................ ................................ ......... [ADDRESS_731135] Accountability  ................................ ..................... 66 
5.5. Dose Delay or Modification  ................................ ................................ ....................... 66 
5.5.1.  Dose Delay or Modification for Ociperlimab or Tislelizumab  ................................ ..67 
5.5.2.  Dose Delay, Interruption, or Modifications for Radiation Therapy  ........................... 68 
5.5.3.  Dose Delay, Interruption, or Modifications for Chemotherapy  ................................ .69 
5.5.4.  Criteria for Discontinuing Chemotherapy Regimens  ................................ ................. 71 
6. PRIOR AND CONCOMITAN T THERAPY  ................................ ............................. 72 
6.1. Prior Therapy  ................................ ................................ ................................ .............. 72 
6.2. Concomitant Therapy  ................................ ................................ ................................ .72 
6.2.1.  Permitted Concomitant Medications/Procedures  ................................ ....................... 72 
[IP_ADDRESS].  Systemic Corticosteroids  ................................ ................................ ............................ 72 
[IP_ADDRESS].  Hepatitis B Treatment  ................................ ................................ ................................ .72 
[IP_ADDRESS].  Hepatitis C Treatment  ................................ ................................ ................................ .73 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 7 6.2.2.  Prohibited Concomitant Medications/Procedures  ................................ ...................... 73 
6.2.3.  Restricted Concomitant Medications/Procedures  ................................ ....................... 73 
6.3. Potential Interactions Between Study Drugs and Conc omitant Medications  ............. 73 
7. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...................... 75 
7.1. Screening  ................................ ................................ ................................ .................... 75 
7.1.1.  Informed Co nsent and Screening Log  ................................ ................................ ........ 75 
7.1.2.  Patient Numbering  ................................ ................................ ................................ ......75 
7.1.3.  Demographic Data and Medical History  ................................ ................................ ....76 
7.1.4.  Female Patients of Childbearing Potential and Contraception  ................................ ...76 
7.1.5.  Pulmonary Function Tests  ................................ ................................ .......................... 76 
7.2. Enrollment  ................................ ................................ ................................ .................. 76 
7.2.1.  Confirmation of Eligibility  ................................ ................................ ......................... 76 
7.2.2.  Enrollment/Randomization  ................................ ................................ ......................... 77 
7.3. Study Drug Dispensation  ................................ ................................ ............................ 77 
7.4. Safety Assessments  ................................ ................................ ................................ .....77 
7.4.1.  Vital Signs, Height, and Weight  ................................ ................................ ................. 77 
7.4.2.  Physical Examinations  ................................ ................................ ................................ 78 
7.4.3.  Eastern Cooperative Oncology Group Performance Status  ................................ ........ 78 
7.4.4.  Laboratory Safety Tests  ................................ ................................ .............................. 78 
[IP_ADDRESS].  Cardiac Enzyme Monitoring  ................................ ................................ ....................... [ADDRESS_731136] Abnormalities  ................................ ................................ ................... 88 
8.4. Definition of a Serious Adverse Event  ................................ ................................ .......88 
8.5. Suspected Unexpected Serious Adverse Reaction  ................................ ..................... 89 
8.6. Timing, Frequency, and Method of Capturing Adverse Events and Serious 
Adverse Events  ................................ ................................ ................................ ........... 89 
8.6.1.  Adverse Event Recording Period  ................................ ................................ ................ 89 
8.6.2.  Reporting Serious Adverse Eve nts ................................ ................................ ............. 90 
[IP_ADDRESS].  Prompt Reporting of Serious Adverse Events  ................................ ............................ 90 
[IP_ADDRESS].  Completion and Transmission of the Serious Adverse Event Report  ........................ 91 
[IP_ADDRESS].  Regulatory Reporting Requirements for Serious Adverse Events  ............................. [ADDRESS_731137]  ................................ ................................ .......................... 101 
9.4. Pharmacokinetic Analysis  ................................ ................................ ........................ 101 
9.5. Immunogenicity Analysis  ................................ ................................ ......................... 102 
9.6. Sample Size Consideration  ................................ ................................ ....................... 102 
9.7. Interim Analyses  ................................ ................................ ................................ .......102 
10. STUDY COMMITTEES AND  COMMUNICATION  ................................ ............ 103 
10.1.  Safety  Monitoring Committee  ................................ ................................ .................. 103 
10.1.1.  Study Safety Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................. 103 
11. SOURCE DOCUMENTS AND  ACCESS TO SOURCE 
DATA/DOCUMENTS  ................................ ................................ ............................. 105 
11.1.  Access to Information for Monitoring  ................................ ................................ ......105 
11.2.  Access to Information for Auditing or Inspections  ................................ .................. 105 
12. QUALITY ASSURANCE AN D QUALITY CONTROL  ................................ .......106 
12.1.  Regulatory Authority Approval  ................................ ................................ ................ 106 
12.2.  Quality Assurance  ................................ ................................ ................................ .....106 
12.3.  Study Site Inspections ................................ ................................ ............................... 106 
12.4.  Drug Accountability  ................................ ................................ ................................ .106 
13. ETHICS/PROTECTION OF  HUMAN PATIENTS  ................................ ................ [ADDRESS_731138]/Independent Ethics Committee  ................................ ....[ADDRESS_731139] KEEPI[INVESTIGATOR_1645]  ................................ .................... 111 
14.1.  Data Collection and Management Responsibilities  ................................ .................. 111 
14.1.1.  Data Entry in the Electronic Case Report Form  ................................ ....................... 111 
14.1.2.  Data Collection  ................................ ................................ ................................ ......... 111 
14.1.3.  Data Management/Coding  ................................ ................................ ........................ 111 
14.2.  Data Integrity and In -house Blinding  ................................ ................................ .......112 
14.3.  Study Records Retention  ................................ ................................ .......................... 112 
14.4.  Protocol Deviations  ................................ ................................ ................................ ..113 
14.5.  Study Report and Publications ................................ ................................ .................. 113 
14.6.  Study and Study Center Closure  ................................ ................................ ............... 114 
14.7.  Information Disclosure and Inventions  ................................ ................................ ....114 
15. REFERENCES  ................................ ................................ ................................ ......... 116 
APPENDIX  1. SCHEDULE OF ASSESSME NTS  ................................ ................................ ..122 
APPENDIX  2. CLINICAL LABORATORY ASSESSMENTS  ................................ .............. 129 
APPENDIX  3. EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG ) 
PERFORMANCE STATUS  ................................ ................................ ..................... 130 
APPENDIX  4. THE RESPONSE EVALUAT ION CRITERIA IN SOLI D TUMORS 
(RECIST) GUIDELINES,  VERSION 1.1  ................................ ................................ 131 
APPENDIX  5. PREEXISTING IMMUNE D EFICIENCIES OR AUTOI MMUNE 
DISEASES  ................................ ................................ ................................ ................ 141 
APPENDIX  6. NEW YORK HEART ASSOC IATION FUNCTIONAL 
CLASSIFICATION  ................................ ................................ ................................ ..142 
APPENDIX  7. IMMUNE -MEDIATED ADVE RSE EVENT EVALUATION  AND 
MANAGEMENT  ................................ ................................ ................................ .....143 
APPENDIX  8. CHRONIC KIDNEY DISEASE EPI[INVESTIGATOR_556672] (CKD -EPI) EQUATION  ................................ ....................... 156 
APPENDIX  9. CONTRACEPTION GUIDEL INES AND DEFINITIONS  OF 
“WOMEN OF CHILDBEA RING POTENTIAL,” “NO  CHILDBEARING 
POTENTIAL”  ................................ ................................ ................................ ........... 157 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 11 APPENDIX  10. EUROPEAN ORGANISATIO N FOR RESEARCH AND 
TREATMENT OF CANCER QUALITY OF L IFE CANCER 
QUESTIONNAIRE (EORTC -QLQ -C30)  ................................ ................................ 159 
APPENDIX  11. EUROPEAN ORGANISATIO N FOR RESEARCH AND 
TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE 
LUNG CANCER (QLQ -LC13) ................................ ................................ ................ [ADDRESS_731140] OF TABLES  
Table  1: Ongoing PD -[ADDRESS_731141] -Targeting Immunotherapy Studies in Limited -Stage 
Small Cell Lung Cancer  ................................ ................................ .............................. 28 
Table  2: Treatment -Emergent Adverse Events by [CONTACT_1196], Preferred 
Term and Maximum Severity (Safety Analysis Set)  ................................ .................. 31 
Table  3: Planned Dose, Frequency of Admini stration, and Route of Administration 
for Study Drugs  ................................ ................................ ................................ ........... 59 
Table  4: Administration of Ociperlimab and Tislelizumab and Monitoring Time  ................... 61 
Table  5 Normal Tissue Dose -Volume Constraints for Conventionally Fractionated 
Radiation Therapy with Concurrent Chemotherapy a ................................ ................. 63 
Table  6: Summary of  Dose Prescription Variations  ................................ ................................ .63 
Table  7: The Summary of the Commonly and Specific Reported Toxicity of the 
Chemotherapeutic Agents  ................................ ................................ ........................... 84 
Table  8: Guidance for Duration of Recording New or Worsening Adverse Events in 
All Treatment Arms  ................................ ................................ ................................ ....90 
Table  9: Timeframes and Documentation Methods for Reporting Serious Adverse 
Events to the Sponsor or Designee  ................................ ................................ ............. 91 
Table  10: Treatment Modifications for Symptoms of Infusion -Related Reactions Due 
to Study Drug(s)  ................................ ................................ ................................ ......... 94 
Table  11: Examples of Immune -Mediated Adverse Events  ................................ ....................... [ADDRESS_731142] OF FIGURES  
Figure  1: Cycle 1 Mean (±  SD) Serum Concentration -Time Profiles of Ociperlimab in 
Study BGB -900-105 ................................ ................................ ................................ ...33 
Figure  2: Study Schema  ................................ ................................ ................................ ............. 49 
 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 12 SYNOPSIS  
Name [CONTACT_790]/Company: BeiGene, Ltd.  
Investigational Product s: Ociperlimab (BGB -A1217) and t islelizumab (BGB -A317)  
Title of Study: A Phase 2, Multicenter, Randomized, 3 -Arm, Open -Label Study to Investigate the 
Preliminary Efficacy and Safety of the Anti -TIGIT Monoclonal Antibody Ociperlimab (BGB -A1217) 
Plus Tislelizumab Plus Concurrent Chemoradiotherapy in Patients With Untreated Limi ted-Stage 
Small Cell Lung Cancer  
Protocol Identifier: AdvanTIG -204 
Phase of Development:  2 
Number of Patients:  Approximately 120 
Study Centers:  Approximately 30 to 40 centers internationally  
Study Objectives:  
Primary:  
• To compare progression -free survival (PFS) between Arm A  (ociperlimab [BGB -A1217] plus 
tislelizumab plus concurrent chemoradiotherapy [cCRT])  and Arm C (cCRT only) and between 
Arm B (tislelizumab plus cCRT) and Arm C as assessed by [CONTACT_556748] 1.1 (RECIST  v1.1) in the 
Intent -to-Treat (ITT) Analysis Set  
Secondary:  
• To compare the following  between Arm A and Arm C and between Arm B and Arm C  as 
assessed by [CONTACT_3143] v1.1 in the ITT Analysis Set:  
- Complete response (CR) rate  
- Overall response rate (ORR)  
- Duration of response (DOR)  
- Overall survival (OS) 
- Distant metastas is-free survi val (DMFS)  
• To evaluate the correlation of  programmed cell death ligand -1 (PD-L1) and T-cell 
immunoglobulin and ITIM domain ( TIGIT ) expression with ORR, PFS , and OS   
• To evaluate the safety and tolerability of ociperlimab combined with tislelizumab plus cCRT 
and tislelizumab  plus cCRT  
Exploratory:  
• To explore prognostic and predictive effects of tis sue- and blood -based biomarkers on efficacy 
and their association with mechanisms of resistance   
• To evaluate health -related quality of life (HRQoL)  
• To assess the utility of circulating tumor  DNA ( ctDNA ) level change as a surrogate marker for 
efficacy   
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 13 • To assess the pharmacokinetics (PK) of ociperlimab and tislelizumab  
• To assess the immunogenicity of ociperlimab and tislelizumab  
Study Endpoints:  
Primary:  
• PFS, defined as the time from  the date of  randomization to the date of the first documented 
disease progression as determined by [CONTACT_76954] v1.1 or death from any 
cause (whichever occurs first ), in the ITT Analysis Set of Arms A, B, and C  
Secondary Endpoints:  
• CR rate, defined as the proportion of patients who had CR as assessed by [CONTACT_556749] v1.1, in the ITT Analysis Set of Arms A, B, and C  
• ORR , defined as the proportion of patients who had CR or partial response (PR) as assessed by 
[CONTACT_76954] v1.1 , in the ITT Analysis Set of A rms A, B, and C  
• DOR , defined as the time from the date of the first occurrence of a documented objective 
response to the date of documented disease progression as assessed  by [CONTACT_556749] v1.1 or death from any cause  (whichever occurs first ), in the ITT Analysis Set of 
Arms A, B, and C  
• OS, defined as the time from the date of randomization to the date of death due to any cause , in 
the ITT Analysis Set of Arms A, B, and C  
• DMFS , defined as the time from the date of randomization to the date of the first documented 
distant metastasis  as assessed  by [CONTACT_76954] v1.1 or death from any cause  
(whichever occurs first ), in the ITT Analysis Set of Arms A, B, and C  
• ORR, PFS , and OS in subgroups based on PD-L1 and TIGI T expression level s 
• The incidence and severity of treatment -emergent adverse events (TEAEs) graded according to 
National Cancer Institute  Common Terminology Criteria for Adverse Events Version 5.0  
(NCI-CTCAE  v5.0). 
Explorat ory Endpoints:  
• Biomarkers from patient -derived tumor tissue(s) and/or blood samples obtained before, during , 
and/or after treatment including but not limited to gene expression profile, tissu e- or 
blood -based gene mutations and tumor mutational burden  (TMB )/microsatellite instability 
(MSI), CD155/CD226 expression, and small cell lung cancer ( SCLC ) subtypi[INVESTIGATOR_007] 
(ASCL1/NEUROD1/POU2F3/YAP1)   
• HRQoL assessment using 2 patient -reported outcomes (PROs ) including the European 
Organisation for Research and Treatment  of Cancer Quality of Life Questionnaire -Core 30 
(EORTC QLQ -C30) and its lung cancer module Quality of Life Questionnaire Lung Cancer 13 
(QLQ -LC13)  
• The ctDNA level change before, during , and after treatment as a surrogate marker for efficacy  
• Serum concentr ations of ociperlimab  and tislelizumab at specified timepoints  
• Assessment of immunogenicity of ociperlimab  and tislelizumab by [CONTACT_556750] (ADAs)   
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 14 Study Design  
This is a Phase 2, multicenter, randomized, 3 -arm, open -label  study to investigate the preliminary 
efficacy and safety of the anti -TIGIT monoclonal antibody ociperlimab  plus tislelizumab plus cCRT 
followed by [CONTACT_556751] (Arm A) and tislelizumab plus cCRT followed by 
[CONTACT_556752]  (Arm B)  compared with cCRT  only (Arm C)  in patients with previously untreated  
limited -stage small cell lung cancer ( LS-SCLC ). 
The primary endpoint is investigator -assessed PFS in the ITT  Analysis Set for the comparisons of 
Arm A versus Arm C and Arm B vers us Arm C .  
Approximately 120 patients will be randomized in a 1:1:1 ratio to receive the study treatment in the 
following 3 arms:  
• Arm A: Ociperlimab  900 mg intravenously once every 3 weeks plus tislelizumab 200 mg 
intravenously once every 3 weeks combined with cCRT for 4  cycles, followed by [CONTACT_556753]  
900 mg intravenously once every 3 weeks plus tislelizumab 200 mg intravenously once every 
3 weeks  
• Arm B: Tislelizumab 200 mg intravenously once every 3 weeks combined with cCRT for 
4 cycles, followed by [CONTACT_556754] 200 mg intravenously once every 3 weeks  
• Arm C: cCRT only  for 4 cycles  
Randomization will be stratified by [CONTACT_123573] (I/II v ersus III) by [CONTACT_556755], 8th edition.  
The chemotherapy regimen is cisplatin 75  mg/m2 on D ay 1 of each cycle for 4 cycles.  If the patient is 
unable to tolerate the 1-day administration  of cisplatin 75 mg/m2, at the investigator’s discretion  (eg, 
patients had concurrent superior vena cava syndrome)  cisplatin 25 mg/m2 dosed on Days  1, 2, and 3 is 
allowed . Etoposide is administered at 100 mg/m2 on D ays 1, 2, and [ADDRESS_731143] cycle.  
If cisplatin is contraindicated or not tolerated, carboplatin and etoposide will be the  alternative  regimen  
(Section  [IP_ADDRESS] ). Carboplatin at a dose of area under the plasma or serum concentration -time curve 5 
(AUC 5) should be administ ered as an intravenous infusion once every 3 weeks on Day 1 of each cycle 
for 4  cycles  and etoposide 100 mg/m2 should be administered  on Days 1, 2, and 3 of each cycle for 4 
cycles.  
For A rm A and Arm B, investigational drug(s) (ociperlimab plus tislelizumab [Arm A] or tislelizumab  
alone  [Arm B]) will be given starting on Cycle 1 Day 1 (C1D1) before  chemotherapy and continued for 
a duration of up to 12 months  (a maximum of 17 cycles  of treatment ) or until disease progression  
according  to RECIST v1.1, unacceptable toxicity, death, or another discontinuation criterion is met, 
whichever occurs first.   
Radi ation therapy  (RT)  should start early within cycle 1 or 2 of systemic therapy . The total dose of RT 
will be  60 to 70 Gy , given in once -daily fractions  over 6 to 7  weeks.  
Prophylactic cranial irradiation  (PCI) is permitted  at the investigator’s discretion. The preferred total 
dose for PCI to the whole brain is 25 Gy in 10  daily fractions . 
 
 
 
 
Study Schema  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 15  
Study Assessments:  
Tumor Assessment s: 
Tumor imaging will be performed ≤ 28 days before randomization. During the study, tumor imaging 
will be performed at approximately 12 weeks (± 7 days) from the date of randomization (an additional 
tumor assessment is allowed if clinically indicated), then every 6 weeks (± 7 days) for the next 
54 weeks, and then every 12 weeks (± 7 days) thereafter based on RECIST v1.1 .  
Administration of study treatment will continue for up to 12 months  (17 cycles maximum)  for Arms A 
and B and for [ADDRESS_731144].  
A patient who discontinues study treatment early for reasons other than disease progression (eg, 
toxicity ) will continue to undergo tumor assessments following the original schedule  until disease 
progression  according to  RECIST v1.1, withdraw al of consent, loss to follow -up, start  of a new 
anticancer therapy, death, or study  termination , whichever occurs first.  
In Arms A and B, treatment with ociperlimab plus tislelizumab or with tislelizumab alone beyond the 
initial investigator -assessed, REC IST v1.1 -defined disease progression is permitted provided that the 
patient has investigator -assessed clinical benefit and is tolerating the study drug (s). The following 
criteria must be met in order to treat patients who may continue to benefit from study drugs after 
disease progression :  
• Absence of clinical symptoms and signs of disease progression (including clinically significant 
worsening of laboratory values).  
• Stable Eastern Cooperative Oncology Group (ECOG) Perfo rmance Status (≤ 2).  
• Absence of rapid progression of disease or of progressive tumor at critical anatomical sites (eg, 
cord compression) that requires urgent alternative medical intervention.  
• Investigators must obtain written informed consent for treatment  beyond radiologic disease 
progression  and inform patients that this practice is not considered standard in the treatment of 
cancer.  
Tumor assessments are required to be performed on schedule regardless of whether the study treatment 
has been administered or held; that is, tumor assessments should not be adjusted for delays in cycles.  
Safety Assessment s: 
Patients will be evaluated for any AEs and serious adverse events (SAEs) occurring up to [ADDRESS_731145] dose of study treatment (all severity grades, per NCI -CTCAE v5.0) or initiation of a new 
anticancer therapy, whichever occurs first, and immune -mediated AEs (imAEs) occurring up to 
[ADDRESS_731146]. All study 
treatment -related SAEs will be followed until they resolve to baseline or ≤ Grade 1, the investigator 
Version .[ADDRESS_731147].  
Safety assessmen ts will also in clude laboratory values (eg, hematology , clinical chemistry, coagulation, 
urinalysis), vital signs, electrocardiograms  (ECGs ), ECOG Performance Status, and physical 
examinations.  
Patient -Reported Outcomes : 
Patient -reported outcomes will be collected using the EORTC QLQ -C30 and QLQ -LC13 questionnaires 
will be completed at predose on Day 1 of every cycle from Cycle 1 (baseline) through Cycle 4, and then 
to coincide with scheduled tumor assessments (every 6 weeks [± 7 days]) until the EOT Visit (Arms A, 
B, and C) . 
Safety Monitoring Committee : 
A Safety Monitoring Committee (SMC)  consisting of qualified investigators who are taking part in the 
study will be implemented to support the study and structure the scientific input. The SMC will 
conduct safety assessment s at the following timepoint s:  
• After approximately 6 patients (≥  2 patients per arm) have completed 2 cycles of study  
treatment  
• After approximately 18 patients ( ≥ 6 patients per arm) have completed [ADDRESS_731148]  
• After the scheduled SMC assessments, the SMC will review data approximately every 
[ADDRESS_731149] 18 months of the study and yearly thereafter  
The SMC could review da ta more frequently if indicated or requested by [CONTACT_556756] . The SMC may recommend study 
modification s including early termination of the study due to safety concerns. Full details of t he SMC 
procedures and processes can be found in the SMC Charter.  
Enrollment may continue during these SMC safety reviews.  
The study will be conducted in compliance with International Council for Harmonisation (ICH) Good 
Clinical Practice (GCP) guidelines.  
Duration of Patient Participation:  
Duration of treatment will be  up to  12 months  for Arms A and B  (17 cycles  maximum ), including  
approximately 3 months (4  cycles)  for concurrent administration of chemo radiotherapy , and 
approximately 3 months (4  cycles) for Arm C . Each patient’s study  course will include:  
• Screening period of up to 28 days  before randomization  
• Treatment for durations described above or until disease progression (or any other reasons for 
discontinuation before progression)  
• Safety Follow -up Visit to occur within 30 days (± 7 days) after the last dose of study treatment  
Survival follow -up information will be collected every [ADDRESS_731150] enrolled patient to the final 
analysis for PFS  is estimated to be approximately 30 months.  
 
 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 17 Study Population:  
The study will enroll approximately 120 patients (randomized at a 1:1:1 ratio) who meet the 
inclusion/exclusion criteria  outlined below.  
Key Eligibility Criteria:  
Key Inclusion Criteria:  
The population under study consists of adult patients ( ≥[ADDRESS_731151]) with histologically or cytologically confirmed 
diagnosis of LS-SCLC  that is considered unresectable  and can be safely treated with definitive 
radiation doses . Patients must not have received prior treatment for LS -SCLC. Patients must submit 
qualified archival tumor tissue with an associated pathology report or agree to a tumor biopsy. All 
patients are al so required to have measurable disease per RECIST v1.1 within 28 days before 
randomization, an ECOG Performance Status ≤ 2, life expectancy ≥  12 weeks, and adequate organ 
function.  For full inclusion criteria, see Section  4.1. 
Key Exclusion Criteria:  
Patients will not have mixed SCLC  histology  (except for mixed SCLC with neuroendocrine carcinoma 
origin)  and will not have received surgical resection for  LS-SCLC. Patients must not have received 
prior therapy with an anti -PD-1, anti -PD-L1, anti -PD-L2, TIGIT or any other antibody or drug 
specifically targeting T -cell costimulation or checkpoint pathways . For full exclusion criteria, see 
Section  4.2. 
Investigational Product, Dose, and Mode of Administration:  
• Ociperlimab  will be administered at a dose of 900 mg intravenously once every 3 weeks on 
Day 1 of each cycle  
• Tislelizumab will be administered at a dose of 200 mg intravenously once every 3 weeks  on 
Day 1 of each cycle  
Reference Therapy, Dose, and Mode of Administra tion:  
Allowed c hemotherapy regimen s: 
• Cisplatin plus etoposide  
− Cisplatin 75 mg/m2 should be administered as an intravenous infusion once every 3 
weeks on Day 1  of each cycle for 4 cycles ; If the patient is unable to tolerate the 1-day 
administration  of cisplatin 75 mg/m2, at the investigator’s discretion  (eg, patients had 
concurrent superior vena cava syndrome ) 
− cisplatin 25 mg/m2 dosed on Days  1, 2, and 3 is allowed.   
− Etoposide (100 mg/m2) should be administered as an intravenous infusion on Days 1, 
2, and 3 of each cycle for 4 cycles . 
• Carboplatin plus etoposide. To be used if cisplatin is contraindicated. Also, patients will be 
allowed to switch from cisplatin to carboplatin if they exhibit intolerance to cisplatin after 
completing ≥ [ADDRESS_731152] atin treatment (Section  [IP_ADDRESS] ) 
− Carboplatin at a dose of AUC 5 should be administered as an intravenous infusion 
once every 3 weeks on Day 1 of each cycle for 4 cycles.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 18 − Etoposide (100 mg/m2) should be administered as an intravenous infusion on Days 1, 
2, and 3 of each cycle for 4 cycles . 
Thoracic radiation therapy  (TRT): 
• Once-daily fractions  for 6 to 7 weeks for a total dose of 60 to 70 Gy   
Statistical Methods:  
Analysis  sets: 
The ITT Analysis Set includes all randomized patients . Patient s will be analyzed according to their 
randomized treatment arm. This will be the primary analysis set for all efficacy analysis.  
The Safety Analysis Set inclu des all patients who have received ≥ 1 dose of any component of study 
drug; it will be the analysis set used for the safety analyses.  
The PK Analysis Set includes all patients who receive ≥ 1 dose of tislelizumab/ ociperlimab  per the 
protocol  and for whom any quantifiable postbaseline PK data are available.  
The ADA Analysis Set, which includes all patients who receive ≥  1 dose of tislelizumab/ ociperlimab  
and for whom both baseline and ≥  [ADDRESS_731153] ≥ 1 evaluable biomarker measurement; it 
will be used for the biomarker analysis.  
Efficacy analysis:  
The efficacy endpoints including PFS, CR rate, ORR, DOR, and OS will be summarized by [CONTACT_556757]. The effic acy endpoints will be compared in Arm A versus Arm C and Arm B versus 
Arm C. These analyses are descriptive and exploratory; no formal testing was designed for this study.  
The primary endpoint is PFS assessed by [CONTACT_431]. PFS per investigator is defin ed as the time from 
the date of randomization  to the date of the first documented disease progression as assessed by [CONTACT_556758] v1.[ADDRESS_731154]. Kaplan -Meier 
methodology will be used to estimat e median or other quartiles of PFS along with its 95% confidence 
interval ( CI); constructed using Brookmeyer and Crowley method). Kaplan -Meier curves will be 
constructed to provide a visual description of the PFS distribution. Event -free rate at selected 
timepoints will be estimated with 95% CI estimated using Greenwood formula. The hazard ratio (HR) 
for PFS for each comparison (ie, Arm A versus Arm C, Arm B versus Arm C) will be estimated using a 
stratified Cox regression model. The 95% CI for the HR will be provided. Unstratified analysis will 
also be presented.  
CR rate is the proportion of patients who had a CR as assessed by [CONTACT_76954] v1.1 in 
all randomized patients with measurable disease at baseline. Patients without any postbaseline 
assessment will be considered as nonresponders. CR rate and its Clopper -Pearson 95% CI will be 
calculated for each arm. The compa rison of CR rate between arms will be evaluated using the Cochran -
Mantel -Haenszel (CMH) Χ2 test with the actual stratification factors as strata. Odds ratio and the 
difference in CR rate, as well as their 2-sided 95% CIs , will be calculated.  
ORR is the proportion of patients who had a CR or PR as assessed by  [CONTACT_76954] v1.[ADDRESS_731155] postbaseline information will be censored at the date of randomization. Similar methodology 
used to evaluate PFS will be applied to the analysis of OS.  
HRQoL i s defined as changes from baseline in PRO  measures . Summary statistics (mean, standard 
deviation, median, and range) of the postbaseline scores and  the changes  from baseline will be reported 
for the EORTC QLQ -C30 and QLQ -LC13  questionnaires . Line charts depi[INVESTIGATOR_235241] (and 
standard errors) over time from the baseline assessment will be provided for each treatment arm.  The 
clinically meaningful changes postbaseline and a mixed model analysis  will be performed  using the 
global health status , physical function and fatigue domains of QLQ -C30, and dyspnoea, coughing, 
haemotysis  and pain in chest, pain in arms  and shoulders and peripheral neuropathy domains of 
QLQ -LC13 . Completion and compliance rates will be summarized at each timepoint by [CONTACT_22058] t arm. 
Only patients in the ITT Analysis Set with a nonmissing baseline assessment and ≥ 1 in-study 
nonmissing postbaseline assessment will be included in the analyses.  
Safety analysis:  
Safety will be assessed by [CONTACT_556759]-CTCAE v5.0 . Safety 
will also be assessed by l aboratory values (eg, hematology, clinical chemistry, coagulation, urinalysis), 
vital signs , ECGs , ECOG Performance Status , and physical examinations. Descriptive statistics will be 
used to analyze all safety data overall and by [CONTACT_556760]. 
Pharmacokinetic Analysis:  
Ociperlimab and t islelizuma b serum concentration data will be tabulated and summarized by [CONTACT_556761]/cycle at which these concentrations are collected. Descriptive statistics will include means, 
medians, ranges, and standard deviations, as appropriate.  
Immunogenicity Analysis:  
The anti-ociperlimab and anti-tislelizumab  antibody  results  will be summarized using descriptive 
statistics by [CONTACT_556762]. The incidence of 
positive ADAs and neutralizing ADAs will be reported for evaluable patients.  
Biomarker Analysis  
Raw b iomarker data will  be normalized to adjust  for batch effect , if applicable , for any biomarker  
analyses. Receiver operating characteristics curves will be generated and  AUC will be calculated based 
on a logistic regression model to evaluate the association between continuous  biomarkers and ORR. 
Youden Index -based optimal cutoffs or/and clinically meaningful cutoffs will be used to divide  the 
biomarker -evaluable population into subgroups . Logistic regression and Cox regression will be used to 
evaluate the prognostic and predic tive effects of the biomarker s on response and survival with 
treatment, biomarker status , and their interaction as the main factors. The potential utility of ctDNA 
level change as a surrogate predictor of efficacy and the mechanisms of resistance will also  be 
assessed.  
Sample size:  
This study is not designed to make explicit power and type I error consideration but rather to obtain 
preliminary efficacy and safety data for ociperlimab plus tislelizumab and tislelizumab monotherapy 
for patients with untreate d LS -SCLC. This study will enroll approximately 120 subjects into 3 arms , 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 20 with approximately 40 patients in each arm. The contribution of tislelizumab to the efficacy results will 
be demonstrated by [CONTACT_556763], ORR, and DOR in the comparison of Arm B versus 
Arm C. The contribution of adding ociperlimab will be demonstrated by [CONTACT_556764] A versus Arm B . With a sample size of 40 patients in each arm, the binomial 
probabilities of detecting ≥ 1 TEAEs with a frequency of 5% and 1% are approximately 0.[ADDRESS_731156]  
ITT Intent -to-Treat  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 22 Abbreviation  Definition  
LS-SCLC  limited -stage small cell lung cancer  
MRI  magnetic resonance imaging  
NCCN  National Comprehensive Cancer Network  
NCI-CTCAE  National Cancer Institute Common Terminology Criteria for Adverse 
Events  
NSCLC  non-small  cell lung cancer  
ORR  overall response rate  
OS overall survival  
PCI prophylactic cranial irradiation  
PD-1 programmed cell death protein -1 
PD-L1 programmed cell death ligand -1 
PET positron emission tomography  
PFS progression -free survival  
PK pharmacokinetic(s)  
PR partial response  
PRO  patient -reported outcomes  
PT preferred term  
PVR poliovirus receptor  
QLQ -LC13  Quality of Life Questionnaire Lung Cancer [ADDRESS_731157] commonly diagnosed cancer and the leading cause of cancer -related  
death  (Bray  et al 2018 ) in the world for many years . As of 2020, the newest data from Globocan 
showed that lung cancer is the second most common cancer worldwide with approximately 2.2 
million new diagnoses and 1.8 million deaths globally . In China, lung cancer is the leading cause 
of cancer -related death in both men and women, with an estimated 610,200 deaths and an 
estimated 733,300 new cases in the year 2015 ( Chen et al 2016 ).  
Small cell lung c ancer (SCLC) is an aggressive form of lung cancer that account s for 
approximately 15% of all lung cancers  (PDQ Adult Treatment Editorial Board [NSCLC] 2020 ). 
Histologically, it is a high -grade neuroendocrine tumor , which originate s from neuroendocrine 
cells in the bronchial epi[INVESTIGATOR_2130]. The disease typi[INVESTIGATOR_556673], 
and mediastinal involvement is common. There is a strong association between smoking and 
SCLC ; nearly all cases of SCLC are  attributable to cigarette smoking. An important prognostic 
factor for SCLC is the extent of disease  progression . At the time of diagnosis, approximately 
30% of patients with SCLC will have tumors confined to the hemithorax of origin, the 
mediastinum, or t he supraclavicular lymph nodes , which can be safely encompassed within a 
radiation field ; these patients are designated as having limited -stage  SCLC (LS -SCLC) . Patients 
with disease beyond the ipsilateral hemithorax, including malignant pleural or pericard ial 
effusion or hematogenous metastases , are designated as having extensive -stage  SCLC  
(ES-SCLC) . The Veterans Administration (VA) Study Group’s 2 -stage classification scheme has 
historically been used to define the extent of disease progression in patients with SCLC  and is 
often used for clinical decision -making.  The National Comprehensive Cancer Network ( NCCN ) 
SCLC Panel adopted a combined approach for staging SCLC using both the American Joint 
Committee on Cancer ( AJCC ) Tumor size, Lymph nodes aff ected, Metastases (TNM) staging 
system and the VA classification scheme for SCLC.  When the TNM classifications are applied 
to the VA system, LS-SCLC  is defined as stage I to III (T any, N any, M0) , excluding T3 -[ADDRESS_731158] tumor/nodal volume that is too large 
to be encompassed in a tolerable radiation plan . ES SCLC is defined as stage IV (T any, N any,  
M1a/b/c) or T3 -4 due to multiple  lung nodules that cannot be safely treated with definitive 
radiation therapy (RT). The TNM system is useful for selecting patients who are eligible for 
surgery and for radiation treatment planning. Clinical research studies normally recommend the 
TNM system because it  allow s for more precise assessments of prognosis and spe cific therapy . 
SCLC clinically differentiates itself from the more prevalent non -small cell lung cancer 
(NSCLC) by [CONTACT_556765], high growth rate, and early appearance of widespread 
metastases. In addition, even if a majority of patients  are sensitive to initial  chemo therapy and 
RT, most of them  have rapid occurrence of tumor relapse or metastasis within months of 
completing initial therapy . A long period  of disease -free survival is rare  and there have not been 
significant improvements in the management of resistance to subsequent second -line therapi[INVESTIGATOR_014] . 
Despi[INVESTIGATOR_556674], the prognosis for patients with LS -
SCLC remains unsatisfactory, with median survival times of 16  to 30 months and 2-year survival 
rates o f 44% to 56%. The median survival ranges from 8  to 13 months for  patients with  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 24 ES-SCLC  and the 2-year survival rate is approximately 5% (Murray et al 1993 ; Turrisi et al 
1999 ; Faivre -Finn et al 2017 ; Lally  et al 2007 ). 
1.2. Current Treatment of Limited -Stage Small Cell Lung Cancer and 
Unmet Clinical Needs  
1.2.1.  Concurrent Chemoradiotherapy With or Without Prophylactic Cranial Irradiation  
as First -Line Therapy for Limited -Stage Small Cell Lung Cancer  
Patients with LS -SCLC are a heterogeneous population who have  early (TNM stages I -II) and 
locally advanced (TNM stage III) tumors. The treatment for all stages of LS-SCLC c an be briefly 
categorized as resectable therapy  and unresectable therapy.   
Briefly, the NCCN guidelines state that surgery  with lobectomy and mediastinal nodal sampling  
is recommended only for patients with stage I to IIA (T1 -2, N0) SCLC in whom mediastinal 
staging has confirmed that mediastinal lymph nodes are not involved . Note that  fewer than 5% of 
patients with SCLC have true stage I to IIA disease.  In most patients with SCLC , survival rates 
are much lower due to aggressive  malignant char acteristics and more advanced  disease with 
lymph node involvement. There is a p aucity of prospective evidence in very early stage SCLC ; 
most of the data regarding the role of surgery in SCLC are from retrospective reviews.  For 
patients with medically inoperable cT1 -2 N0  disease , concurrent chemoradiotherapy (cCRT) has 
been the historical standard. Considering the encouraging results in early -stage NSCLC, 
stereotactic ablative radiotherapy (SABR) is increasingly being utilized for well -staged 
medically inoperable SCLC ( Verma et al  2017 ). 
The current standard of care for most patients with advanced LS-SCLC is cCRT with etoposide 
plus cisplatin  (EP) along with thoracic radiation therapy (TRT) . Patients who have attained a 
complete or partial response  to initial therapy  can be considered for prophylactic cranial 
irradiation  (PCI).  
EP is the most commonly used initial combination chemotherapy regimen for patients with 
LS-SCLC. In clinical practice, carboplatin is used as a substitute for cisplatin to reduce the risk 
of emesis, neuropathy, and nephropathy. However, the use of carboplatin carries a greater risk of 
myelosuppression. According to a meta -analysis of individual patient data from 4 randomized 
studies compar ing cisplatin-based versus carboplatin -based regimens in patients with SCLC, 
which includ ed 32% of 663 patients with limited -stage disease , no significant difference was 
observed in efficacy outcomes  (Rossi et al 2012 ). 
TRT improves  local control rates by 25% in patients with limited -stage disease and is associated 
with improved survival  (Pi[INVESTIGATOR_556675] 1992 ; Warde and Payne 1992 ). The current standard of care 
in patients with LS -SCLC is based on a randomized controlled trial that compared once -daily 
(45 Gy in 25 fractions over 5 weeks) to twice -daily (45 Gy in 30  fractions over 3  weeks) RT 
delivered concurrently with EP, showing the superiority of twice -daily  RT in terms of survival  
(Turrisi et al 1999 ). However, there has been a lack of consensus regarding the routine use of 
twice -daily  RT, despi[INVESTIGATOR_556676], due to concerns regarding toxicity and logistical issues. 
More recently, t he CONVERT trial ( Faivre -Finn et al 2017 ) compared twice -daily RT (45 Gy in 
30 fractions over 3 weeks) to a higher dose of RT delivered once daily (66  Gy in 33 fractions 
over 6.5 weeks), both given con currently with chemotherapy; overall survival (OS) outcomes did 
Version .[ADDRESS_731159] reported 
that early concurrent RT results in a small but significant improvement in OS when compared 
with late concurrent or s equential RT. Concurrent chemoradiotherapy  where RT starts with an 
early cycle (1st or 2nd) of chemotherapy is more effective compared with delayed -start RT or 
sequential chemoradiotherapy . Early RT yielded better survival than delayed RT (eg, at Cycle 4 
of chemotherapy), about 10% improvement in survival rate at 2 years ( Fried et al  2004 ). 
In SCLC with early and extensive metastatic spread, i ntracranial metastases occur in more than 
50% of patients. The role of PCI in SCLC has evolved over time ; PCI confers an OS benefit in 
patients with LS -SCLC and is considered the standard of care . In a meta -analysis  (Aupérin et al 
1999 ) comparing PCI versus  no PCI in 987 patients in 7 clinical trials, the data demonstrated that 
PCI reduced the risk of brain metastasis by 54% and improve d the 3-year survival rate by 5.4%.  
In general, little significant progress has been made in the treatment of SCLC for more than 
[ADDRESS_731160]-line setting for patients with ES -SCLC. LS -SCLC has the 
same characteristics of high metastatic potential and invariable recur rence  after initial treatmen t 
as ES -SCLC. D espi[INVESTIGATOR_556677] e novel treatment paradigms for 
LS-SCLC, there are no approved novel agents, including immunotherapy , for LS -SCLC . There is 
thus a significant unmet clinical need for new agents with novel mechanisms of action and 
nonoverlappi[INVESTIGATOR_556678].  
1.2.2.  Anti -PD-1/PD -L1 Therapy for Limited -Stage Small Cell Lung Cancer  
Immunotherapy with checkpoint inhibitors  and antibodies against programmed cell death  
protein -1 (PD -1) and its ligand, programmed cell death ligand -1 (PD-L1), is an active area of 
research . In cancer tissues, PD -1 is upregulated on tumor -infiltrating lymphocytes, while PD -L1 
is expressed on many types of cancer cells. Cancer cells express PD-L1 to escape immune 
surveillance via ligation to PD -1 expressed in an adaptive immune response  (Pardoll  2012 ). 
SCLC has a strong association with smoking and consequently has a high load of somatic 
mutations induced by [CONTACT_556766]. Importantly, the high tumor mutational burden  
(TMB)  of SCLC might provide opportunities for therapeutic intervention, owing to its positive 
correlation with response to immune checkpoint therapy , which has been demonstrated in the 
CheckMate -032 trial  (Antonia et al 2016 ). TMB is defined as the total number of 
nonsynonymous mutations within a tumor genome and can be considered as a surrogate for the 
load of neoantigens expressed by [CONTACT_307964] r. Of note, in the IMpower -133 trial, a blood -based 
TMB measurement did not correlate with outcomes with the addition of atezolizumab ; so, 
prospective confirmation is needed  (Horn et al 2018 ). Little is known about the  best way to 
assess TMB , and  available data suggest that it may behave as a continuum biomarker and that a 
cutoff may be identified.  
PD-L1 expression shows a statistically significant association with response to checkpoint 
inhibitors  in NSCLC , but the same has not been observed in SCLC. A meta -analysis  
(Acheampong et al 2020 ) including 2792 patients from 27 studies  showed large inter-study 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 26 differences in the rate s of PD -L1 expression in SCLC tumors, with rates varying  from 0% to 
82.8%. The pooled estimate of PD -L1 expression was 22.0% (after removing outlying studies), 
which is consistent with the low prevalence of PD -L1 expression in this disease. Although the 
meta -analysis indicated that expression of PD -L1 appears t o confer longer OS  in SCLC patients, 
the correlation was not statistically significant, a result that is also consistent with previous 
reports  (Zhan g et al 2017 ). 
Strategies targeting the PD-[ADDRESS_731161] alone or in combination  with other anticancer agents , 
including chemotherapy, RT, or anti-cytotoxic T -lymphocyte -associated protein -4 (CTLA -4) 
agents , have been tested in the front -line setting  as maintenance  therapy  or as late-line p alliative 
treatment . 
Until now, as for checkpoint inhibitor monotherapy, the [LOCATION_002] Food and Drug 
Administration (US FDA ) has approved pembrolizumab and nivolumab  monotherapi[INVESTIGATOR_556679] -line or later -line treatment in  pretreated ES -SCLC . In the KEYNOTE -028 trial (Ott et al 
2017 ), pembrolizumab  showed a response rate of 33.3%, with a median duration of response 
(DOR) of 19.4 months, a m edian progression -free survival ( PFS) of 1.9 months, and m edian OS 
of 9.7 months  for patients with PD -L1-expressing  tumors  (tumor proportion score ≥ 1% as 
measured using the 22C3 antibody) . In the KEYNOTE -158 trial (Chung et al 2019 ), 
pembrolizumab  showed an overall response rate (ORR) of 18.7%, m edian PFS of 2.0 months, 
and median OS of 9.1 months  regardless of PD-L1 expression.  Nivolumab demonstrated similar 
efficacy  in the CheckMate 032 study  for treating patients with metastatic SCLC whose cancer 
had progressed after platinum -based chemotherapy  and ≥ 1 other line of therapy  (Antonia et al 
2016 ). Other single agent s tested as monotherapi[INVESTIGATOR_556680] e durvalumab for pretreated SCLC , 
where it showed  an ORR of 9.5% and m edian OS of 4.8 months  (Goldman et al 2018 ) and 
atezolizumab  tested in a randomized study compared with cCRT , where atezolizumab did  not 
increase ORR or PFS (Pujol et al 2019 ).  
Based on the observed anticancer activity and survival benefit  of checkpoint inhibitor 
monotherapy  in SCLC, anti-PD-1/PD -L1 antibodies are being investigated in combination with 
chemotherapy or cCRT in SCLC .  
In the past several decades, only atezolizumab  and durvalumab , PD-L1 inhibitor s, have been 
approved by [CONTACT_556767] -line setting for patients with ES -SCLC. The 
IMpower133 study demonstrated improvements in PFS and OS when atezolizumab was added to 
first-line chemotherapy and continu ed into the maintenance phase. The m edian PFS by 
[CONTACT_171326] 5.2  months with atezolizumab combined with cCRT compared with 4.3 months 
with cCRT alone ; the median OS was 12.3 months  versus  10.3 months , respectively . The rate of 
Grade 3 or 4 adverse eve nts (AEs) was similar in both groups (56%) ( Horn et al 2018 ). The 
CASPI[INVESTIGATOR_556681] d urvalumab plus chemotherapy significantly improved median OS 
compared with the chemotherapy arm (13.0 versus 10.3 months; HR0.73, 95%CI: 0.59 –0.91; 
p = 0.0047)  (Paz-Ares et al 2019 ).  
Given the  positive results of trials adding immunotherapy to standard of care treatment in 
stage  III NSCLC  (Anton ia et al 2018 ) and ES -SCLC, an ongoing question is whether 
immunotherapy could improve survival in the limited -stage setting.  
There are currently several  studies , either planned or active , that are investigating the role of 
checkpoint inhibitors in limite d-stage disease ; these studies  include two therapeutic models : 
Version .[ADDRESS_731162] of currently ongoing studies shown in Table  1. 
 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 28 Table  1: Ongoing PD -[ADDRESS_731163] -Targeting Immunotherapy Studies in L imited -Stage Small Cell Lung Cancer  
 
IO + cCRT   IO + cCRT  IO after cCRT  IO after cCRT  IO after cCRT  IO after cCRT  
Study name [CONTACT_114981] -LU005  
([STUDY_ID_REMOVED])  [STUDY_ID_REMOVED]  ADRIATIC  
([STUDY_ID_REMOVED])  ML41257  
([STUDY_ID_REMOVED])  STIMULI  
([STUDY_ID_REMOVED])  ACHILES  
([STUDY_ID_REMOVED])  
Sponsor  NCI [COMPANY_006]  [COMPANY_008]  [COMPANY_002]  Bristol -Myers Squibb  [COMPANY_002]  
Phase  Phase 2/[ADDRESS_731164] 1 pre -
registration cycle 
of chemotherapy  LS-SCLC , 
ES-SCLC  After 4 cycles of cCRT  After 4 cycles of 
cCRT  After 4 cycles of 
cCRT  After 4 cycles of 
cCRT  
Study 
treatment  • cCRT  + 
atezolizumab for 
3 cycles followed 
by [CONTACT_70152]  
(17 cycle s; 1 
year)  
• cCRT for 3 
cycles followed 
by [CONTACT_556768]-SCLC : 
pembro lizumab  + 
cCRT for 4 cycles 
followed by 
[CONTACT_556769] 12 cycles  
 • Durvalumab  + place bo for 4 
cycles followed by 
[CONTACT_556770] 2 year s 
• Durvalumab +  tremelimumab 
for 4 cycles followed by 
[CONTACT_556770] 2 year s 
• Placebo for 4 cycles followed 
by [CONTACT_26230]  • 2 cycles 
chemo therapy + 
atezolizumab for 
12 months  
• 2 cycles 
chemo therapy + 
placebo  • Nivo lumab + 
ipi[INVESTIGATOR_251430] 4 
cycles followed 
by [CONTACT_556771]  
12 months   • Atezolizumab 
for 12 months   
Primary 
endpoint  Phase 2:  PFS 
Phase 3: OS Safety  PFS + OS  PFS + OS  PFS + OS  2-year survival  
Status  Recruiting (US 
only)  Recruiting (US 
only)  Recruiting (global, including 
China and US) Not yet recruiting 
(China only)  Ongoing  (AUS, EU)  Recruiting (EU)  
Start to 
estimated 
primary 
completion  28 May 2019  to 
Dec 2026  22 Jul 2015 to 31  
July 2023  27 Sep 2018 to Feb 2024  NA to Sep 2022  28 Jul 2014 to Dec 
2020  31 Jul 2018 to 
Dec 2023  
Abbreviations: AUS, Australia; cCRT, concurrent chemoradiotherapy; ES -SCLC, extensive -stage small cell lung cancer; EU, European Union; 
IO, immuno -oncology; LS -SCLC, limited -stage small cell lung cancer; NA, not applicable; NCI, National Cancer Institute; OS, overall survival; 
PD-1, programmed cell death protein -1; PFS, progression -free survival, US, [LOCATION_002] .
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 29 The STIMULI trial did not meet its primary endpoint of improving PFS with nivolumab and 
ipi[INVESTIGATOR_556682] , the study closed early in 2019 due to slow accrual  
(Peters  et al 2020 ). Another clinical trial test ing the role of immunotherapy is the Phase 3, 
randomized, double -blind, international ADRIATIC study sponsored by [CONTACT_38227] 
(Study Registry ID: [REMOVED]). This is a 3-arm studying evaluating the efficacy 
of durvalumab or durvalumab with tremelimumab compared with placebo for consolidation in 
patients with LS-SCLC that has not progressed after cCRT . The primary endpoints of this 
Phase  3 study are PFS and OS .  
Overall, there are no approved novel agents/immunotherapy in LS -SCLC . Even if  there is a  high 
response in initial cCRT , most responses are transient,  and most patients experience disease 
recurrence after a few months. Relapsed SCLC is often resistant to second -line therapi[INVESTIGATOR_014]. Median 
survival ranges from 15 to 20 months for LS -SCLC.  Because of the dismal prognosis and 
relative resistance to salvage therapi[INVESTIGATOR_014], there is  an urgent need for therapeutic innovations with 
novel mechanisms of action and nonoverlappi[INVESTIGATOR_5171], which can be combined with 
established treatments to manage this  disease . 
1.3. Background Information on Ociperlimab ( BGB -A1217 ) 
1.3.1.  Nonclinical Summary  
[IP_ADDRESS].  Pharmacology  
Ociperlimab  (BGB -A1217)  is a humanized immunoglobulin G (IgG) [ADDRESS_731165] T -cell immunoglobulin and ITIM domain (TIGIT) under clinical development for the 
treatment of human malignancies.  
Ociperlimab  binds to the extracellular domain of human TIGIT with high specificity and affinity 
(equilibrium dissociation constant [K D] = 0.135 nM), as demonstrated by [CONTACT_232798] -binding assays 
and surface p lasmon resonance  characterization. Ociperlimab  has shown antitumor activity in 
both the GL261 mouse glioma tumor model and the CT26.WT mouse colon cancer model in 
humanized TIGIT knock -in mice. In the MC -38 mouse colon cancer model in humanized TIGIT 
knock -in mice, ociperlimab  in combination with anti -mouse PD -1 significantly inhibited tumor 
growth compared with either therapy alone.  
Ociperlimab  has the constant region of a wild -type human immunoglobulin G1 (IgG1) to enable 
Fc-mediated effector functions. Ociperlimab  has demonstrated competent binding t o C1q and all 
Fc gamma receptors ( FcγRs) and induces antibody -dependent cellular cytotoxicity  (ADCC)  
against a TIGIT -overexpressing cell line, but no ADCC  or complement -dependent cytotoxicity 
against primary T cells in cell -based assays.  
Refer to the Ociperlimab ( BGB -A1217 ) Investigator’s Brochure  for detailed information 
regarding pharmacology studies.  
[IP_ADDRESS].  Toxicology  
Humanized TIGIT knock -in mice containing human TIGIT gene and cynomolgus monkeys were 
selected for noncl inical safety evaluation of ociperlimab  based on the homology of the TIGIT 
amino acid sequence, binding affinity, and efficacy studies.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 30 Ociperlimab  demonstrated a comparable binding affinity in TIGIT receptor occupancy assays 
with CD3+ splenocytes from hu manized TIGIT knock -in mice compared with CD3+ human 
peripheral blood mononuclear cells (with EC 50 of 48.8 ng /mL versus 63.2 ng/m L, respectively). 
In addition, ociperlimab  showed a significant inhibition of GL261 tumor growth in humanized 
TIGIT knock -in mice at a dose of ≥  0.4 mg/kg via weekly intraperitoneal dosing.  
The toxicity and safety profile of ociperlimab  was characterized in a 4 -week repeated -dose 
toxicology study in humanized TIGIT knock -in mice and a 13 -week repeated -dose toxicology 
study in cynomolgus monkeys. Ociperlimab  was also evaluated in a 4 -week repeated -dose study 
in humanized TIGIT knock -in mice with subcutaneous MC -38 tumors. The cynomolgus monkey 
was c onsidered the relevant species for toxicity studies based upon the target sequence homology 
and cross -species TIGIT -binding activities of ociperlimab . 
No apparent toxicity was noted in monkeys following repeated dosing at 10, 30, or 100  mg/kg 
once every 2 weeks for 13 weeks. The toxicokinetic profile in the monkey study showed that 
systemic exposure appeared to be dose proportional with no sex difference. No accumulation 
was observed over the 13 -week dosing period in monkeys. No immunotoxicity was apparent as 
no changes in clinical pathology or histopathology were observed. Positive antidrug antibodies 
(ADAs ) against ociperlimab  were observed in 6/10, 3/10, and 4/10 animals during the dosing 
period, and 3/4, 2/4, and 2/4 animals during the recovery period, a t dose levels of 10, 30, and 
100 mg/kg, respectively. The anti -ociperlimab  antibodies showed a rapid clearance of 
ociperlimab  in serum in a few individual animals but did not appear to have an effect on the 
overall systemic exposure (area under the plasma or serum concentration -time curve [AUC]) or 
toxicity assessment.  
No specific binding of ociperlimab  was noted with normal human tissues. A variety of factors 
might contribute to the negative results, including negligible target expression in normal tissues  
(Yang  2016 ; Human Protein Atlas ) and sensitivity of the immunohistochemistry method.  
No significant increase in cytokine release was observed from an in vitro cytokine relea se assay 
following treatment of nonactivated peripheral blood mononuclear cells with ociperlimab  when 
compared with human IgG. The results suggest that ociperlimab  has potentially low probability 
of causing acute cytokine release syndrome.  
Overall, no appa rent toxicity was noted in the monkey toxicity study. No unexpected tissue 
cross -reactivity was found in human or monkey tissues. The toxicokinetic profile showed dose-
proportional increases in systemic exposure without apparent accumulation or sex differe nce. 
Immunogenicity was observed without apparent immunotoxicity or effect on the systemic 
exposure. The no -observed -adverse -effect level (NOAEL) of ociperlimab  was 100 mg/kg in the 
13-week monkey toxicity study. The safety profile of ociperlimab  is considered adequate to 
support first -in-human dosing.  
Refer to the Ociperlimab (BGB -A1217) Investigator’s Brochure  for detailed information 
regarding toxicology studies.  
1.3.2.  Prior Clinical Experience With Ociperlimab   
As of 16 June 2020, a Phase 1 study (BGB -900-105) was investigating the safety/tolerability, 
pharmacokinetic s (PK), and preliminary antitumor activity of ociperlimab  in combination with 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 31 tislelizumab with or without chemotherapy in patients  with unresecta ble locally advanced or 
metastatic solid tumors.  
Patients enrolled in Study BGB -900-105 were treated with escalating doses of ociperlimab  
(50, 150, 450, or 900  mg) in combination with tislelizumab 200  mg once every 3 weeks; all 
patients cleared the dose -limiting toxicity (DLT) period without DLTs. The maximum tolerated 
dose was not reached and the recommended Phase 2 dose (RP2D) was determined to be [ADDRESS_731166] commonly 
reported treatment -emergent adverse events ( TEAEs ; Table  2) were fatigue (3  out of 11 patients) 
and diarrhoea and aspartate aminotransferase (AST) increased (2  patie nts each out of 11 
patients). Most TEAEs were Grade 1 or Grade 2, with the exception of three Grade 3 TEAEs of 
atrial flutter, pericardial effusion malignant and dyspnea, which were serious and deemed not 
related to study drugs (1 patient each).  
Treatment -related TEAEs ( ociperlimab , tislelizumab, or both) occurred in [ADDRESS_731167] increased, and dry skin in 1  patient; abdominal pain, dry eye, and 
diarrhea in 1  patient; and fatigue in 1  patient. All treatment -related TEAEs were Grad e 1. No 
infusion reactions were reported.  
The study is currently enrolling patients at the RP2D. Ociperlimab  continues to appear to be safe 
and well-tolerated. Preliminary results also show that 100% receptor occupancy was achieved at 
50 mg. 
Refer to the Ociperlimab (BGB -A1217) Investigator’s Brochure  for detailed information 
regarding clinical experience with ociperlimab . 
Table  2: Treatment -Emergent Adverse Events by [CONTACT_1196], Preferred 
Term and Maximum Severity (Safety Analysis Set)  
System Organ Class  
Preferred Term  Tislelizumab 200 mg  
Total  
(N = 11)  
n (%)  Ociperlimab 
50 mg 
(N = 1) 
n (%)  Ociperlimab  
150 mg 
(N = 3)  
n (%)  Ociperlimab  
450 mg 
(N = 4)  
n (%)  Ociperlimab  
900 mg 
(N = 3)  
n (%)  
Patients with ≥  1 TEAE  1 (100.0)  3 (100.0)  3 (75.0)  1 (33.3)  8 (72.7)  
Gastrointestinal disorders  1 (100.0)  1 (33.3)  2 (50.0)  0 (0.0)  4 (36.4)  
Diarrhoea  0 (0.0)  1 (33.3)  1 (25.0)  0 (0.0)  2 (18.2)  
Abdominal pain  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Constipation  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Dry mouth  1 (100.0)  0 (0.0)  0 (0.0)  0 (0.0)  1 (9.1)  
General disorders and 
administration site conditions  1 (100.0)  0 (0.0)  1 (25.0)  1 (33.3)  3 (27.3)  
Fatigue  1 (100.0)  0 (0.0)  1 (25.0)  1 (33.3)  3 (27.3)  
Musculoskeletal and connective 
tissue disorders  0 (0.0)  1 (33.3)  1 (25.0)  1 (33.3)  3 (27.3)  
Back pain  0 (0.0)  1 (33.3)  0 (0.0)  0 (0.0)  1 (9.1)  
Flank pain  0 (0.0)  0 (0.0)  0 (0.0)  1 (33.3)  1 (9.1)  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 32 System Organ Class  
Preferred Term  Tislelizumab 200 mg  
Total  
(N = 11)  
n (%)  Ociperlimab 
50 mg 
(N = 1) 
n (%)  Ociperlimab  
150 mg 
(N = 3)  
n (%)  Ociperlimab  
450 mg 
(N = 4)  
n (%)  Ociperlimab  
900 mg 
(N = 3)  
n (%)  
Groin pain  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Infections and infestations  1 (100.0)  0 (0.0)  1 (25.0)  0 (0.0)  2 (18.2)  
Influenza  1 (100.0)  0 (0.0)  0 (0.0)  0 (0.0)  1 (9.1)  
Otitis externa  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Investigations  1 (100.0)  1 (33.3)  0 (0.0)  0 (0.0)  2 (18.2)  
Aspartate aminotransferase 
increased  1 (100.0)  1 (33.3)  0 (0.0)  0 (0.0)  2 (18.2)  
Nervous system disorders  1 (100.0)  0 (0.0)  1 (25.0)  0 (0.0)  2 (18.2)  
Neuralgia  1 (100.0)  0 (0.0)  0 (0.0)  0 (0.0)  1 (9.1)  
Somnolence  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Respi[INVESTIGATOR_696], thoracic, and 
mediastinal disorders  0 (0.0)  1 (33.3)  1 (25.0)  0 (0.0)  2 (18.2)  
Cough  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Dyspnoea  0 (0.0)  1 (33.3)  0 (0.0)  0 (0.0)  1 (9.1)  
Skin and subcutaneous tissue 
disorders  1 (100.0)  0 (0.0)  0 (0.0)  1 (33.3)  2 (18.2)  
Drug eruption  0 (0.0)  0 (0.0)  0 (0.0)  1 (33.3)  1 (9.1)  
Dry skin  1 (100.0)  0 (0.0)  0 (0.0)  0 (0.0)  1 (9.1)  
Blood and lymphatic system 
disorders  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Anaemia  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Cardiac disorders  1 (100.0)  0 (0.0)  0 (0.0)  0 (0.0)  1 (9.1)  
Atrial flutter  1 (100.0)  0 (0.0)  0 (0.0)  0 (0.0)  1 (9.1)  
Ear and laby[CONTACT_33994]  0 (0.0)  1 (33.3)  0 (0.0)  0 (0.0)  1 (9.1)  
Ear discomfort  0 (0.0)  1 (33.3)  0 (0.0)  0 (0.0)  1 (9.1)  
Eye disorders  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Dry eye  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Neoplasms benign, malignant 
and unspecified (incl cysts and 
polyps)  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Cancer pain  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Pericardial effusion 
malignant  0 (0.0)  0 (0.0)  1 (25.0)  0 (0.0)  1 (9.1)  
Psychiatric disorders  0 (0.0)  1 (33.3)  0 (0.0)  0 (0.0)  1 (9.1)  
Confusional state  0 (0.0)  1 (33.3)  0 (0.0)  0 (0.0)  1 (9.1)  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 33 Abbreviations: AE, adverse event;  MedDRA, Medical Dictionary for Regulatory Activities;  N, total patients treated; 
NCI-CTCAE v5.0, National Cancer Institute Common Terminology Criteria for Adverse  Events Version 5.0; TEAE , 
treatment -emergent adverse event.  
Notes: A patient with multiple occurrences of an AE is counted only once in the AE category. MedDRA Version 22.0 was used 
to code AEs. AEs were graded using NCI -CTCAE v5.0. Events are sorted in d escending order of the number of patients for 
System Organ Class and P referred Term  in the Total column.  
1.3.3.  Ociperlimab  Clinical Pharmacology  and Pharmacodynamics  
As of the data cutoff date of 16 June 2020, preliminary PK data of ociperlimab  are available 
from a total of 11 patients treated with ociperlimab  at the 50 mg (n  = 1), 150 mg (n  = 3), 450 mg 
(n = 4), and 900 mg (n  = 3) dose levels in combination with tislelizumab 200 mg in the 
dose-escalation portion of Study BGB -900-105. Ociperlimab  serum concentrations declined in a 
biexponential manner after intravenous infusion and ociperlimab  exposures ( maximum observed 
concentration  and AUC) increased approximately dose -proportionally from 50 mg to 900  mg 
(Figure  1).  
Peripheral TIGIT receptor occupancy data were available for 11 enrolled patients treated with 
ociperlimab  at the 50 mg (n  = 1), 150 mg (n  = 3), 450 mg (n  = 4), and 900 mg (n  = 3) do se levels 
in Study BGB -900-105. Complete TIGIT receptor occupancy (100%) was observed on CD8, 
CD4, natural killer ( NK), and T regulatory cells in peripheral blood at all the tested dose levels.  
Figure  1: Cycle 1 Mean (± SD) Serum Concentration -Time Profiles of Ociperlimab  in 
Study BGB -900-105 
 
Abbreviations: conc, concentration; n,  number of patients; SD, standard deviation.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 34 1.4. Background Information on Tislelizumab  
1.4.1.  Pharmacology  
Tislelizumab (also known as BGB -A317) is a  humanized, immunoglobulin G4 (IgG4) -variant 
monoclonal antibody against PD -1 under clinical development for the treatment of several 
human malignancies.  
Tislelizumab acts by [CONTACT_556772] -1 with high specificity 
and affin ity (K D = 0.15 nM). It competitively blocks the binding of both PD -L1 and programmed 
cell death protein ligand -2 (PD -L2), thus inhibiting PD -1-mediated negative signaling in T cells. 
In in vitro cell -based assays, tislelizumab was observed to dose -dependen tly enhance the 
functional activity of human T cells and pre -activated primary peripheral blood mononuclear 
cells. Tislelizumab has also demonstrated in vivo antitumor activity in several allogeneic 
xenograft models, in which peripheral blood mononuclear c ells were coinjected with human 
cancer cells (A431 [epi[INVESTIGATOR_131715]]) or tumor fragments (BCCO -028 [colon cancer]) into 
immunocompromised mice.  
In vitro assays with tislelizumab suggest either low or no ADCC , antibody -dependent cellular 
phagocytosis , or complement -dependent cytotoxicity effects in humans (Labrijn et al 2009 ; 
Zhang et al 2018 ). Tislelizumab was specifically engineered to abrogate these potential 
mechanisms of T -cell clearance and potential resistance to anti -PD-1 therapy.  
Please refer to the Tislelizumab Investigator’s Brochur e for additional details regarding 
nonclinical studies of tislelizumab.  
1.4.2.  Toxicology  
The toxicity and safety profile of tislelizumab was characterized in single -dose toxicology 
studies in mice and cynomolgus monkeys and in a [ADDRESS_731168] on the systemic 
exposure. The NOAEL of tislelizumab in the 13 -week monkey toxicity study was considered to 
be 30  mg/kg. The safety profile of tislelizumab is considered adequate to support the curr ent 
study, AdvanTIG -204. 
Please refer to the Tislelizumab Investigator’s Brochure  for more detailed information on the 
toxicology of tislelizumab.  
1.4.3.  Clinical Pharmacology  
Population PK analysis was conduct ed using data from 798  patients with solid tumors or 
classical Hodgkin lymphoma who received doses of 0.5, 2.0, 5.0, and 10  mg/kg once every 
2 weeks, 2.0 and 5.0  mg/kg once every [ADDRESS_731169] chara cterized using a 3 -compartmental linear population PK model with 
linear clearance mechanisms. No time -varying clearance was observed in tislelizumab PK. The 
typi[INVESTIGATOR_556683] (CL), central volume (V c), and peripheral volumes (V 2, V3) were 
0.164 L/day, 2.92  L, 0.928  L, and 1.39  L, respectively, with moderate inter -individual variability 
in CL (32.2%), V c (16.7%), V 2 (56.6%), and V 3 (94.2%). The volume of distribution at steady 
state (V ss) was 5.[ADDRESS_731170] IgG monoclonal antibody ( Deng et al 2012 ; Dirks and Meibohm 2010 ; 
Keizer et al 2010 ; Ryman and Meibohm 2017 ). Based on population PK analysis, tislelizumab 
PK was characterized by a terminal half -life of approximately 25.[ADDRESS_731171] on tislelizumab exposure. Exposure -response analysis 
indicated a lack of clinically significant exposure -response relationships for ORR and safety 
endpoints across a variety of advanced solid tumors and classical Hodgkin lymphoma for 
tislelizumab. Population PK analysis supports fixed  dosing across different ethnic groups.  
1.4.4.  Prior Clinical Experience With Tislelizumab  
As of 20  May 2020, 1181  patients with solid tumors had been treated with tislelizumab 
monotherapy in 5 clinical studies.  
A pooled monotherapy analysis was conducted to provide a comprehensive review of the 
tislelizumab safety profile. Patients included in t his analysis (N  = 1181) had a median age of 
60.0 years , with 67.1% of them being male. Median treatment exposure duration was 3.7 (range: 
0.1 to 55.3) months and median study follow -up duration was 9.9 (range: 0.1 to 58.9)  months . 
Refer to the Tislelizumab Investigator's Brochure  for more detailed information on tislelizumab 
safety data when given as monotherapy or in combination with chemotherapy . 
[IP_ADDRESS].  Treatment -Emergent Adverse Events Assessed as Related to Tislelizumab  
Of the 1181 patients with solid tumors treated with tislelizumab  monotherapy, 788 (66.7%) 
experienced ≥ [ADDRESS_731172] commonly occurring TEAEs (≥ 5% of 
patients) assessed as related to tislelizumab irrespective of grade we re AST increased 
(136 patients, 11.5%), alanine aminotransferase (ALT) increased (125  patients, 10.6%), 
hypothyroidism (106  patients, 9.0%), rash (97  patients, 8.2%), and pruritus and fatigue 
(95 patients each, 8.0%).  
A total of 167 patients (14.1%) experi enced at least 1 ≥  Grade [ADDRESS_731173] frequent ≥  Grade  3 TEAEs that occurred in ≥  1% of the patients were 
AST increased (21  patients, 1.8%), ALT increased (17  patients, 1.4%), and anaemia (13  patients, 
1.1%).  
[IP_ADDRESS].  Treatme nt-Emergent Serious Adverse Events  
Of the 1181 patients with solid tumors treated with tislelizumab monotherapy, 415 (35.1%) 
experienced ≥ 1 treatment -emergent serious adverse event (SAE). The most commonly occurring 
treatment -emergent SAEs (irrespective of relationship to study drug) were pneumonia 
(41 patients, 3.5%), and pyrexia and ascites (15  patients each, 1.3%).  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 36 A total of 107 patients  (9.1%) experienced ≥ [ADDRESS_731174] common treatment -emergent SAEs deemed related to tislelizumab were pneumonitis 
(11 patients, 0.9%); AST increased (6 patients, 0.5%); and colitis, ALT increased, and pyrexia 
(5 patients each, 0.4%). All other tislelizumab -related treatment -emergent SAEs occurred in 
< 5 patients.  
[IP_ADDRESS].  Immune -Mediate d Adverse Events  
Anti-PD-1 therapi[INVESTIGATOR_556684] -mediated adverse events (imAEs) in some 
patients and therefore have been defined as adverse events (AEs) of special interest (AESI) in 
tislelizumab clinical studies and as such are being monit ored closely.  
Immune -mediated AEs are consistent with an immune -related mechanism or immune -related 
component for which noninflammatory etiologies (eg, infection or tumor progression) have been 
ruled out. Immune -mediated AEs can include events with an alte rnate etiology that were 
exacerbated by [CONTACT_104155]. There is a potential temporal relationship 
between the initiation of tislelizumab treatment and the onset of an imAE that spans a window of 
days to several months.  
All imAEs presented h ere are assessed as related to the study drug by [CONTACT_556773] . Certain imAEs have multiple Medical 
Dictionary for Regulatory Activities (MedDRA) terms associated with the same category. 
Special categories have been created to group patients experiencing these events.  
Of the 1113 patients with solid tumors included in the pooled analysis of imAEs , 233 (20.9%) 
experienced ≥ [ADDRESS_731175] commonly occurring imAEs of any grade were  
hypothyroidism (69 patients, 6.2%), hyperthyroidism (37 patients, 3.3%), and rash (34  patients, 
3.1%). A total of 52 patients (4.7%) experienced at least 1 ≥  Grade [ADDRESS_731176] commonly 
occurring ≥ Grade 3 imAEs were ALT increased (9 patients, 0.8%) a nd AST increased and 
pneumonitis (7 patients each, 0.6%).  
[IP_ADDRESS].  Infusion -Related Reactions  
Infusion -related reactions, including high -grade hypersensitivity reactions, following 
administration of tislelizumab are uncommon . Of the 1181  patients treated with tisle lizumab 
monotherapy, 45 (3.8 %) experienced ≥ [ADDRESS_731177] 
commonly occurring infusion -related reactions of any grade were infusion -related reactions 
(28 patients, 2. 4%), pyrexia (10  patients, 0. 8%), and nausea (4 patie nts, 0.3%). Two patients 
(0.2%) had ≥ Grade 3 infusion -related reactions and all other events occurred in single instances ; 
these included rash, flushing , hypotension, and spi[INVESTIGATOR_18172].  
[IP_ADDRESS].  Liver Laboratory Abnormalities  
Of the 932 patients with solid tumors included in the analysis of drug -induced liver injury, 
34 patients (3.6%) experienced increases in ALT or AST levels > 5  x upper limit of normal 
(ULN ) but ≤ [ADDRESS_731178], 11  patients (1.2%) had ALT or AST elevations >[ADDRESS_731179] but 
≤ [ADDRESS_731180], and 1  patient (0.1%) had ALT or AST elevations > [ADDRESS_731181]. Bilirubin  
elevation  > [ADDRESS_731182] was observed in 43 patients (4.6%).  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 37 Concomitant ALT/AST and bilirubin elevation in the absence of alkaline phosphatase increases 
were observed in 2  patients (0.2%). These patients had diagnoses of advanced metastatic gastric 
or liver cancer and both presented with extensive hepatic involvement and confirmed hepatic 
disease progression at the time of the observed abnormalities in liver laboratory valu es; these 
cases therefore did not meet the criteria for Hy’s law.  
[IP_ADDRESS].  Fatal Adverse Events  
Out of 1181 patients treated with tislelizumab monotherapy who were included in the analysis, 
18 patients (1.5%) experienced a fatal AE ≤  [ADDRESS_731183] ug dose. A total of 
9 patients (0.8%) experienced fatal AEs that were deemed related to tislelizumab, including 
hepatic failure (2 patients, 0.2%); and large intestinal obstruction, pneumonitis, respi[INVESTIGATOR_13374], 
respi[INVESTIGATOR_1399], hepatitis acute, bra in oedema, and death (1 patient each, 0.1%).  
1.4.5.  Efficacy Assessment of Tislelizumab  
Efficacy data are available from 2 of the ongoing Phase 1 monotherapy studies in solid tumors, 
BGB -A317_Study_001 and BGB -A317 -102, which are summarized below (data cut -off 
20 May 2019) and from a Phase 3 combination study, BGB -A317 -304, in NSCLC (data cut-off 
06 December 2019; Wang et al 2020 ).  
Study BGB -A317_Study_001 is a Phase 1a/1b study consisting of a dose-escalation phase (1a) 
and a dose-expansion phase (1b) designed to establish the maximum tolerated dose  and schedule, 
determine the RP2D, and investigate the preliminary efficacy of tislelizumab in previously 
treated patients with select tumor types.  
The RP2D and schedule for tislelizumab was determined to be 200 mg administered once every 
3 weeks. Across all disease cohorts (N  = 441), 5  patients (1.1%) experienced a CR and 
55 patients (12.5%) had a confirmed PR, yielding an ORR of 13.6%. Stable disease was 
observed in 142  patients (32.2%). The d isease control rate was 45.8% (95% CI: 41.1, 50.6) and 
clinical benefit rate (CBR) was 26.5% (95%  CI: 22.5, 30.9).  
Study BGB -A317 -102 is a nonrandomized, Phase 1/[ADDRESS_731184] advanced solid tumors . It 
showed the recommended dose of tislelizumab 200 mg every 3 weeks was generally well 
tolerated and demonstrated a manageable safety profile in Chinese patients with advanced solid 
tumors.  Preliminary antitumor acti vities were observed in the overall patient population and 
across multiple indications. Across all tumor types, the ORR was 17.0% (51 patients; 95% 
CI:12.9%, 21.7%). There was 1 patient with a confirmed CR, who was diagnosed with squamous 
cell carcinoma of  the larynx. The CBR (CR + PR + durable stable disease ≥ 24 weeks) was 32% 
and the DCR was 44.7%.  
Study BGB -A317 -206 (data on file) was investigating tislelizumab in combination with 
chemotherapy as first -line treatment in patients with lung cancer. One of  the cohorts enrolled 
17 ES-SCLC patients who were treated with tislelizumab combined with  etoposide plus cisplatin 
or carboplatin for 4 -6 cycles followed by [CONTACT_556774]. As of 25 Feb 
2019, the confirmed ORR was 76.5% (95%  CI: 50.1, 93.2) and the disease control rate was 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 38 88.2%  (95%  CI: 63.6, 98.5). The median DOR  was 6.5 months and the median PFS was 6.9 
months  (95%  CI: 4.90,10.09).  
1.5. Study Rationales  
1.5.1.  Rationale for Combination of Ociperlimab and Tislelizumab  in the Treatment of 
Limite d-Stage Small Cell Lung Cancer  
SCLC is typi[INVESTIGATOR_556685], unstable TP53  and RB1 genes, and high mutation 
rate of the DNA damage response  pathway. However, SCLC  has lower PD-L1 expression than 
other lung cancers. Certain advances have been made in the use of immune checkpoint inhibitors 
for the treatment of SCLC . Combination of first -line immune checkpoint inhibitors with 
chemotherapy for ES -SCLC has shown improved clinical benef it. Besides  atezolizumab , which  
has been approved in combination with standard chemotherapy, durvalumab  combined with EP 
has also show n significant survival improvement and long -term clinical benefit in the CASPI[INVESTIGATOR_556686] ( Paz-Ares  et al 2019 ). Pembrolizumab also demonstrated significant ly improved PFS in the 
KEYNOTE  604 study  (Rudin et al 2020 ). However , the role of PD -1/PD -L1 antibodies in 
LS-SCLC has not been determined.  Further investigations on novel  strategies  of immune 
checkpoint inhibitors combined with other agent s may be helpful in overcoming the treatment 
challenges in SCLC . Other agents that may be investigated for the treatment of SCLC include 
those that target immune checkpoints other than PD -1/PD -L1 or those that modulate the immune 
metabolism of the tumor microenvironment.  
TIGIT is a receptor found on the surface of NK cells, T  regulatory  cells, and activated T cells, 
and it has a high -affinity ligand CD155, also known as poliovirus receptor (PVR) ( Hu et al 
2020 ). Upregulation of TIGIT expression in tumor infiltrating lymphocytes has been re ported in 
NSCLC ( Tassi et al 2017 ). Blockade of  the TIGIT receptor has been shown both in vitro and in 
vivo to rescue functionally “exhausted” T  cells ( Johnston et al 2014 ).  
A recent study using SCLC samples showed that PVR, an immune checkpoint protein expressed 
on tumor cells, is highly expressed in SCLC cell lines and tumor tissues ( Yu et al 2018 ). 
According to the same group, PVR mediate s the inhibition of T cells by [CONTACT_556775], which indicate s that the PVR -TIGIT pathway may be a promising target for 
immunotherapy in SCLC and also highlights the potential for the combination of checkpoint 
blocking agents (eg, PD -L1) for improved SCLC immunotherapy.   
Although targeting  TIGIT  could eliminate immune suppression by [CONTACT_556776] T effector cells 
and NK cells, TIGIT blockade alone (ie, ociperlimab  monotherapy) is unlikely to result in an 
effective antitumor response according to existing anti -TIGIT clinical data.  
Ociperlimab  and tislelizumab have nonoverlappi[INVESTIGATOR_556687]/or added activity. The refore, the  combination use of ociperlimab  and tislelizumab 
concurrent with standard cCRT is designed to evaluate the effect of ociperlimab  in combination 
with tislelizumab in maximizing the potential therapeutic benefit w hile simultaneously achieving 
clinical benefit  for patients .  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 39 1.5.2.  Rationale for the Selection of Ociperlimab  Dose  
Ociperlimab  doses ranging from 50 mg to 900 mg administered once every 3 weeks, in 
combination with 200  mg of tislelizumab once every 3 weeks , were explored in the ongoing 
Phase 1/1b Study BGB -900-105. All the tested ociperlimab  dose levels cleared the DLT window 
without any significant safety or tolerability events. Ociperlimab  exposures increased in an 
approximately dose -proportional manner ( Ociperlimab (BGB -A1217) Investigator’s Brochure ). 
As of [ADDRESS_731185] the 
occupancy in tumor tissues. Preliminary results show that near complete TIGIT receptor 
occupancy in tumor tissues is predicted at doses ≥  [ADDRESS_731186] of immunogenicity on the ociperlimab  PK and based on the emerging  safety and 
tolerability data, a dose of 900 mg was selected. This dose level is expected to increase the 
likelihood of efficacious concentrations and saturation of TIGIT receptors in tumor tissues 
completely over the entire dosing interval. The a bsence of  any dose -dependent safety events in 
the ongoing study additionally supports the selection of this dose for further evaluation. The 
preliminary ociperlimab  PK data from the ongoing BGB -900-105 study indicate a lack of a 
significant relationship between ociperlimab  exposure and the patient’s body weight and support 
the selection of a fixed dose for ociperlimab . 
1.5.3.  Rationale for Selection of Tislelizumab Dose  
The clinical fixed dose of 200  mg intravenously once every 3  weeks was selected based on 
comparable safe ty and efficacy profiles between 2  and 5 mg/kg in BGB -A317_Study_001.  
Rates of treatment -related AEs and SAEs observed in patients receiving 2  mg/kg and 5  mg/kg 
once every 2  weeks and once every 3  weeks were comparable, suggesting no clear 
dose-dependence across these regimens. Additionally, PK data also showed no relationship 
between exposure and treatment -emergent imAEs ( Wu et al 2019a ; Wu et al 2019b ). 
Confirmed response rates in patients t reated with tislelizumab once every 3  weeks were 
favorable compared with those in patients treated once every 2  weeks. While there are 
differences in response rates between dose levels, this is more likely a reflection of the small 
sample size and patient heterogeneity than of dose response.  
Clearance of tislelizumab was not dependent on body weight, and the observed serum exposure 
of a 200  mg dose fell between the serum exposure s observed after 2  mg/kg and 5  mg/kg doses. 
Therefore, clinical activity with a  manageable and tolerable safety profile is expected to be 
maintained in patients receiving tislelizumab 200  mg once every 3  weeks.  
Exposure -response analysis indicated a lack of clinically significant exposure -response 
relationships for ORR and safety end points across a variety of advanced solid tumors and 
classical Hodgkin lymphoma for tislelizumab. These findings support the use of the 200 mg once 
every 3  weeks dose regimen for pi[INVESTIGATOR_36491].  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 40 In conclusion, the observed clinical activity in patients wi th advanced tumors, coupled with a 
manageable safety profile and supportive data, support the use of the proposed tislelizumab dose 
of 200  mg intravenously once every 3  weeks as the recommended dose for pi[INVESTIGATOR_36491] ; please 
refer to the Tislelizumab Investigator’s Brochure  for further details . 
1.5.4.  Rationale for Chemoradiotherapy  as the Component of the Combination 
Treatment  
Platinum -based chemotherapy is the standard of care for first -line therapy in LS -SCLC. The 
platinum agents most commonly used are cisplatin and carboplatin, which are often combined 
with the non -platinum agent etoposide. The addition of RT to standard comb ination 
chemotherapy improves both local control and OS. Early cCRT is recommended for patients 
with LS -SCLC based on the longer survival time reported in patients treated concurrently 
compared with the survival times for those treated  sequentially. For th e comparator arm  and the 
[ADDRESS_731187] of care . Patients will receive 
4 cycles of EP (or carboplatin  plus etoposide if cisplatin is contraindicated or not tolerated) 
concurrent with RT as backbone treatmen t. 
1.5.5.  Rationale  for Combination of Concurrent Chemoradiotherapy  and 
Immunotherapy  
The rationale for immunotherapy in combination with cCRT has been shown in a multitude of 
preclinical studies, including xenograft models of some solid tumors ( Deng et al 2014 ). Both 
chemotherapy and RT can upregulate major histocompatibility complex class I antigens, increase 
tumor antigen release, drive a polyclonal T-cell response, enhance CD8þ T -cell infiltration, limit 
T-cell exhaustion, modulate the immune environment, provoke an interferon gamma response, 
and upregulate the expression of PD -L1 (Gandhi  et al 2018 ; Kordbacheh et al 2018 ), which 
could make such tumors sensitive to a PD -1/PD -L1-directed therapy.  In this setting, 
chemotherapy and RT act as priming agents for immunotherapy; elimination of cancer cells by 
[CONTACT_556777]/or RT triggers release of antigens, which can turn poor ly immunogenic or 
immunosuppressive tumors into an immunogenic environment ( Vanneman and Dranoff 2012 ). 
The PACIFIC trial was the first randomized Phase 3  study to clinically validate these findings. 
This is a global Phase 3 trial of the anti -PD-L1 agent , durvalumab, being compared with placebo 
as consolidation therapy following ≥ 2 cycles of platinum -based chemotherapy administered 
concurrently with RT without progression in patients with unresectable  stage III NSCLC. The 
trial demonstrated that median PFS was significantly longer with durvalumab than with placebo 
(median PFS 16.8 months versus 5.6 months, stratified HR for disease progression or death 
0.52), with a similar safety profile in the 2 grou ps (Antonia et al 2017 ). 
In SCLC, both the IMpower133  (Horn et al 2018 ) and the CASPI[INVESTIGATOR_204681] (Paz-Ares et al 2019 ) trials 
reported that the addition of an immune checkpoint inhibitor to chemotherapy modestly 
improved survival. The BGB -A317 -[ADDRESS_731188] -line treatment for patients with ES -SCLC (see Section  1.4.5 ). Although immune 
checkpoint inhibition in combination with chemotherapy demonstrated clinical benefits, s urvival 
curves separated late in randomized trials, and patients who would benefit could not be 
identified. Given that radiation to a primary tumor leads to tumor -antigen release and a tumor -
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 41 specific adaptive i mmune response, which is enhanced by [CONTACT_44859] -stimulating agents, it is 
possible that the addition of RT to a chemo therapy and  immune checkpoint inhibitor  regimen 
could make SCLC more immunogenic. As for LS -SCLC, the result from a Phase 1/2 trial of 
pembroli zumab combined with c CRT  for patients with LS -SCLC showed that cCRT and 
pembrolizumab was well tolerated and yielded favorable outcomes, providing a basis for 
randomized studies  (Welsh et al 2020 ).  
More insight into the biological mechanisms underlying treatment resistance is needed to 
improve patient outcome . Combination with PD -1/PD -L1 and T IGIT  blockade might rescue 
functionally “exhausted” T  cells and result in a durable control of cancer. This trial will evaluate 
whether the addition of an anti -PD-1 therapy and anti -TIGIT therapy to combined modality 
therapy can benefit patients with LS -SCLC.  
In addition, improvement in antitumor effects has been observed preclinically when RT is given 
concurrent ly with or immediately after anti -PD-L1 rather than sequentially ( Dovedi  et al 2014 ). 
However, sequential delivery of checkpoint inhibitors did not improve response to RT at local or 
distant sites  (Dovedi et al 2017 ). The results of the PACIFIC trial, which suggested that the OS 
was better when durvalumab was given within 2 weeks after the end of cCRT, was consistent 
with preclinical data  (Antonia et al 2017 ). Therefore, the earlier introduction of tislelizumab + 
ociperlimab  given simultaneously with cCRT may lead to further enhancement of 
immune -mediated antitumor efficacy.  
As a novel immunotherapy combination, anti -PD-L1 plus anti -TIGIT g iven concurrently with 
RT has been evaluated in a mouse  model ( Grapin et al 2019 ). The experiment compared the 
tumor response during treatment with anti -PD-L1 plus anti -TIGIT plus RT with single agent 
therapy plus RT or RT alone. In the CT26 model, 3 x 8  Gy hypofractionated RT was 
dramatically more effective in combination with anti -TIGIT and anti -PD-L1 therapy , with a CR 
rate of 90%  (9/10 mice ) compared with that of 20%  (2/10 mice ), 30%  (3/10 mice ), and 0% 
(0/10 mice ) for anti -TIGIT, anti -PD-L1, and RT alone, respectively. A CR with anti-TIGIT and 
anti-PD-L1 therapy in combination with 18  x 2 Gy normofractionated  RT was observed in 7/12 
(58.3%) mice compared with 3/12 (25%), 8/12 (66.7%), and 1/10  (10%)  mice  for anti -TIGIT, 
anti-PD-L1, and RT alone  with the same fractionated  RT, respectively .  
Based on those preclinical and clinical supportive data, this study is designed to study  cCRT 
combined with anti -PD-[ADDRESS_731189] of care of systemic therapy for patients with LS-SCLC. It has 
been widely applied for initial treatment in LS -SCLC for over 3 decades. In clinical practice, 
carboplatin is used as a substitute for cisplatin to reduce the risk of emesis, neuropathy, and 
nephro pathy. However, it also carries a greater risk of myelosuppression. During systemic 
therapy concurrent with RT, EP is recommended (category  1) as the preferred regimen. In this 
study, patients in each cohort will receive 4 cycles of EP; if cisplatin is contraindicated or not 
tolerated, carboplatin may be used.  
Version .[ADDRESS_731190] RT procedure according to NCCN SCLC Panel recomm endations. The RT 
dose in LS -SCLC  therapy may be given as a once -daily  or twice -daily  regimen ; both regimen s 
have show n improved survival outcome for patients with LS-SCLC and  there is  no significant 
difference between t he 2 options. The Phase 3 CONVERT tr ial compared total doses of  66 Gy 
with once -daily  fractionation  and 45 Gy with twice -daily  fractionation  in 547 patients with 
LS-SCLC ; OS outcomes did not significantly differ between the 2  groups.  
Based on  this study , the higher doses of 60 to 70 Gy with once -daily fractionation became 
another acceptable option  (Miller et al 2003 ; Roof et al 2003 ; Bogart et al 2004 ). The once -daily 
regimen was selected for this study because the twice -daily regimen carries some concerns about 
tolerance, presents logistic issues for the RT department, and is inconvenient for patients.  
The PCI regimen was standardized at [ADDRESS_731191] of care based on a 
meta -analysis  (Aupérin et al 1 999) that reported decreased incidence of brain metastases (relative 
risk =  0.46, p < 0.001) and a 5.4% absolute improvement in 3-year OS (20.7%  versus  15.3%) 
with the addition of PCI . 
1.5.8.  Rationale for Biomarker Strategy  
Biomarker assays will be performed usi ng patient -derived tumor tissue(s) and/or blood samples 
to evaluate the predicative biomarkers associated with  tislelizumab plus ociperlimab . These 
biomarker s will include  but not limit to  gene expression profile, tissue - or blood -based gene 
mutations and TMB/ microsatellite instability ( MSI), PD-L1/TIGIT/ CD155/CD226 expression, 
and SCLC subtypi[INVESTIGATOR_007] (ASCL1/NEUROD1/POU2F3/YAP1).  
Despi[INVESTIGATOR_556688] -PD-1/PD -L1 inhibitors, predictive 
biomarkers for SCLC clinical efficacy are yet to be well-established and biomarker research for 
LS-SCLC is very scarce. PD -L1 expression is under investigation in ES -SCLC immunotherapy 
and its correlation with clinical effica cy has not been well-established, which might be due to 
different scoring algorithms and combination treatment regimens. In Keynote  158, improved 
ORR was observed in the PD-L1 combined positive score ≥  1 subgroup treated with 
pembrolizumab monotherapy for second -line or further -line treatment of SCLC 
(Chung  et al 2018 ). Other studies investigating PD -L1 tumor cell expression or immune cell 
expression showed no association with clinical benefit ( Hellmann et al 2017 ). More data are 
needed to further evaluate the predic tive power of PD -L1 expression using different scoring 
algorithm s in SCLC. Another potential predictive biomarker reported in SCLC immunotherapy 
was tissue and blood TMB. Improved ORR was observed in the Checkmate  032 trial in 
TMB -high SCLC patients treated with nivolumab ( Antonia et al 201 6). However, in the 
IMpower  133 trial, no correlation of TMB with OS was observed in patients with SCLC treated 
with atezolizumab plus chemotherapy ( Horn et al 2018 ). The predictive value of TMB will be 
further evaluated in the current study. Moreover, there is a lack of evidence indicating whether 
genetic mutations could have a correlation with the benefit of immunotherapy in patients with 
SCLC. SCLC is characterized by [CONTACT_556778] ( Yu et al 2018 ). The expression of TIGIT pathway 
molecules including TIGIT, CD226, CD155, and CD112 will be measured to explore their 
Version .[ADDRESS_731192] been increasingly clearly defined (A/N/P/I) in 
recent years, and SCLC -I subtype is characterized by [CONTACT_556779], 
suggesting its sensitivity to immunotherapy ( Gay et al 2019 ). Therefore, SCLC subtypi[INVESTIGATOR_556689] e xplored . 
1.6. Benefit -Risk  Assessment  
Tislelizumab monotherapy and in combination with chemotherapy have shown meaningful 
antitumor activity and manageable safety profiles in various types of tumors including 
ES-SCLC. Other immune checkpoint inhibitors combined with first-line chemotherapy have also 
show n improved efficacy in ES -SCLC in both the IMpower  133 trial (Horn et  al 2018 ) and the 
CASPI[INVESTIGATOR_556690]  (Paz-Ares et al 2019 ). Base d on increased evidence for the combination of 
immunotherapy and RT, the synthetic anticancer activity  of immunotherapy has been prove n by 
[CONTACT_103222]. Checkpoint inhibitor s with cCRT ha ve provided favorable benefit -
risk profile s in the PACIFIC trial for patients with unresectable stage III NSCLC  (Antonia et al 
2017 ). Earlier tr eatment with  potentially more effective treatment options might further improve 
the clinical benefit.  
As discussed earlier, there is extensive evidence supporting TIGIT’s role in regulating immune 
response and the interaction between the TIGIT and PD -1 pat hways has been shown to promote 
tumor immune escape. The clinical efficacy demonstrated for tislelizumab and preliminary 
results with an anti -TIGIT/anti -PD-L1 competitor combination suggest that ociperlimab  has the 
potential to improve and/or extend the th erapeutic benefits of tislelizumab in the treatment -naïve 
setting. The novel therapeutic strategy of using ociperlimab and tislelizumab combined with 
cCRT seeks to augment the current modest improvement in SCLC, especially in LS -SCLC , 
which still only has cCRT as the standard initial therapy.  
PD-1 blockade by [CONTACT_556780] 1350 patients with a safety and 
efficacy profile similar to what has been reported for other anti -PD-1/PD -L1 therapi[INVESTIGATOR_556691].  Based on the mechanism(s) of action and the nonclinical and 
preliminary clinical data, the combined blockade of TIGIT and PD -1 by [CONTACT_556781], respectively, is expected to result in immune -mediated toxicities similar to what has 
been obse rved with tislelizumab alone. Preliminary safety results from the CITYSCAPE trial 
(N = 135) support  this hypothesis and demonstrate  that patients treated with the 
anti-TIGIT/ anti-PD-L1 combination experienced < 10% increase in overall and Grade 3 or 
4 TEAEs compared with patients treated with anti -PD-1 and placebo  (Rodriguez -Abreu et al 
2020 ). 
As for the safety profile  of immunotherapy combined with cCRT , the Phase 3 PACIFIC trial and 
the P hase 2 trials NIC OLAS  (Peters et al 2019 ) and DETERRED (Lin et al 2020 ) have released 
preliminary safety data  of anti -PD-1/PD-L1 administered at the same time as cCRT . Most of 
AEs were Grade [ADDRESS_731193] established a monitoring plan to monitor, 
diagnose, and manage imAEs . A Safety Monitoring Committee (SMC) will be established to 
regularly monitor the safety of  ociperlimab plus  tislelizumab  and tislelizumab alone in 
combination with cCRT (Section  10.1). 
Given the unmet medical need and limited treatment options in this indication, the benefit /risk 
assessment for this study is favorable , based on strong scientific rationale  indicating  that the 
blockade of PD -[ADDRESS_731194] cCRT  may result in enhanced antitumor activity as compa red with cCRT alone without 
a major increase in the risk of immune -mediated  toxicities.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 45 2. STUDY OBJECTIVES AND  ENDPOINTS  
2.1. Study Objectives  
2.1.1.  Primary Objective  
• To compare progression -free survival (PFS) between Arm A (ociperlimab plus 
tislelizumab plus cCRT) and Arm C ( cCRT only) and between Arm B (tislelizumab 
plus cCRT) and Arm C as assessed by [CONTACT_556782] 1.1 (RECIST  v1.1) in the Intent -to-Treat 
(ITT) Analysis Set  
2.1.2.  Secondary Objectives  
• To compare the following between Arm A and Arm C and between Arm B and Arm 
C as assessed by [CONTACT_3143] v1.1 in the ITT Analysis Set:  
− Complete response (CR) rate  
− Overall response rate (ORR)  
− Duration of response (DOR)  
− Overall surviv al (OS)  
− Distant metastas is-free survival (DMFS)  
• To evaluate the correlation of PD -L1 and TIGIT expression with ORR, PFS, and OS  
• To evaluate the safety and tolerability of ociperlimab combined with tislelizumab 
plus cCRT and tislelizumab plus cCRT  
2.1.3.  Explorato ry Objectives  
• To explore prognostic and predictive effects of tissue - and blood -based biomarkers on 
efficacy and their association with mechanisms of resistance   
• To evaluate health -related quality of life (HRQoL)  
• To assess the utility of circulating tumor DNA ( ctDNA ) level change as a surrogate 
marker for efficacy  
• To assess the PK of ociperlimab and tislelizuma b 
• To assess the immunogenicity of ociperlimab and tislelizumab  
2.2. Study Endpoints   
2.2.1.  Primary Endpoint  
• PFS, defined as the time from  the date of  randomization to the date of the first 
documented disease progression as determined by  [CONTACT_76954] v1.1 
or death from any cause  (whichever occurs first ), in the ITT Analysis Set of Arms A, 
B, and  C 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 46 2.2.2.  Secondary Endpoints  
• CR rate, defined as t he proportion of patients who had CR as assessed by [CONTACT_76955] v1.1, in the ITT Analysis Set of Arms A, B, and C  
• ORR , defined as the proportion of patients who had CR or partial response (PR) as 
assessed by  [CONTACT_76954] v1.1 , in the ITT Analysis Set of Arms A, B, 
and  
• DOR , defined as the time from the date of the first occurrence of a documented 
objective response to the  date of documented disease progression as determined by 
[CONTACT_76954] v1.1 or death from any  cause  (whichever occurs first ), in 
the ITT Analysis Set of Arms A, B, and C  
• OS, defined as the time from the date of randomization to the date of death due to any 
cause in the ITT Analysis Set, in the ITT Analysis Set of Arms A, B, and C   
• DMFS , defined as  the time from the date of randomization to the date of the first 
documented distant metastasis as assessed by [CONTACT_76954] v1.1 or 
death from any cause  (whichever occurs first ), in the ITT Analysis Set of Arms A, B, 
and C  
• ORR, PFS , and OS i n subgroups based on PD -L1 and TIGIT expression levels  
• The incidence and severity of treatment -emergent adverse events (TEAEs) graded 
according to National Cancer Institute -Common Terminology Criteria for Adverse 
Events  Version 5.0  (NCI-CTCAE v5.0 ). 
2.2.3.  Exploratory Endpoints  
• Biomarkers from patient -derived tumor tissue(s) and/or blood samples obtained 
before, during , and/or after treatment including but not limited to gene expression 
profile, tissue - or blood -based gene mutations and TMB/MSI, CD155/CD226 
expression, SCLC subtypi[INVESTIGATOR_007] (ASCL1/NEUROD1/POU2F3/YAP1)   
• HRQoL  assessment using 2 patient -reported outcomes (PROs) including the 
European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire -Core 30 (EORTC QLQ -C30)  and its lung cancer module Quality of 
Life Questionnaire Lung Cancer 13 ( QLQ -LC13)  
• The ctDNA level change before, during , and afte r treatment as a surrogate marker for 
efficacy  
• Serum concentrations of ociperlimab and tislelizumab  at specified timepoints  
• Assessment of immunogenicity of ociperlimab and tislelizumab by [CONTACT_556783] .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 47 3. STUDY DESIGN  
3.1. Summary of Study Design  
This is a Phase 2, multicenter, randomized, 3 -arm, open -label study to investigate the 
preliminary efficacy and safety of  ociperlimab  plus tislelizumab plus cCRT followed by 
[CONTACT_556751] (Arm A) and tislelizumab plus cCRT followed b y tislelizumab 
only (Arm B) compared with cCRT only (Arm C) in patients with previously untreated 
LS-SCLC.  
The primary endpoint is investigator -assessed PFS in the ITT Analysis Set for the comparisons 
of Arm  A versus Arm C and Arm B versus Arm C .  
Approximately 120 patients will be randomized in a 1:1:1 ratio to receive the study treatment in 
the following 3 arms:  
• Arm A: Ociperlimab  900 mg intravenously once every 3 weeks plus tislelizumab 200 
mg intravenously once every 3 weeks combined with cCRT f or 4 cycles, followed by 
[CONTACT_556753]  900 mg intravenously once every 3 weeks plus tislelizumab 200 mg 
intravenously once every 3  weeks  
• Arm B: Tislelizumab 200 mg intravenously once every 3 weeks combined with cCRT 
for 4  cycles, followed by [CONTACT_556784] 20 0 mg intravenously once every 3 weeks  
• Arm C: cCRT only  for 4 cycles  
Randomization will be stratified by [CONTACT_123573] (I/II versus III) by [CONTACT_556785], 
8th edition .  
The chemotherapy regimen is cisplatin 75  mg/m2 on D ay 1 of each cycle for 4 cycles. If the 
patient is unable to tolerate the 1-day administration  of cisplatin  75 mg/m2, at the investigator’s 
discretion  (eg, patients had concurrent  superior vena cava syndrome ), cisplatin 25  mg/m2 dosed 
on Days 1, 2, and 3 is allowed. E toposid e is administered at 100 mg/m2 on D ays 1,  2, and [ADDRESS_731195] cycle.  
If cisplatin is contraindicated or not tolerated  (Section  [IP_ADDRESS] ), carboplatin and etoposide will be 
the alternative chemotherapy regimen. Carboplatin at a dose of area under the plasma or serum 
concentratio n-time curve 5 (AUC 5 ) should be administ ered as an intravenous infusion once 
every 3  weeks on Day 1 of each cycle for 4 cycles  and etoposide 100 mg/m2 should be 
administered on Days 1, 2, and 3 of each cycle for 4 cycles.  
For Arm A and Arm B, investigational drug(s) (ociperlimab plus tislelizumab [Arm A] or 
tislelizumab alone  [Arm B]) will be given starting on Cycle 1 Day 1 (C1D1) before  
chemotherapy and continued for a duration of up to 12 months (a maximum of 17  cycles of 
treatment) or until disease progression  according to  RECIST v1.1, unacceptable toxicity, death, 
or another discontinuation criterion is met , whichever occurs first.  
RT should start early within  cycle 1 or 2 of systemic therapy . The total dose of RT will be 60 to 
70 Gy , given in once -daily fractions over 6 to 7 weeks.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 48 PCI is permitted at the investigator’s discretion. The preferred total dose for PCI to the whole 
brain is 25 Gy in 10  daily fractions.  
The study design schematic is presented in  Figure  2.
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 49 Figure  2: Study Schema  
 
Abbreviations: AJCC, American Joint Committee on Cancer; cCRT, concurrent chemoradiotherapy; CR, complete response; D1,  Day 1; DMFS, distant 
metastasis -free survival; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; LS -SCLC, limited -stage small cell lung cancer; ORR, overall 
response rate; OS, overall survival; PFS, progression -free survival; PS, performance status; Q3W, once every 3 weeks ; R, randomization.  
For all study procedures, see Section  7 and Appendix  1. 
 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 50 3.2. Screening Period  
Screening evaluations will be performed within 28 days before  randomization. Patients who 
agree to participate in this study will sign the informed consent form (ICF) before  undergoing 
any screening procedure. Patients who are suspected to have conc urrent serious respi[INVESTIGATOR_556692] a 
pulmonary function test (refer to Section  7.1.5  and Appendix  1 for details). Screening 
evaluations may be repeated as needed within the screening period; the investigator is to assess 
preliminary patient eligibility according to the latest screening assessment results.  
Archival tumor tissue must be collected for the purpose of biomarker analysis. If no archival 
samples are available, a fresh tumor biopsy at baseline is requ ired. Refer to Section  7.7 for 
details.  
3.3. Treatment Period  
After completing all screening activities, eligible patients will be randomized in a 1:1 :1 ratio to 
receive either ociperlimab  plus tislelizumab plus cCRT followed by [CONTACT_556786] (Arm A), tislelizumab plus cCRT followed by [CONTACT_556752] (Arm B), or cCRT 
only (Arm  C). Randomization will be stratified according to stage ( stage I/II versus stage III).  
Patients will receive open -label treatment with one of the following:  
• Arm A: Ociperlimab  900 mg intravenously once every 3 weeks plus tislelizumab 200 
mg intravenously once every 3 weeks combined with cCRT for 4  cycles, followed by 
[CONTACT_556753]  900 mg intravenously once every 3 weeks plus tislelizumab 200 mg 
intravenously once every 3  weeks  
• Arm B: Tislelizumab 200 mg intravenously once every 3 weeks combined with cCRT 
for 4  cycles, followed by [CONTACT_556784] 200 mg intravenously onc e every 3 weeks  
• Arm C: cCRT only  for 4 cycles  
For Arm A and Arm B, investigational drug(s) will be given starting on Cycle 1 Day 1 (C1D1) 
before  chemotherapy and continued for a duration of up to [ADDRESS_731196] v1.1 -defined disease progression is permitted 
provided that the patient has investigator -assessed clinical benefit and is tolerating study drug. 
Specific requirements for patients with disease progression to be able to continue treatment  with 
ociperlimab and tislelizumab are d escribed in Section  7.5. 
During the study, tumor imaging will be performed at approximately 12  weeks (±  7 days) from 
the date of randomization (an ad ditional tumor assessment is allowed if clinically indicated), then 
every 6  weeks (±  7 days) for the next 54  weeks, and then every 12  weeks (±  7 days) thereafter 
based on RECIST v1.1. Tumor response will be assessed by [CONTACT_431]. Details are provided 
in Section  7.5. 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 51 Safety will be assessed throughout the study by [CONTACT_42466]/SAEs (toxicity grades assigned 
per NCI-CTCAE  v5.0 and laboratory results. Vital signs, physical examinations, Eastern 
Cooperative Oncology Group ( ECOG ) Performance Status change, electrocardiogram (ECG) 
results, and other examinations will also be used for safety assessment. Safety assessments are 
further detailed in Section  7.4 and the Schedule of Assessments ( Appendix  1). 
3.4. End of Treatment/Safety Follow -up 
The End -of-Treatment (EOT ) Visit and Safety Follow -up Visit are planned to be conduct ed 
when the investigator determines that study treatment will no longer be used. The EOT Visit 
should be conducted within 7 days after the decision  to discontinue study treatment  or upon 
completion of study treatment . If routine laboratory tests (eg, hematology, serum chemistry) are 
completed within 7  days before the planned EOT  or Safety Follow -up Visit , these tests need not 
to be repeated. Tumor assessment is not speci fically required at the EOT  or Safety Follow -up 
Visit and should follow the regular tumor evaluation schedule  detailed in Section  7.5. However , 
in some cases , the time window of tumor assessment might overlap with the EOT and/or Safety 
Follow -up Visit. 
Patients who discontinue study treatment for any reason will be asked to return to the clinic for 
the Safety Follow -up Visit, which is required to be conducted 3 0 days (±  7 days) after the last 
dose/last day  of study treatment  (including cCRT) , or initiation of new anticancer therapy , 
whichever occurs first.   
For Arms A and B, patients should return to the site or telephone contacts with patients should be 
conducted  to assess imAEs  and concomitant medications (if appropriate, ie,  associated with an 
imAE or is a new anticancer therapy) at 60  and 90  days (±  7 days) after the last dose of 
ociperlimab or tislelizumab , regardless  of whether patients start a new a nticancer therapy. If 
patients report a suspected imAE at a telephone follow -up contact, the investigator should 
arrange an unscheduled visit if further assessment is indicated . 
The EOT Visit may be used as the Safety Follow -up Visit if it occurred 30 days  (± 7 days) after 
the last dose of study treatment, eg, at an EOT Visit right after a response assessment showed 
disease progression  resulting in patient discontinuation. Patients who discontinue study treatment 
or complete study treatment before disease p rogression  will have their tumors assessed as 
outlined in Section  7.5. If the EOT Visit is used as the Safety Follow -up Visit, the assessment 
that has been performed at the EOT Visit does not need to be repeated.  
All AEs, including SAEs, will be collected as described in Section  8.6. 
Patients who discontinue or complete study treatment before  disease progression will need to 
undergo tumor assessments as outlined in Section  7.5. 
For patients who have disease progression during the study, an optional biopsy will also be taken 
at the EOT or Safety Follow -up Visit from accessible tumor sites, which could be used for 
exploratory study including , but not limited to , study of the resistance mechanism. If feasible, 
any follow -up biopsy should be ideally taken from the same tumor lesion as the baseline biopsy. 
Written informed consent is required before fresh tumor biopsies.  
See Appendix  1 for assessments to be performed at the EOT and Safety Follow -up Visit s. 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 52 3.5. Survival Follow -up 
Patients will be followed for survival and to obtain information on subsequent anticancer t herapy 
after discontinuation of study treatment via telephone calls, patient medical records, and/or clinic 
visits approximately every 3  months (±  14 days) after the  Safety Follow -up Visit or as directed 
by [CONTACT_397770], withdrawal of consent, l oss to follow -up, or end of study.  
3.6. Discontinuation From the Study Treatment or From the Study  
3.6.1.  Patient Discontinuation From Study Treatment  
Patients have the right to discontinue study treatment at any time for any reason. In addition, the 
investigator has the right to discontinue a patient from the study treatment at any time. Patients 
who discontinue  study treatment for reasons other than disease progression  should be followed 
for assessments of antitumor activity (Section  7.5), safety (Section  7.4) and survival 
(Section  3.5), if possible.  
The primary reason for discontinuation from the study treatment should be documented  in source 
documents and on the appropriate electronic case report form  (eCRF). Pati ents may discontinue 
study treatment for reasons which include, but are not limited to, the following:  
• Radiographic disease progression per RECIST v1.1  
• Adverse event  
• Patient decision  
• Pregnancy  
• Any medical condition that the investigator or sponsor determin es may jeopardize the 
patient’s safety, if he or she were to continue the study treatment  
• Use of any concurrent anticancer therapy (ie, chemotherapy, hormonal therapy, 
immunotherapy, or standard or investigational agents [including Chinese (or other 
Countr y) herbal medicine and Chinese (or other Country) patent medicines] for the 
treatment of cancer)  
• Patient noncompliance  
Investigative site staff should first counsel patients who are significantly 
noncompliant (eg, missing 2 treatment cycles) on the importance of study drug 
compliance and drug accountability. The investigator may, in consultation with the 
medical monitor, discontinue patients from treatment who are consistently 
noncompliant.  
• Completion of study treatment  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 53 3.6.2.  Patient Discontinuation From S tudy (End of Study for an Individual Patient)  
Patients may discontinue study for reasons which include, but are not limited to, the following:  
• Patient withdrawal of consent  
• Death  
• Loss to follow -up 
3.7. End of Study  
The end of study is defined as the timepoint when the final data point is collected from the last 
patient in the study. This is when the last patient dies, withdraws consent, completes all study 
assessments, or is lost to follow -up. Alternatively, the end of study is when the sponsor decides 
to termi nate the study.  
The sponsor has the right to terminate this study at any time. Reasons for terminating the study 
early may include, but are not limited to, the following:  
• The incidence or severity of AEs in this or other studies indicates a potential healt h 
hazard to patients  
• Overall patient enrollment is unsatisfactory  
The sponsor will notify each investigator if a decision is made to terminate the study. Should this 
be necessary, prematurely discontinued patients should be seen as soon as possible for an EOT 
Visit and Safety Follow -up Visit.  
The investigators may be informed of additional procedures to be followed to ensure that 
adequate consideration is given to the protection of the patient’s interests. The investigator will 
be responsible for informing Institutional Review Boards (IRBs)/Independent Ethics Committees 
(IECs) of the early termination of the study.  
The sponsor has the right to close a site at any time. The decision will be notified to the site in  
advance. Reasons for closing a site may inclu de but are not limited to the following:  
• Excessively slow recruitment  
• Poor protocol adherence  
• Inaccurate or incomplete data recording  
• Good Clinical Practice (GCP) noncomplianc e 
• Study activity is completed (ie, all patients have completed, and all obligations have  
been fulfilled)  
Version .[ADDRESS_731197] meet all the following criteria:  
1. Able to provide written informed consent and can understand and agree to comply with 
the requirements of the study and the schedule of assessments  
2. Age ≥  18 years (or the legal age of consent in the jurisdiction in which the study is taking 
place)  on the day of signing the informed consent form  
3. Patient has pathologically (histologically or cytologically) proven diagnosis of small cell 
lung cancer  
4. Has limited -stage disease (stage Tx, T1 -T4, N0 -3, M0; AJCC staging, 8th edition), and 
can be safely treated with definitive radiation doses . Note: Patients with stage T3 -[ADDRESS_731198] tumor/nodal 
volume that is too large to be encompassed in a tolerable radiation plan are ineligible  
5. Patient has not received  any prior treatment  for LS-SCLC  
6. Patient  has measurable disease  as assessed according to  RECIST v1.1  that is appropriate 
for selection as a target lesion for r epeat measurement, as determined by [CONTACT_509014]/radiology review  
7. Patients must agree to provide  an archival tumor tissue with an associated pathology 
report  or agree to perform a fresh tumor biopsy during screening  (formalin -fixed 
paraffin -embedded block or approximately 15 unstained slides [8 slides minimum ]) 
Note:  If < 8 unstained slides are available, a discussion with the sponsor is required  
8. ECOG Performance Status ≤  [ADDRESS_731199] a life expectancy of ≥  12 weeks  
10. Adequate organ function as indicated by [CONTACT_556787]  7 days before  randomization:  
a. Absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, hemo globin 
≥ 90 g/L. Note: Patients must not have undergone a blood transfusion or received 
growth factor support ≤ 14 days before sample collection at screening  
b. International normalized ratio or prothrombin time  ≤ 1.[ADDRESS_731200]  
c. Activated partial thromboplastin ti me (aPTT) ≤ 1.[ADDRESS_731201]  
d. Serum total bilirubin ≤ 1.[ADDRESS_731202] (total bilirubin must be < [ADDRESS_731203] for patients  
with Gilbert ’s syndrome)  
e. AST  and ALT ≤ 2.[ADDRESS_731204]  
f. Calculated creatinine clearance (CrCl ) ≥ 45 mL/min (Cockcroft -Gault formula) 
(Appendix  12) 
Version .[ADDRESS_731205] be willing to use a highly effective method of 
birth control for the duration of the study ; and fo r ≥ [ADDRESS_731206] dose of 
ociperlimab  and tislelizumab  in Arm A  or tislelizumab in Arm B , or ≥ [ADDRESS_731207] dose of radiotherapy or chemotherapy  (except for cisplatin ), or ≥ [ADDRESS_731208] dose of cisplatin , whichever occurs later; and have a negative urine or serum 
pregnancy test ≤ [ADDRESS_731209] be willing to use a highly effective method of birth control for the 
duration of the study ; and for ≥  [ADDRESS_731210] dose of ociperlimab and 
tislelizumab  in Arm  A or tislelizumab in Arm B , or ≥ [ADDRESS_731211] dose  of 
radiotherapy or chemotherapy  (except for cisplatin ), or ≥ [ADDRESS_731212] dose of 
cisplatin , whichever occurs later.  
• A sterile male is defined as one for whom azoospermia has been previously 
demonstrated in a semen sample examination as definitive evidence of infertility.  
• Males with know n “low sperm counts” (consistent with “sub -fertility”) are not to be 
considered sterile for purposes of this study.  
4.2. Exclusion Criteria  
Patients who meet any of the following criteria are not eligible to enroll:  
1. Mixed small cell  lung cancer  histology . Note:  mixed SCLC with the component of 
neuroendocrine carcinoma origin is considered eligible  
2. Have received  surgical resection for LS -SCLC  
3. Any patient for whom the tumor is considered resectable by [CONTACT_556788] /stereotactic ablative radiotherapy  should be considered ineligible  
4. Is expected to require any other form of antineoplastic therapy while on study.  
5. Prior therapy with an anti -PD-1, anti -PD-L1, anti -PD-L2, anti -TIGIT,  or any other 
antibody or drug specifically targeting T-cell costimulation or checkpoint pathways  
6. Receipt of interleukin, interferon, thymosin , or any investigational therapi[INVESTIGATOR_6523] 
14 days or 5  half-lives (whichever is longer) before randomization  
7. Patient’s radiation treatment plans are likely to encompass  a volume of whole lung 
receiving ≥  20 Gy in total (V20) of > 38% of lung volume. Prior tangent fields for breast 
cancer with minimal overlap with target volumes are allowed per approval of the 
principal investigators  
8. Active autoimmune diseases or history of autoimmune diseases that may relapse  
Note: Patients with the following diseases are not excluded and may proceed to further 
screening:  
a. Controlled type I diabetes  
b. Hypothyroidism (provided it is managed with hormone replacement therapy only)  
c. Controlled celiac disease  
d. Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia)  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 56 e. Any other disease that is not expected to recur in the absence of external triggering 
factors  
9. Any active malignancy ≤  2 years before randomization except for the specific cancer 
under investigation in this study and any locally recurring cancer that has been treated 
curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, 
carcinoma in situ of the cervix or breast)  
10. Any condition t hat required systemic treatment with either corticosteroids (>  10 mg daily 
of prednisone or equivalent) or other immunosuppressive medication ≤  14 days before  
randomization  
Note: Patients who are currently or have previously been on any of the following st eroid 
regimens are not excluded:  
a. Adrenal replacement steroid (dose ≤  10 mg daily of prednisone or equivalent)  
b. Topi[INVESTIGATOR_2855], ocular, intra -articular, intranasal, or inhaled corticosteroid with minimal 
systemic absorption  
c. Short course (≤  7 days) of corticosteroid  prescribed prophylactically (eg, for contrast 
dye allergy) or for the treatment of a non -autoimmune condition (eg, delayed -type 
hypersensitivity reaction caused by [CONTACT_13132]  
11. Uncontrolled diabetes or >  Grade  [ADDRESS_731213] medical management or ≥ Grade 3 hypoalbuminemia 
≤ [ADDRESS_731214] 
undergo an assessment of pulmonary function at scr eening (see Section  7.1.5 ) 
13. Infection (including tuberculosis infection, etc) requiring systemic antibacterial, 
antifungal , or antiviral therapy withi n 14 days before randomization  
Note: Antiviral therapy is permitted for patients with hepatocellular carcinoma or chronic 
hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.  
14. Untreated chronic hepatitis B or chronic HBV carriers with HBV DNA >  500 IU/mL (or 
> 2500  copi[INVESTIGATOR_014]/mL) at screening  
Note: Inactive hepatitis B surface antigen (HBsAg) carriers  and those with  treated and 
stable hepatitis B (HBV DNA < 500 IU/mL or <  2500  copi[INVESTIGATOR_014]/mL) can be enrolled. 
Patients with detectable hepatitis B surface antigen (HBsAg) or detectable HBV DNA 
should be managed per treatment guidelines. Patients receiving antiviral  therapy  at 
screening should have been treated for >  2 weeks before randomization . 
15. Patients with active hepatitis C  
Note: Patients with a negative HCV antibody test at screening or a positive HCV 
antibody test followed by a negative HCV RNA test at screening are eli gible. The HCV 
RNA test will be performed only for patients testing positive for HCV antibody. Patients 
receiving antiviral  therapy  at screening should have been treated for >  2 weeks before 
randomization . 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 57 16. Known history of HIV infection  
17. Any major surgical procedure ≤  28 days before randomization  (except for placement of 
vascular access) . Patients must have recovered adequately from the toxicity and/or 
complications from the intervention before randomization  
18. Prior allogeneic stem cell transplantation or orga n transplantation  
19. Any of the following cardiovascular risk factors:  
a. Cardiac chest pain, defined as moderate pain that limits instrumental activities of 
daily living, ≤  28 days before randomization  
b. Pulmonary embolism ≤  28 days before randomization  
c. Any histo ry of acute myocardial infarction ≤ 6 months before randomization  
d. Any history of heart failure meeting [LOCATION_001] Heart Association Classification III 
or IV (Appendix  6) ≤ 6 months before randomization  
e. Any event of ventricular arrhythmia ≥  Grade  2 in severity ≤  6 months before 
randomization  
f. Any history of cerebrovascular accident ≤  [ADDRESS_731215] anti -hypertension 
medications ≤  28 days before randomization  
h. Any epi[INVESTIGATOR_397675] ≤  28 days before randomization  
20. A history of severe hypersensitivity reactions to other monoclonal antibodies  
21. A history of allergic reactions to cisplatin, carboplatin, other platinum -containing 
compounds, or etoposide.  
22. Patients with toxicities (as a result of prior anticancer therapy) which have not recovered 
to baseline or stabilized, except for AEs not consider ed a likely safety risk (eg, alopecia, 
neuropathy and specific laboratory abnormalities)  
23. Was administered a live vaccine ≤  28 days before randomization  
Note: Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. 
Intranasal vac cines are live vaccines and are not allowed.  
24. Underlying medical conditions (including laboratory abnormalities) or alcohol or drug 
abuse or dependence that will be unfavorable for the administration of study drug, or 
affect the explanation of drug toxicity  or AEs, or result in insufficient or impaired 
compliance with study conduct  
25. Women who are pregnant, breastfeeding, or planning to get pregnant during the study.  
26. Concurrent participation in another therapeutic clinical study  
 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 58 5. STUDY TREATMENT  
5.1. Formulation, P ackaging, and Handling  
5.1.1.  Ociperlimab  
Ociperlimab is a monoclonal antibody formulated for intravenous injection in a single -use vial 
(20 mL glass vial, USP Type I) containing a total of [ADDRESS_731216] be kept at the temperature condition as specified on the label. Shaking 
should be avoided.  
Refer to the pharmacy manual for details regarding intravenous administration, accountability, 
and disposal. Refer to the Ociperlimab (BGB -A1217) Investigator’s Brochure  for other details 
regarding ociperlimab.  
5.1.2.  Tislelizumab  
Tislelizumab is a monoclonal antibody formulated for intravenous injection in a single -use vial 
(20R glass, [LOCATION_002]  Pharmacopeia [USP] type I), containing a total of [ADDRESS_731217] be kept at the temperature condition as specified on the label.  Shaking 
should be avoided.  
Refer to the pharm acy manual for details regarding intravenous administration, accountability, 
and disposal. Please also refer to the Tislelizumab Investigator’s Brochure  for other details 
regarding tislelizumab.  
5.1.3.  Chemotherapy  
Management (ie, handling, storage, administration, and disposal) of cisplatin , carboplatin, and 
etoposide will be in accordance with the relevant local guidelines and/or prescribing 
information/summary of product characteristics.  
For further details, see the manufacturer’s prescribing information for the respective 
chemotherapeutic agents.  
5.2. Dosage, Administration, and Compliance  
Dosing schedules for all treatment arms, broken out by [CONTACT_397774], are provided in  Table  3. 
The first dose of study drug is to be administered within [ADDRESS_731218] dose of ociperlimab or tislelizumab . 
Ociperlimab and ti slelizumab and will be given starting from C1D1 in the cCRT phase and 
continued for a duration of up to 12 months after C1D1. During the cCRT phase, ociperlimab 
and tislelizumab should be administered before  chemotherapy;  in case the logistical 
circumstances do not allow for all of the intravenous study drug s (including ociperlimab, 
tislelizumab, and platinum -based doublet chemotherapy) to be administered on the same day , 
ociperlimab and tislelizumab administration on the same day should be guaranteed  and then 
chemotherapy should start as soon as possible within the following 3 days. For Arm C (cCRT 
only) , C1D1 is defined as the day of administration of the first dose of chemotherapy.  
All patients will be monitored continuo usly for AEs. Treatment modifications (eg, dose delay, 
reduction, interruption , or discontinuation) will be based on specific laboratory and AE criteria, 
as described in Section  5.5. 
Table  3: Planned Dose, Frequency of Administration, and Route of Administration 
for Study Drugs  
Study drug Dose  Frequency of 
administration  Route of 
administration  Duration of 
treatment  
Ociperli mab 900 mg  Day 1 of each cycle 
(3-week cycles ) Intravenous  See Section  3.3 
Tislelizu mab 200 mg  Day 1 of each cycle 
(3-week cycles ) Intravenous  See Section  3.3 
Cisplatin + 
Etoposide  
Cisplatin  75 mg/m2   
75 mg/m2: Day 1 of 
each cycle  
If the patient is 
unable to tolerate 
the 1-day 
administration of 
cisplatin 75 mg/m2, 
at the investigator’s 
discretion  cisplatin 
25 mg/m2 dosed on 
Days 1, 2 and 3 is 
allowed.  
(3-week cycles ) Intravenous  First 4 cycles  
Etoposide  100 mg/m2 Days 1, 2, and 3 of 
each cycle  
(3-week cycles ) Intravenous  First 4 cycles  
Carboplatin + 
Etoposide  Carboplatin  AUC 5  Day 1 of each cycle 
(3-week cycles ) Intravenous  First 4 cycles  
Etoposide  100 mg/m2 Days 1, 2, and 3 of 
each cycle  
(3-week cycles ) Intravenous  First 4 cycles  
Abbreviation: AUC, area under the plasma or serum concentration -time curve . 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 60 5.2.1.  Ociperlimab and Tislelizumab  
In Arm A, tislelizumab 200  mg followed by [CONTACT_556753] 900 mg will be administered on Day 1 
of each cycle (once every 3  weeks).  In Arm B  tislelizumab 200  mg will be administered on 
Day 1 of each cycle (once every 3  weeks) ,  
Ociperlimab and t islelizumab and will be administered by [CONTACT_556789] a sterile, non -pyrogenic, low -protein -binding 0.[ADDRESS_731219] preparation and administration are 
provided in the Pharmacy Manual.  
The initial 2 infusions for Arms A and B (Day 1 of Cycles 1 and 2) will be delivered over 
60 (± 5) minutes each for ociperlimab and tislelizumab ( Table  4); if these infusions are well 
tolerated, then the subsequent infusions may be administered over 30  (± 5) minutes, which is the 
shortest time period permissible for infusion. Ociperlimab and t islelizumab and must not be 
concurrently ad ministered with any other drug (refer to Section  6). 
Use of a volumetric pump is recommended to control the infusion speed and to avoid potential 
infusion reactions associated with too rapid administration. The pump may not be needed if the 
infusion speed is controlled through alternative means and consistent with approved institutional 
procedures.  
At the end of the infusion period, the line will be flushed with enough normal saline to make sure 
the complete doses of ociperlimab and tislelizumab are administered . 
As a routine precaution, after infusion of tislelizumab followed by [CONTACT_556753]  (Arm A) and 
tislelizumab (Arm B) on Day [ADDRESS_731220] be monitored in an area with 
resuscitation equipment and emergency agents for ≥  [ADDRESS_731221] s, a 
≥ 60-minute monitoring period in an area with resuscitation equipment and emergency agents is 
required ( Table  4). 
Guidelines for dose modification, treatment interruption, or discontinuation and for the 
management of imAEs and infusion -related reactions are provided in detail in Section  8.7 and 
Appendix  7. 
Refer to the Pharmacy Manual for detailed instructions on drug preparation, storage, and 
administration.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 61 Table  4: Administration of Ociperlimab and Tislel izumab and Monitoring Time  
Arm  Cycle  Ociperlimab in combination with t islelizumab or 
tislelizumab alone  a 
Arm A  Cycle 1 Day 1  Tislelizumab infusion over 60 (± 5) minutes followed by  
[CONTACT_556790] 60 (± 5) minutes  
Patient monitoring for ≥ 120 minutes  
Cycle 2 Day  1  Tislelizumab infusion over 60 (± 5) minutes followed by  
[CONTACT_556790] 60 (± 5) minutes  
Patient monitoring for ≥ 120 minutes  
Cycle 3 Day 1 
onwards  Tislelizumab infusion over 30 (± 5) minutes followed by  
[CONTACT_556790] 30 (± 5) minutes  
Patient monitoring for ≥ 60 minutes  
Arm B  Cycle 1 Day 1  Tislelizumab infusion over 60 (± 5) minutes  
Patient monitoring for ≥  120 minutes  
Cycle 2 Day 1  Tislelizumab infusion over 60 (± 5) minutes  
Patient monitoring for ≥  120 minutes  
Cycle 3 Day 1 
onwards  Tislelizumab infusion over 30 (± 5) minutes  
Patient monitoring for ≥  60 minutes  
a  There is no required monitoring period between tislelizumab infusion and ociperlimab infusion . 
5.2.2.  Chemotherapy  
[IP_ADDRESS].  Cisplatin  + Etoposide   
Cisplatin 75 mg/m2 will be administered on Day 1 for 4 cycles. If the patient is unable to tolerate 
the 1-day administration of cisplatin 75  mg/m2, at the investigator’s discretion  (eg, patients had 
concurrent superior vena cava syndrome) cisplatin 25  mg/m2 dosed on Days 1, 2, and 3 is 
allowed. Etoposide  100 mg/m2 will be administered on Days 1, 2, and [ADDRESS_731222] 4  
cycles by [CONTACT_5204].  
For cisplatin, all patients should receive adequate hydration (including pretreatm ent hydration) 
and diuretics. Urinary output >  [ADDRESS_731223] practice.  
If a patient is contraindicated for cisplatin , carboplatin plus etoposide is the alternative 
chemotherapy regimen. Also, patients will be allowed to switch from cisplatin to carboplatin if 
they exhibit intolerance to cisplatin after completing ≥ 1 cycle of cisp latin treatment 
(Section  [IP_ADDRESS] ). 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 62 Contraindication or intolerance to cisplatin is indicated if the patient has a history of allergy or 
hypersensitivit y to cisplatin, has had intolerable toxicity to cisplatin, has met Hy’s law criteria 
after receiving cisplatin -containing treatment, or has blood creatinine clearance <  60 mL/min.  
[IP_ADDRESS].  Carboplatin + Etoposide  
If patient s have contra indication or intolera nce to cisplatin, carboplatin will be used in the 
chemotherapy regimen  in place of cisplatin . 
Carboplatin at a dose of AUC 5 will be administered on Day 1 and etoposide 100 mg/m2 will be 
administered on Days 1, 2, and [ADDRESS_731224] 4 cycles by [CONTACT_160509].  
Carboplatin dose should be calculated before each dose using actual weight if the patient’s body 
weight changes by [CONTACT_726] 10% from baseline (or the newly referred body weight) and current  
serum creatinine level according to local prescri bing information and local practice.  
5.2.3.  Thoracic Radiation Therapy  
Before enrolling a patient in this study, the radiation oncologist will evaluate the thoracic  CT 
scan or MRI to ensure that the treatment volumes are unlikely to significantly exceed the  
specified normal tissue constraints and that it is feasible to administer the RT dose at the range as 
allowed  in the protocol  for a patient. A patient will be excluded if his/her radiation treatment 
plans are likely to  encompass a volume of the whole lung receiving ≥ 20 Gy in total (V20) of 
more than 38% of lung  volume.  All patients will receive RT using either a standardized 
3-dimensional conformal  RT technique or intensity -modulated radiotherapy or volumetric 
modulated  arc therapy on a linear accelerator delivering a beam energy of ≥ 6 MV.  
RT should start early  within cycle 1 or 2 of systemic therapy.  The total dose of RT will be 60 to 
70 Gy to the initial primary tumor target volume  and be delivered once daily over 6 to 7 weeks.  
While 60  to 70 Gy in 6  to 7 weeks is the target dose of radiation, concern about patient tolerance 
discovered during treatment planning or delivery, for example, a V20 exceeding that 
recommended in the protocol, may dictate that a lower dose be administered  after consulting  
with sponsor medical monitor . Definitive RT will be considered as receiving a minimum of 
56 Gy to the planning target volume (PTV) . 
Contouring of normal tissues and organs for radiotherapy planning will be in accordance with the 
NCCN  guideline  or local instit utional guidelines .  
[IP_ADDRESS].  Radiation Dose Specifications  
Patients will receive treatment  for 5 days per week, in once -daily fractions, to a target dose of 
60 to 70 Gy in 6  to 7 weeks. Normalization of the treatment plan will cover 95% of the PTV with 
the prescription dose. The minimum PTV dose should ideally not fall below 93% of the 
prescription dose. All radiation doses will be calculated with inhomogeneity corrections that t ake 
into account the density differences within the irradiated volume ( ie, air in the lung and bone). 
The maximum and minimum point doses (within the PTV) will be reported.  
For patients with LS -SCLC who experience tumor  shrinkage with chemotherapy, treati ng all 
involved nodal stations (at time of diagnosis) and post -chemotherapy lung parenchymal tumor is 
recommended.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 63 Organs at Risk  
Normal tissue constraints are prioritized in Table  5 for treatment planning.  
Table  5 Normal Tissue Dose -Volume Constraints for Conventionally Fractionated 
Radiation Therapy with Concurrent Chemotherapy  a 
Organ at risk   Constraints in 30 –[ADDRESS_731225]  Max ≤ 50 Gy  
Lung  V20 ≤  35%–40%b,c; MLD ≤  20 Gy  d 
Heart  V50 ≤  25%; Mean ≤  20 Gy  
Esophagus  Mean ≤  34 Gy; Max ≤105% of prescription dose; V60 ≤  17%; 
contralateral sparing is desirable  
Brachial plexus  Max ≤ 66 Gy 
Abbreviations: DLCO, diffusing capacity of the lung; ; FEV1, forced expi[INVESTIGATOR_3741] 1 second; Gy, Gray; max, 
maximum; MLD, mean lung dose ; NCCN, National Comprehensive Cancer Network; OAR, organ at risk; PFT, 
pulmonary function test  
a These constraints represent dose s that generally should not be exceeded, based on a consensus survey of NCCN 
Member Institutions. Because the risk of toxicity increases progressively with dose to normal tissues, a key principle 
of radiation treatment planning is to keep normal tissue dos es "as low as reasonably achievable" while adequately 
covering the target. The doses to any given organ at risk should typi[INVESTIGATOR_556693].  
b Use V20  < 35%, especially for the following: elderly ≥ 70 years, and poor PFTs (such as FEV1 or DLCO < 50% 
normal). Use more conservative limits with a diagnosis or radiologic evidence of idiopathic pulmonary fibrosis 
(IDP)/usual interstitial pneumonia (UIP) (the tolerance of these patients is lower though not well characterized).  
c Vxx = % of the whole OAR  receiving  ≥ xx Gy 
d MLD, being the volumes of both lungs minus the gross tumor volume  
[IP_ADDRESS].  Variations of Dose Prescription  
The variations in dose prescription are described below , and also summarized in Table  6 (NCCN 
2021 ). 
Per Protocol : ≥ 99% of the PTV receives at least 93% of the prescribed dose, and no volume 
≥ 1 cm3 within the PTV receives > 110% of the prescribed dose, and no more than a contiguous 
volume of 1 cm3 outside the PTV receives a maximum of 110% of the prescribed dose, and the 
percent volume of both lungs (excluding PTV) receiving a dose of 5 Gy or higher  (V5) is ≤ 60%.  
Variation Acceptable : Deviations of this magnitude are not desirable but are acceptable. 
Between < 99% but ≥ 95% of the PTV receives at least 93% of the prescribed dose, or a 
contiguous volume  of > 1 cm3 within the PTV receives >  110%  but ≤ 115%  of the  prescribed 
dose, or a contiguous volume of >1cm3 outside  the PTV receives >  110%  but ≤ 115%  of the  
prescribed dose, or V5 is > 60%  but ≤62%.  
Table  6: Summary of  Dose Prescription Variations  
 Per Protocol  Acceptable  Variation   
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 64 PTV  volume   coverage  ≥ 99%  of PTV  receives  
at least 93% of prescribed  dose ≥ 95% but < 99% of  PTV receives at 
least 93% of prescribed  dose 
Excessive  dose  within  
PTV  No contiguous volume  
> 1 cm3 within the  PTV  receives  > 
107%  of prescribed  dose > 1 cm3 contiguous  volume within PTV  
receives  > 107%  but 
≤ 110%  of prescribed  
dose 
Excessive  dose  outside  
PTV  No contiguous volume  
> 1 cm3 outside PTV  receives > 105% 
of prescribed  dose > 1 cm3 contiguous  volume outside 
PTV  receives  > 105%  but 
≤ 107%  of prescribed  
dose 
Spi[INVESTIGATOR_556694]  ≤ 50 Gy  50 Gy < Dmax ≤ 52 Gy  
Excessive  Lung  V5 ≤60%  V5 >  60% but ≤ 62% 
V5/V20  /mean  dose V20 ≤ 38% 
Mean  dose ≤ 20 Gy  
Heart  V50 ≤ 25% 
Mean  dose ≤ 20 Gy 25% <  V50 ≤ 33% 
20 Gy < Mean dose  ≤22Gy  
Esophagus  Mean  dose ≤ 34 Gy 
Dmax ≤105% of prescription dose; V60 
≤ 17%;  
contralateral sparing is desirable  34 Gy  < Mean dose  ≤ 36 Gy  
V60 ≤ 1 9%; 
contralateral sparing is desirable  
Brachial  Plexus  Dmax ≤ 66 Gy  Dmax ≤ 68 Gy  
Abbreviations: Dmax, Maximum dose; Gy, Gray ; PTV, planning target volume; Vxx, perce ntage of the whole organ 
at risk  receiving ≥  xx Gy  
[IP_ADDRESS].  Localization, Simulation, and Immobilization  
Each patient will be positioned in an institution -specific immobilization device in the treatme nt 
position on a flat table. All planning CT scans should be performed in the treatment position 
using the same immobilization device for setup as is used at the linear accelerator. Optimal 
immobilization is critical for this protocol in order to ensure re producibility of the daily setup. 
Either a conventional (non -4D CT) treatment planning CT study or a 4 -dimensional computed 
tomography (4DCT) will be performed. Conventional CT scans will be performed during quiet, 
uncoached respi[INVESTIGATOR_556695] u ndertakes a normal respi[INVESTIGATOR_1516], using at least 5 -mm 
slices through the entire target volume. The whole thorax (cricoid to L2) should be covered using 
< [ADDRESS_731226], hear t, and esophagus. A treatment planning FDG -PET/CT scan (or FDG -PET alone) with 
the patient in the treatment position can be used for treatment planning. Where a PET/CT is 
obtained in the treatment position, the CT from this study may be used as the plannin g CT scan.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 65 The gross tumor volume (GTV), internal target volume (ITV) and PTV will be defined on all 
appropriate slices (see definitions in Section [IP_ADDRESS]  ). Intravenous contrast  (if no 
contraindication exists)  during the planning CT is optional, provided that a recent diagnostic 
chest CT was done with contrast to delineate the major blood vesse ls. If not, intravenous contrast 
can be administered during the planning CT, if this is considered necessary in the view of the 
radiation oncologist. If contrast is used, the densities can be overridden or the contrast scan could 
be registered to a non -contrast scan for planning purposes. Acceptable methods of accounting for 
tumor motion include design of the PTV to cover the excursion of the lung primary cancer and 
nodes during breathing such as an ITV approach, breath -holds (eg, Eleckta ABC device), or 
respi[INVESTIGATOR_125344] (for example, Varian RPM system).  
During patient treatment, daily image guided radiation therapy (IGRT) using orthogonal X -ray, 
cone beam CT, CT on rails, or MR guidance must be used for all patients, regardless of radiation 
techniques. Da ily image guidance that allows for 3D shifts is the minimum requirement for this 
trial. Most advanced imaging techniques can be utilized as long as they also allow for 3D shifts. 
The setup margin in this trial is tied to the use of daily image guidance. Re gistering anatomy 
using soft tissue will be most effective for localization. Other soft tissues in the lung such as the 
carina can help for mediastinal alignment. Fiducial markers can be used for localization as 
needed. Any linear shifts seen that are ≥2 mm should be applied prior to treatment.  
[IP_ADDRESS].  Radiation Treatment Planning  
Three -Dimensional Conformal Radiotherapy (3DCRT)  
The PTV is to be treated with any combination of coplanar or noncoplanar 3D conformal fields 
shaped to deliver the specified dose while re stricting the dose to the normal tissues. The 
treatment plan used for each patient will be based on an analysis of the volumetric dose, 
including dose -volume histogram analyses of the PTV and critical normal structures. Each field 
is to be treated daily.  
Intensity Modulated Radiation Therapy (IMRT)  
The use of IMRT is recommended, provided that the institution has been using this technique for 
treating lung cancer for at least 6 months before study activations, as IMRT results in a greater 
proportion of out of target lung receiving radiation outside the PTV.  
Detailed Specification  
Target volumes : the definitions of volumes will be in accordance with the ICRU 50 (1999) for 
3DCRT and ICRU 83 (2010) for IMRT.  
GTV : The primary tumor and clinically positive lymph nodes seen on the planning CT (> 1 cm 
short axis diameter) or pre -treatment PET scan (SUV > 3) will constitute the GTV. This 
volume(s) may be disjointed. In the event of a collapsed lobe or lung segment, the use of PET to 
distinguish tumor from fluid/atele ctasis is encouraged.  
CTV : The CTV is defined to be the GTV plus a 0.5 cm margin as appropriate to account for 
microscopic tumor extension. The CTV should be adjusted to not expand into other organs such 
as esophagus, heart, major blood vessels, or bone un less clinically indicated. If an ITV approach 
is used , then the ITV plus 0.5 cm margin forms the CTV.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 66 PTV : The PTV will be equal to the CTV plus 0.5 cm setup margin in all directions.  
5.2.4.  Prophylactic cranial irradiation (PCI)  
For patients with stage II -III LS -SCLC who are less than 70 years of age with good performance 
status (ECOG 0 to 2), without impaired neurocognitive function, and attain a complete or partial 
response to initial systemic therapy, PCI is  recommend ed.  
The preferred dose for PCI to the whole brain is 25 Gy in 10 daily fractions. The decision for 
PCI administration should be made according to investigator’s discretion and local institutional 
guidelines.  
Only standard prophylactic whole brain radiation therapy  is allowed in the trial. Memantine may 
be used for prevention of brain irradiation -induced cognitive toxicity at the investigator’s 
discretion.   
During the PCI treatment period (about 2 weeks), the immunotherapy, including tislelizumab 
monotherapy and the  combination of ociperlimab plus tislelizumab, will be temporarily 
suspended.  
5.3. Incorrect Administration or Overdose  
Any incorrect administration of any study drug or overdose of tislelizumab (defined as ≥  600 mg 
in a 24 -hour period) , ociperlimab , cisplatin,  carbopla tin, or etoposide  should be noted in the 
patient’s chart and on the appropriate eCRF.  
AEs associated with an overdose or incorrect administration of study drug will be recorded on 
the AE eCRF. Any SAEs associated with an overdose or incorrect admi nistration must  be 
reported within [ADDRESS_731227] Accountability  
The investigational medicinal products (IMPs) required for completion of this study 
(ociperlimab, tislelizumab , cisplatin, carboplatin,  and etoposide ) will be provided by [CONTACT_556791] , as required by [CONTACT_556792] -specific 
guidance. The investigational site will acknowledge rece ipt of IMPs. Any damaged shipments 
will be replaced.  
Accurate records of all IMP s received, dispensed, returned, and disposed of should be recorded 
on the site’s Drug Inventory Log. Refer to the Pharmacy Manual for details of IMP management.  
5.5. Dose Delay or Modification  
A dose delay is a deviation from prescribed dosing schedule (ie, the drug is withheld beyond 
visit window). A dose interruption is an interruption of an infusion.  
Every effort should be made to administer the study drug(s) according to the pla nned dose and 
schedule. In the event of significant toxicities, dosing may be delayed and/or reduced based on 
the guidelines below. Reasons for dose modifications or delays, the supportive measures taken, 
and the outcome will be documented in the patient's  chart and recorded in the eCRF.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 67 The dose modification guidelines in this section are not intended to be a substitute for clinical 
judgment. Investigators may delay or modify doses for other reasons (eg, AEs, declining weight, 
laboratory findings) as appro priate.  
5.5.1.  Dose Delay or Modification for Ociperlimab or Tislelizumab  
There will be no dose reduction for ociperlimab or tislelizumab  in this study.  
If a dose delay is required, ociperlimab and tislelizumab will be delayed for Arm A (ie, 
ociperlimab and tisle lizumab must both be delayed in Arm A and, if applicable, restarted at the 
same time) and tislelizumab will  be delayed in Arm B .  
Ociperlimab and tislelizumab in Arm A or tislelizumab  in Arm B may be temporarily suspended 
if the patient experiences a toxicity that is considered related to ociperlimab or tislelizumab  and 
requires a dose to be withheld. Investigational drug(s)  should resume as soon as possible after the 
AEs recover to baseline or Grade 1 , whichever is more severe , except for AEs that, in the 
opi[INVESTIGATOR_871], are not considered a safety risk to the patient. If a treatment delay is 
due to laboratory results worsening, eg, hematologic or biochemical parameters, the frequen cy of 
relevant blood tests should be increased as clinically indicated.  
In general, dose delays for reasons other than management of AEs are prohibited. A dose delay 
of ≤ [ADDRESS_731228] igator 
after consultation with the medical monitor or designee.  
If the administration of the study drug (s) can resume within ≤  10 days, the drug(s) should be 
administered in the current cycle. If the study drug needs to be withheld for >  10 days, it should  
be omitted from the current cycle and administration should continue at the start of the next 
cycle. If the patient is unable to resume ociperlimab plus tislelizumab or tislelizumab alone 
≤ [ADDRESS_731229] dose of study treatment , then the patient should be discontinued from 
treatment. If the patient is not able to resume ociperlimab plus tislelizumab or tislelizumab alone 
≤ [ADDRESS_731230] dose for unforeseen non -drug-related reasons, continued treatment may 
be allowed if  approved by [CONTACT_7195].  
If imAEs are persistent without any improvement for >[ADDRESS_731231] 4 cycles of 
treatment for reasons other than disease progression,  the other component of chemotherapy may 
be continued per the guidelines in the study protocol and as per local practice. Ociperlimab plus 
tislelizumab (Arm A) or tislelizumab alone  (Arm B) may continue as indicated.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 68 If both components of the chemotherapy are withheld because of toxicity for > 6 we eks, 
chemotherapy should be discontinued; ociperlimab plus tislelizumab or tislelizumab alone may 
be continued if the toxicity resulting in chemotherapy discontinuation is not considered by [CONTACT_556793] . Exceptions 
based on clinical benefit require the prior approval of the medical monitor.  
Specific treatment modifications to manage tislelizumab - or ociperlimab -related toxicities, such 
as imAEs and infusion -related reactions, are described in Section  8.7.1  and Appendix  7.  
5.5.2.  Dose Delay, Interruption , or Modifications for Radi ation T herapy  
Investigators will be advised to suspend the use of chemotherapy and/or ociperlimab plus 
tislelizumab or tislelizumab alone given with RT if they believe that continuing administration of 
chemotherapy  and/or ociperlimab plus tislelizumab or tislelizumab alone will compromise 
delivery of full -dose RT in a timely manner.  
Reversible or permanent alopecia, bone marrow toxicity, esophagitis , and skin pi[INVESTIGATOR_556696]. Radiation -induced myocarditis and sp inal cord injury rarely occur at 
doses lower than 50 Gy. Radiographic evidence of radiation -induced changes and subsequent 
fibrosis of the lung may occur within lung volumes receiving ≥ [ADDRESS_731232] er to avoid symptomatic lung injury.  
• In case of radiation dose delay due to machine breakdown or public holidays or any 
dose delay of RT up to 7 days, radiation should be completed to the prescribed doses. 
Total number of fractions and elapsed days should be carefully reported.  
• During the cCRT phase, esophagitis is managed according to Appendix  [ADDRESS_731233] to RT. During this cCRT period, chemotherapi[INVESTIGATOR_34497]/or 
ociperlimab plus tislelizumab or tislelizumab alone should be withheld if the  
investigator believes that continued use will jeopardize the delivery of full -dose RT  
and RT is to be continued. Retreatment with chemotherapi[INVESTIGATOR_13265]/or ociperlimab plus 
tislelizumab or tislelizumab alone is permitted if there is resolution of the esophagitis  
to ≤ Grade 2.  
• If Grade 4 esophagitis relate d to RT, chemotherapi[INVESTIGATOR_014], or ociperlimab plus 
tislelizumab or tislelizumab alone occurs, RT, chemotherapi[INVESTIGATOR_014], and/or ociperlimab 
plus tislelizumab or tislelizumab alone  should be held until resolution of the 
esophagitis to ≤  Grade  2. 
• During the cCRT phase, i n case of Grade 3 or Grade 4 radiation pneumonitis/lung 
infiltrates related to RT, the recommendation is to hold RT, chemotherapi[INVESTIGATOR_556697] . Retreatment with RT, 
chemotherapi[INVESTIGATOR_556698] ≤ Grade 1 or are controlled on prednisolone ≤  10 mg/day (or 
equivalent corticosteroids). Discontinue study treatment if symptoms persist with 
corticosteroid treatment.  
Radiation toxicities will be assessed according to NCI-CTCAE v5.[ADDRESS_731234] fractionated RT  (Wei et al 2006 ), and 
include a sensation of difficult swallowing (dysphagia). This may progress to painful swallowing 
of food and saliva (odynophagia) and later to constant pain not necessarily related to swallowing.  
In sev ere cases, patients may not be able to swallow at all and may require intravenous  
hydration, feeding through a gastric tube and, in rare cases, parenteral nutrition.  Symptomatic 
esophagitis is common with combined modality therapy  (Werner -Wasik 2005 ) and it does not 
constitute a reason to delay RT or chemotherapy, provided oral intake is  sufficient to maintain 
hydration. Symptoms of acute esophagitis may persist for [ADDRESS_731235] their treatment dose delayed in order to allow for healing of the esophageal mucosa.  
Recommended dose modifications of the chemotherapy regimens in cases of Grade 3 or 4 
esophagitis  are presented in Appendix  13. 
Information regarding e sophagitis grading according to NCI-CTCAE v5.0  and management of 
radiation esophagitis throu gh diet and medications is presented i n Appendix  14. 
Pneumonitis  
Pneumonitis has been reported in association with use of anti -PD-L1/anti -PD-1 antibod ies. It is 
also seen in 5% to 15% of patients irradiated for breast, lung, and mediastinal tumors. Thus, 
pneumonitis may be immune -related or as a result of late toxicity to RT. The risk of developi[INVESTIGATOR_556699], the amount of radiation 
given, and the use of cCRT. Additional risk factors include comorbid lung disease, poor baseline 
pulmonary function testing, and low performance status.  
Symptoms of radiation pneumonitis, including low -grade fe ver, congestion, dry cough, pleuritic 
chest pain, and a sensation of chest fullness, usually develop 1 to 3 months after completion of 
RT. Diagnosis is difficult, often complicated by [CONTACT_556794] (eg, esophagus, pericardium). Prednisone, in dosages of at least 50 to 60  mg 
per day for 1 week followed by [CONTACT_556795], has been shown to abate symptoms and 
improve lung function. Bronchodilators and supplemental oxygen may be necessary.  
5.5.3.  Dose Delay, Inte rruption , or Modifications for Chemotherapy  
Dose modifications for chemotherapy should be performed per applicable local prescribing 
information and per local practice according to the investigator’s clinical judgment.  
Recommended dose modifications for ke y chemotherapy toxicities are outlined in  Appendix  13. 
If chemotherapy -related toxicities warrant a dosing delay, chemotherapy administration may 
restart as soon as is feasible. Chemotherapy may be dela yed up to [ADDRESS_731236] investigator judgment and applicable local label 
recommendations if more stringent.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 70 Baseline body weight is used to calculate the required chemotherapy doses. Dose modifications 
are required if the patient’s body weight changes by ≥  10% from baseline (or the new reference 
body weight). Chemotherapy doses should not be modified for any body weight change of 
˂ 10%.  
Reduction of one chemotherap y agent and not the other agent is appropriate if, in the opi[INVESTIGATOR_13046], the toxicity is clearly related to one of the treatments. If, in the opi[INVESTIGATOR_1070], the toxicity is related to the combination of both chemotherapy agents,  both drugs 
should be held/modified according to recommended dose modifications.  
Study drug -related toxicities must be resolved to baseline or Grade  1 (whichever is more severe) 
before  administering the next dose, except for alopecia or ≤  Grade  [ADDRESS_731237] be discontinued.  
The interval between the start of 2 consecutive chemotherapy regimens should b e ≥ 3 weeks. If 
chemotherapy -related toxicities warrant a dosing delay, chemotherapy administration may restart 
as soon as is feasible. For example, chemotherapy administration can occur during an 
unscheduled visit and resynchronize with ociperlimab plus tislelizumab or tislelizumab alone at 
subsequent cycle(s), if possible. Dosing intervals of subsequent cycles of ociperlimab plus 
tislelizumab or tislelizumab alone may be shortened or extended as clinically feasible to allow 
for resynchronization, but the time between [ADDRESS_731238] 10  days. If clinically appropriate, the investigator may 
delay all treatment components up to a maximum of 7  days to allow synchronized administratio n 
of all agents and realigned dosing of treatment cycles according to the original schedule.  
If the patient is unable to resume chemotherapy treatment ≤  [ADDRESS_731239] dose of 
chemotherapy, then the patient should be discontinued from treatment. If  the patient is not able 
to resume chemotherapy ≤  [ADDRESS_731240] dose because of unforeseen non -drug-related 
reasons, continued treatment may be allowed if approved by [CONTACT_7195].  
SELECTED PRECAUTIONS  FOR CHEMOTHERAPY : 
• Neutropenia: Fever o r other evidence of infection must be assessed promptly and treated 
aggressively following the local clinical practice and/or the guidelines.  
• Renal Toxicity:  
o Nephrotoxicity is common with cisplatin. Encourage oral hydration.  Avoid 
nephrotoxic drugs such as aminoglycoside antibiotics.  
o Patients should not be given cisplatin or carboplatin if their creatinine clearance is 
< 60 mL/min or < 45 mL/min, respectively.  
o Etoposide dosage should be reduced to 75% of dose in patients with a creatinine 
clearance from 1 5 to 50 mL/min .  
o Patients will be allowed to switch from cisplatin to carboplatin if patients become 
ineligible for cisplatin due to toxicity related to cisplatin if they have completed 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 71 ≥ 1 cycle of cisplatin treatment. Reasons for platinum switch should b e documented 
in source documents and eCRF.  
• Ototoxicity and sensory neural damage should be assessed before  each cycle. Cisplatin is 
contraindicated in patients with a preexisting hearing deficit.  
For toxicities not listed above, dose modifications are perm itted per local standards.  
5.5.4.  Criteria for Discontinuing Chemotherapy Regimens  
Except where specified above, both chemotherapy drugs in the platinum -based doublet regimen 
should be discontinued for any of the following:  
• Any Grade 4 peripheral neuropathy  
• Persi stent Grade 3 paresthesia  
• Grade 3 or 4 drug -related thrombocytopenia associated with clinically significant 
bleeding  
• Any drug -related liver function test abnormality value that meets any of the following 
criteria requires discontinuation:  
− AST or ALT > [ADDRESS_731241] for > 2 weeks  
− AST or ALT > [ADDRESS_731242] or  
− Total bilirubin > [ADDRESS_731243] or  
− Concurrent AST or ALT > [ADDRESS_731244] and total bilirubin > [ADDRESS_731245]  
• Any drug -related AE that recurs after 2 prior dose reductions  (1 dose reduction for 
carboplatin)  for the same drug -related AE requires discontinuation of the drug(s).  
• Any Grade 3 or 4 drug -related hypersensitivity reaction or infusion reaction requires 
discontinuation of the drug(s) assessed to be causing the reaction. The drug assessed 
as not relate d to the hypersensitivity reaction or infusion reaction may be continued.  
• Any Grade 4 AE that the investigator considers related to study drug and 
inappropriate to be managed by [CONTACT_29874](s) requires discontinuation of drug(s). 
The drug not assessed t o be related to the event may be continued.  
• If any significant toxicity does not resolve within 21 days, that component will be 
discontinued.  
For toxicities not listed above, the investigator would determine whether the chemotherapy 
regimen should be disc ontinued per clinical judgment, patient’s well -being, and local standards.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 72 6. PRIOR AND CONCOMITAN T THERAPY  
6.1. Prior Therapy  
The eligibility criteria (Section  4) specify that patients should not have received any prior 
treatment for LS -SCLC; prior therapi[INVESTIGATOR_107900] -1, PD -L1, PD -L2, TIGIT, T -cell 
costimulation or checkpoint pathways; immunotherapy (eg, interleukin, interferon, or thymosin); 
or investigational therapy ≤ 14 days or 5 half -lives (whichever is longer) before randomizatio n. 
6.2. Concomitant Therapy  
6.2.1.  Permitted Concomitant Medications/Procedures  
Unless otherwise noted, m ost concomitant medications and therapi[INVESTIGATOR_556700] (eg, antiemetics, antidiarrheals) and in a patient’s interest are allowed. Opi[INVESTIGATOR_556701]. Patients must notify the 
investigator of all concurrent medications used during the st udy. 
All concomitant medication s will be recorded on the eCRF including all prescription  and 
over-the-counter  medications , herbal  supplements, and intravenous medications and fluids.  
[IP_ADDRESS].  Systemic Corticosteroids  
Systemic corticosteroids given for the control of imAEs must be tapered gradually (see 
Appendix  7) and given  at nonimmunosuppressive doses (≤  10 mg/day of prednisone or 
equivalent) before the next  administration of  ociperlimab plus tislelizumab or tislelizumab alone . 
The short -term use of steroids as prophylactic treatments (eg, for patients with contrast allergies 
to diagnostic imaging contrast dyes) is permitted.  
[IP_ADDRESS].  Hepatitis B Treatment  
Patients with active hepatitis B, defined as HBV DNA ≥ 500 IU/mL at screening, must initiate 
treatment [ADDRESS_731246] dose of study 
drug(s). Patients should continue effective antiviral treatment dur ing the study to decrease 
potential viral re -activation risk. Tenofovir and entecavir are recommended in the American 
Association for the Study of Liver Disease (AASLD) guideline because patients are unlikely to 
develop  resistance to these drugs with long -term use ( Terrault et al 2016 ; AASLD/IDSA HCV 
Guidance Panel 2015 ). The investigator may approve the use of other antiviral agents, if 
appropriate, following local guidelines. However, interferon -based therapy for hepatitis B is not 
permitted on study.  
Management of prophylactic antiviral therapy for patients with inactive, treated, and stable 
hepatitis B (HBV DNA <  500 IU/mL) is at the discretion of the investigator, in accordance  with 
local guidance. Such medications must be documented in the patient’s chart and recorded in the 
eCRF. Patients receiving antiviral  therapy  at screening should be treated for >  2 weeks before 
randomization  and continue treatment during the study and for 6  months after study treatment 
discontinuation.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 73 [IP_ADDRESS].  Hepatitis C Treatment  
Patients who are receiving treatment for hepatitis C at screening should remain on continuous, 
effective antiviral therapy during the study. Investigators can consider treatment with sofosbuvir 
alone or in combination with other antivirals following the AASLD guideline or local guidelines 
as appropriate. How ever, interferon -based therapy for HCV is not permitted on study. Patients 
who are given antiviral therapy must initiate treatment >  2 weeks before randomization . 
6.2.2.  Prohibited Concomitant Medications/Procedures  
Live vaccines ≤  28 days before randomization an d ≤ [ADDRESS_731247] dose of study drug(s) 
are prohibited.  
The following medications are prohibited during screening , through the EOT Visit or disease 
progressio n, whichever occurs later :  
• Any concurrent anticancer therapy, including chemotherapy, ho rmonal therapy, 
immunotherapy, standard anticancer agents, or investigational anticancer agents  
• Any investigational anticancer therapy  
• Herbal remedies for the treatment of cancer or Chinese patent medicines with 
approval from the China National Medical Pro ducts Administration (NMPA) f or use 
as anticancer treatment (regardless of cancer type)   
• Herbal remedies with immune -stimulating properties (eg, mistletoe extract) or that 
are known to potentially interfere with liver or other major organ functions (eg, 
hypericin)   
Patients must notify the investigator of all herbal remedies used during the study . 
6.2.3.  Restricted Concomitant Medications/Procedures  
The following medications are restricted during screening and through the EOT Visit : 
• Immunosuppressive agents (except to treat a drug -related AE)  
• Systemic corticosteroids >  10 mg daily (prednisone or equivalent), except to treat or 
control a drug -related AE (per protocol) or for short -term use as prophylactic 
treatment . In addition, use of inhaled and intranasal c orticosteroids is permitted  
• Patients should not abuse alcohol or other drugs during the study  
• Use of potentially hepatotoxic drugs in patients with impaired hepatic function should 
be carefully monitored  
6.3. Potential Interactions Between Study Drugs and Concomitant 
Medications  
Information regarding clinical drug interactions with ociperlimab  is not available and no 
dedicated drug -drug interaction studies are planned. However, the  potential for drug -drug 
interaction between the study drugs ( ociperlimab  and tislelizumab)  and small molecule drug 
products is very low  because ociperlimab  and tislelizumab are therapeutic monoclonal 
Version .[ADDRESS_731248] values (that must be 
available before any dosing) have been reviewed and found to be acceptable per protocol 
guidelines.  
7.1. Screening  
Screening evaluations will be performed within [ADDRESS_731249] day a screening procedure is conducted. Screening evaluations may be 
repeated as needed within the screening period; the  investigator is to assess patient eligibility 
according to the latest screening assessment results.  
Results of standard -of-care tests or examinations performed before  obtaining informed consent 
and ≤  [ADDRESS_731250] (refer 
to Appendix  1 for details)  based upon the treatment physician’s judgement.  For the description 
of other assessments that are conducted during screening, as well as throughout the study, refer 
to Safety Assessments (Section  7.4), Tumor and Response Evaluations (Section  7.5) and 
Biomarkers (Section  7.7) sections.  The PK sampling schedule is shown in Appendix  1. 
Rescreening under limited conditions may be allowed after consultation with the sponsor , eg, 
when a patient narrowly misses a laboratory criterion and it is correctable and not due to rapi[INVESTIGATOR_556702]. Rescreening is allowed only once.  
7.1.1.  Informed Consent and Screening Log  
Voluntary, written informed consent for participation in the study must be obtained before 
performing any study -specific procedures. Informed consent forms for enrolled patients and for 
patients who are screened but not enrolled will be maintained at the study site.  
All screening evaluations must be completed and reviewed to confirm that patients meet all 
eligibility criteria before randomization. The investigator will maintain a scr eening log to record 
details of all patients screened and to confirm eligibility or record reasons for screening failure, 
as applicable.  
7.1.2.  Patient Numbering  
After obtaining informed consent, study site personnel will access the Interactive Response 
Technolog y (IRT) system to assign a unique patient number to each potential study participant.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 76 7.1.3.  Demographic Data and Medical History  
Demographic data will include age or year of birth, sex, and self -reported race/ethnicity.  
Medical history includes any history of c linically significant disease, surgery, or cancer; 
reproductive status (ie, of childbearing potential or no childbearing potential); history of alcohol 
consumption and tobacco (ie, former or current or never); and all medications (eg, prescription 
drugs, o ver-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by 
[CONTACT_25701] [ADDRESS_731251] response, and reason for discontinuation. Data from 
radiographic studies performed before study entry may be collected for review by [CONTACT_1275].  
Preexisting AEs at baseline should be recorded as medical history . 
7.1.4.  Female  Patients  of Childbe aring Potential and Contraception  
Childbearing potential is defined as the physiological ability to  becom e pregnant. Refer to 
Appendix  9 for contrac eption guidelines and definitions of “women of childbearing potential” 
and “no childbearing potential.”  
A urine or serum pregnancy test (for women of childbearing potential, including women who 
have had a tubal ligation) must be performed and documented as  negative within [ADDRESS_731252] and with exercise, or alternatively, assessment of diffusion capacity, are to 
be performed as clinically indicated  (eg, patient is having sy mptoms of lung problems or has 
medical history of chronic lung disease) during the Screening Period to assist the determination 
of suitability on the study. Respective test results need to be submitted to the sponsor.  
For test results indicative of significantly impaired pulmonary function, eg, resting pulse 
oximetry <  90% on room air and further desaturation upon exercise, forced expi[INVESTIGATOR_12194] 
(FEV1) <  60% or diffusing capacity of the lungs for carbon monoxide ( DLCO ) (if performed) 
< 60% of age - and sex -adjusted predicted performance levels ( Pellegrino et al 2005 ), the medical 
monitor needs to be consulted to confirm eligibility.  
Tests may be repeated as clinically indicated while on study.  
7.2. Enrollment  
7.2.1.  Confi rmation of Eligibility  
The investigator is responsible for ensuring that each patient meets the eligibility criteria for this 
study. The investigator will assess and confirm the eligibility of each patient. All results from the 
screening procedures and rel evant medical history must be available before eligibility can be 
Version .[ADDRESS_731253] be met and none of the exclusion criteria may be met. No 
eligibility waivers will be granted.  
After a patient is screened and the investigator determ ines that the patient is eligible, study site 
personnel will complete the Treatment Eligibility Form (TEF) by [CONTACT_556796]/exclusion criteria, significant medical history, concomitant medications, disease 
history, pathology diagnos is, information from relevant imaging reports (as applicable), prior 
anticancer therapi[INVESTIGATOR_556703].  
To confirm eligibility, the TEF will be sent by [CONTACT_556797], via 
secure  transmission, for review during the screening period. Per the patient 
privacy/confidentiality provisions in this protocol, the TEF should be coded with the patient ’s 
screening ID number to protect the  patient ’s personal data in accordance with local laws and 
regulations and BeiGene requirements (eg, direct identifiers such as names, initials and full date 
of birth should never be shared, and personal data not specifically required by [CONTACT_556798]).   
The medica l monitor will review the  TEF and confirm the investigator has accurately assessed 
that all inclusion criteria have been met and none of the exclusion criteria apply and 
communicate their conclusion to the site.  If the medical monitor raises concerns abou t the 
eligibility of a potential patient or the contents of the TEF, the investigator is responsible for 
reviewing and responding to the medical monitor’s concerns and/or correcting the contents of the 
TEF, as appropriate.  A patient cannot be started on st udy drug until confirmation of eligibility 
from the medical monitor or designee is received and filed in the patient’s records.  
7.2.2.  Enrollment/Randomization  
Site personnel will access the IRT system to randomize patients to treatment assignment and to 
enable  study drug  dispensation . Study treatment must  commence within 3 business days after 
randomization/treatment assignment.  
7.3. Study Drug  Dispensation  
All study drugs will be dispensed and administered as described in Section  5.2. 
7.4. Safety Assessments  
7.4.1.  Vital Signs , Height, and Weight  
Vital signs will include measurements of body temperature, pulse rate, and blood pressure 
(systolic and diastolic) .  
Vital signs will be assessed in Arms A, B, and C at screening, before study drug administration 
on Day s 1, 8, and [ADDRESS_731254] 2  cycles for all patients  at the beginning of each subsequent 
cycle, at the EOT Visit, and at the Safety Follow -up Visit ( Appendix  1).  
The patient’s vital signs must  be recorded within [ADDRESS_731255] infus ion of ociperlimab plus tislelizumab  (as a whole infusion)  in Arm A or tislelizumab 
alone  in Arm B  at each cycle visit  for 2 cycles . For subsequent cycles , vital signs will be 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 78 collected within 60  minutes before the infusion , if clinically indicated, during  and 30  minutes 
after the infusion.   
Pulse rate and blood pressure should be collected while the patient is in a seated position after 
resting for 10  minutes  and before the start of any treatment . Weight will be assessed at screening, 
before study drug adm inistration on Day 1 of each cycle, at the EOT Visit, and at the Safety 
Follow -up Visit. Height will be recorded at screening only.  
7.4.2.  Physical Examinations  
During the Screening Visit, a complete physical examination will be conducted including 
evaluations of 1) head, eyes, ears, nose, throat, 2) cardiovascular, 3) dermatological, 4) 
musculoskeletal, 5) respi[INVESTIGATOR_696], 6) gastrointestinal, and 7) neurological sys tems. Any 
abnormality identified during screening will be graded according to NCI-CTCAE v5.0  and 
recorded on the eCRF with appropriate disease/condition terms.  
At subsequent visits (and as clinically indicated) , limited  (especially for respi[INVESTIGATOR_556704] ), symptom -directed physical examinations will be performed. New or 
worsened clinically significant abnormalities are to be recorded as AEs on the eCRF. Refer to 
Section  8.3 regarding AE definitions and reporting and follow -up requirements.  
7.4.3.  Eastern Cooperative Oncology Group Performance Status  
ECOG Performance Status ( Appendix  3) will be assessed during the study  as outlined in 
Appendix  1. 
7.4.4.  Laboratory Safety Tests  
Local laboratory assessments of serum chemistry, hematology, coagulation, and urinalysis will 
be conducted  as outlined in Appendix  2. 
If laboratory tests at screening are not performed within 7  days before the administration of study 
drug(s) on Day  1 of Cycle 1 , these t ests should be repeated and reviewed before administra tion 
of study drug(s).  
Hematology , serum chemistry (including liver function tests) , and coagulation assessments  will 
be performed at the timepoints specified in Appendix  1. 
Urinalysis is to be conducted at screening and during the treatment period only if clinically 
warranted.  
Thyroid assessments ( free or total triiodothyronine  [T3]; free or total  thyroxine  [T4], and 
thyroid -stimulating hormone  [TSH]) will be performed at the timepoints specified in 
Appendix  1. 
[IP_ADDRESS].  Cardiac Enzyme Monitoring  
Although immune -related myocarditis is a rare complicat ion of immune checkpoint inhibitors, 
serum creatinine kinase (CK) and CK cardiac isoenzyme (CK -MB) will be  monitored to protect 
study participants and to quantify the risk of muscle inflammation (see Appendix  1 for the blood 
collection schedule and Appendix  7 for guidelines for management of suspe cted immune -related 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 79 myocarditis). Serum troponins may be substituted per local guidelines if used consistently 
throughout the study.  
7.4.5.  Electrocardiograms  
The 12-lead ECG recordings will be obtained during screening, as clinically indicated during the 
treatme nt period, at the EOT Visit, and at the Safety Follow -up Visit (Appendix  1). 
For safety monitoring purposes, the investigator must review, sign, and da te all ECG tracings. 
Paper or electronic copi[INVESTIGATOR_26650] ’s permanent study 
file at the site.  
Patients should rest in semirecumbent supi[INVESTIGATOR_19636] ≥ 10 minutes before  ECG collection.  
When coinciding with blood  draws at the same timepoint, ECG assessment should be performed 
before blood draws  and study treatment  infusions . 
7.4.6.  Adverse Events  
AEs will be graded and recorded throughout the study according to NCI-CTCAE v5.0. 
Characterization of toxicities will include severity, duration, and  time to onset.  
All AEs, including SAEs, will be collected as described in Section  8.6. 
7.4.7.  Hepatitis B and C Testing  
Testing will be performed by [CONTACT_556799]/HCV serology (HBsAg, HBsAb, HBcAb, and HCV antibody) . After screening, viral load 
assessment (HBV DNA and HCV RNA)  may be pe rformed if clinically indicated . Patients who 
have detectable HBV DNA at screening or upon repeat testing will undergo the respective viral 
load test every 4 cycles  (eg, Cycles 4, 8, and 12) (Appendix  1). 
7.5. Tumor and Response Evaluations  
Tumor imaging will be performed within 28  days before randomization. During the study, tumor 
imaging will be performed at approximately  12 weeks (±  7 days)  from the date of randomization  
(an additional tumor assessment is allowed if clinically indicated) , then every 6 weeks (±  7 days)  
for the next 54 weeks , and then every 12  weeks (±  7 days) thereafter  based on RECIST v1.1.  If a 
tumor assessment is missed or con ducted outside of the specified assessment window, all 
subsequent scans should be conducted on the planned schedule . 
Screening assessments and each subsequent assessment of the tumor must include computed 
tomography (CT) scans (with oral/intravenous contra st, unless contraindicated) or magnetic 
resonance imaging (MRI) of the chest, abdomen, and pelvis. Other known or suspected sites of 
disease must be included in the imaging assessments (neck, brain, etc).  
All measurable and evaluable lesions should be assessed and documented at the Screening Visit 
and reassessed at each subsequent tumor evaluation. The same radiographic procedure used to 
assess disease sites at screening must  be used throughout the study (e g, the same contrast 
protocol for CT scans).  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 80 • Imaging of the brain (preferably MRI) at baseline is required for all screened patients. 
Screening evaluations will be performed within 28 days before  randomization  and 
additional evaluations may also be perform ed as clinically indicated during the study . 
• If a patient is known to have a contraindication to CT contrast media or develops a 
contraindication during the study, a non -contrast CT of the chest plus a 
contrast -enhanced MRI (if possible) of the abdomen and  pelvis should be performed.  
• If a CT scan for tumor assessment is performed on a positron emission tomography 
(PET)/CT scanner, the CT acquisition must be consistent with the standards of a 
diagnostic CT scan.  
• Bone scans (Technetium -99m [Tc -99m]) or PET sh ould be performed at screening if 
clinically indicated.  
• CT scans of the neck or extremities should be performed at screening only if 
clinically indicated . 
• At the investigator’s discretion, other methods of assessment of target lesion s and 
nontarget lesion s per RECIST v1.[ADDRESS_731256] v1.1 (see Appendix  4). The same 
evaluator should perform asse ssments, if possible, to ensure internal consistency across visits.  
Administration of study treatment will continue until up to [ADDRESS_731257].  
A patient who discontinues study treatment early for reasons other than disease progression (eg, 
toxicity) or completes study t reatment will continue to undergo tumor assessments following the 
original schedule  until disease progression per RECIST v1.1, withdraw al of consent, loss to 
follow -up, the start of a new anticancer therapy, death, or study terminat ion, whichever occurs 
first. 
In Arms A and B, treatment with ociperlimab plus tislelizumab or with tislelizumab alone 
beyond the initial investigator -assessed, RECIST v1.1 -defined disease progression is permitted 
provided that the patient has investigator -assessed clinical benefit and is tolerating the study 
drug(s). The following criteria must be met in order to treat patients who may continue to benefit 
from study drugs after disease progression : 
• Absence of clinical symptoms and signs of disease progression (including clinically 
significant worsening of laboratory va lues)  
• Stable ECOG Performance Status (≤ 2) 
• Absence of rapid progression of disease or of progressive tumor at critical anatomical 
sites (eg, cord compression) that requires urgent alternative medical intervention  
• Investigators must obtain written informed consent for treatment beyond radiologic 
disease progression and inform patients that this practice is not considered standard in 
the treatment of cancer  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 81 The investigator should obtain written agreement from the sponsor medical monitor on 
continuing study drug(s) beyond the initial investigator -assessed progression, and the decision 
must be documented in the study records.  
Tumor assessments should continue as planned in patients receiving study drug(s) beyond initial 
investigator -assessed progression. Tumor  assessments in such patients should continue until 
study treatment discontinuation.   
Tumor assessments are required to be performed on schedule regardless of whether study 
treatment has been administered or held; that is, tumor assessments should not be a djusted for 
delays in cycles.  
7.6. Pharmacokinetic and Antidrug Antibody Testing  
Checkpoint inhibitor drugs may elicit an immune response. Patients with signs of any potential 
immune response to ociperlimab or tislelizumab will be closely monitored. Validated s creening 
and confirmatory assays will be employed to detect ADAs at multiple timepoints throughout the 
study ( Appendix  1). The immunogenicity evaluatio n will utilize a risk -based immunogenicity 
strategy ( Koren et al 2008 ; Worobec and Rosenberg 2004a ; Worobec and Rosenberg 2004b ) to 
characterize ADA responses to ociperlimab  and tislelizumab in support of the clinical 
development program. In addition, blood samples will be collected for characterization of 
ociperlimab  and tislelizumab PK at the timepoints specified in the Schedule  of Assessments 
(Appendix  1).  
The following assessments will be performed at a central laboratory:  
• ADA assays: serum samples will be tested for the p resence of ADAs to ociperlimab 
or tislelizumab using a validated immunoassay  
• PK assay: serum samples will be assayed for ociperlimab or tislelizumab 
concentration using  a validated immunoassay  
Shippi[INVESTIGATOR_007], storage, and handling of samples for the assessment o f ociperlimab and tislelizumab 
PK and ADA assays will be managed through a central laboratory. Instruction manuals and 
supply kits will be provided for all central laboratory assessments.  
7.7. Biomarkers  
Shippi[INVESTIGATOR_007], storage, and handling of blood, archival tumor,  fresh tumor, and leftover tumor tissue 
for the assessment of biomarkers will be managed through a central laboratory. Refer to the 
laboratory manual for details of sample handling.  
Patients must agree to provide an archival tumor tissue  with an associated pathology report  or 
agree to perform a fresh tumor biopsy during  screening  (formalin -fixed paraffin -embedded block 
or approximately 15 unstained slides [8 slides  minimum ]). Note: If < 8 unstained slides are 
available, a discussion with the sponsor is required . PD-L1 and TIGIT expressio n by 
[CONTACT_556800].  In addition to PD -L1 and TIGIT 
expressio n, other exploratory predictive biomarkers, including but not limited to  gene expression 
profile, tissue - or blood -based gene mutations and TMB/MSI, CD155/CD226 expression, and 
SCLC subtypi[INVESTIGATOR_556705] .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 82 (ASCL1/NEUROD1/POU2F3/YAP1) , which may be related to the clinical benefit of 
ociperlimab and tislelizumab , may also be evaluated.  If no archival samples are available, a fresh 
tumor biopsy at baseline is required. For fresh biopsy specimens, acceptable sam ples include 
core needle biopsies for deep tumor tissue or excisional, incisional, punch, or forceps biopsies 
for cutaneous, subcutaneous, or mucosal lesions .  
For patients who have confirmed disease progression during the study , optional biopsies will als o 
be taken from accessible tumor sites to obtain samples to explore resistance mechanism s. If 
feasible, any follow -up biopsy should be ideally taken from the same tumor lesion as the baseline 
biopsy. Written patient consent is required for  fresh tumor biop sies. Biomarker testing for 
optional biopsy samples will include PD -L1 and TIGIT  as well as other exploratory biomarkers . 
(Note:  for the sites in China mainland, tissue  and blood samples  will be obtained to test the 
expression of PD -L1 and TIGIT, gene expression profile, tissue - or blood -based gene mutations 
and TMB/MSI  and ctDNA level change , CD155/CD226 expression, and SCLC subtypi[INVESTIGATOR_556706] (ASCL1/NEUROD1/POU2F3/YAP1) . 
Tumor tissue should be of good quality based on  total and viable tumor content . Cytology 
samples including f ine-needle aspi[INVESTIGATOR_1516], brushing, cell pellets from pleural effusion, and lavage 
samples are not acceptable.  
Blood samples will be collected at screening and at defined timepoints  durin g treatment  as well 
as at the time of confirmed disease progression  (see Appendix  1 for the specifi ed timepoints ) for 
assessment of blood-based tumor mutation profile and ctDNA level change before and after 
treatment. The association of ctDNA level  change with ORR, PFS , and OS will be analyzed to 
evaluate the potential utility of ctDNA as a surrogate marker for clinical efficacy . 
Sample coll ection and biomarker testing will be performed after relevant regulatory approval . 
7.8. Patient -Reported Outcomes  
Patients will be asked to complete questionnaires before any clinical activities (including blood 
draws or imaging scans) are performed during on -study clinic visits according to the schedule in 
Appendix  1. These questionnaires will include the EORTC -QLQ -C30 ( Appendix  10) and its 
lung cancer module QLQ -LC13 ( Appendix  11). The questionnaires will be provided in the 
patient’s preferred language.  
7.9. Visit Windows  
All visits must occur within ±  3 days from the scheduled date, unless otherwise noted (see 
Appendix  1). All assessments will be performed on the day of the specified visit unless an 
acceptable time window is specified. Assessments scheduled on the day of study treatment 
administration (Day  1) of eac h cycle should be performed before  study treatment infusion/dose 
unless otherwise noted. Laboratory results are required to be reviewed before  dosing.  
If the timing of a protocol -mandated study visit coincides with a holiday, weekend, or other 
event, the visit should be scheduled on the nearest feasible date (the visit window is provided in 
Appendix  1), with subsequent visits conducted according to the planned schedule every 3  weeks 
from Day  1 of Cycle  1. 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 83 7.10. Unscheduled Visits  
Unscheduled visits may be performed at any time at the patient’s or  the investigator’s request 
and may include vital signs/focused physical examination; ECOG Performance Status; AE 
review; concomitant medications and procedures review; radiographic assessments; physical 
examination of liver, spleen, and lymph nodes; disea se-related constitutional symptoms; and 
hematology and chemistry laboratory assessments. The date and reason for the unscheduled visit 
must be recorded in the source documentation.  
If an unscheduled visit is necessary to assess toxicity or for suspected di sease progression, then 
diagnostic tests may be performed based on the investigator assessment as appropriate, and the 
results of these tests should be entered on the unscheduled visit eCRF.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 84 8. SAFETY MONITORING AN D REPORTING  
The investigator is responsible for the monitoring and documentation of events that meet the 
criteria and definition of an AE or SAE as provided in this protocol.  
8.1. Risks Associated With Study Drug s 
8.1.1.  Risks Associated With Ociperlimab  and Tislelizumab  
Ociperlimab  and t islelizumab are investi gational agent s that are currently in clinical 
development. Limited safety data are available in patients, and the full safety profile has not been 
characterized. The following recommendation is based on results from nonclinical and clinical 
studies with ociperlimab and tislelizumab and published data on other molecules within the same 
biologic class.  
The PD -L1/PD -[ADDRESS_731258] is involved in peripheral immune tolerance; therefore, such therapy 
may increase the risk of i mAEs, specifically the induction or enhan cement of autoimmune 
conditions. AEs observed with anti -PD-[ADDRESS_731259] of potential side effects.  
Table  7: The Summary of the Commonly and Specific Reported Toxicity of the 
Chemotherapeutic Agents  
Agents  Specific toxicity  Common toxicity  
Cisplatin  Nephrotoxicity; ototoxicity; peripheral 
neuropathies  Myelodepression with leukopenia, 
thrombocytopenia and anemia; 
infectious complications; 
nausea/vomiting and other 
gastrointestinal  toxicity; hepatic 
impairment; fatigue; anorexia; 
constipation  Carboplat in Ototoxicity , peripheral neuropathies  
Etoposide  Hypersensitivity reactions; ocular; 
respi[INVESTIGATOR_696]; skin; neurologic  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 85 8.1.3.  Risks Ass ociated With Radi ation T herapy  
AEs related to RT include nausea/vomiting, diarrhea, weight loss, fatigue, hematolog ical 
toxicity, skin erythema, subcutaneous fibrosis, esophagitis, esophageal stricture, esophageal 
fistula, carditis, myelitis, acute radiation pneumonitis, and late pulmonary fibrosis.  
8.2. General Plan to Manage Safety Concerns  
8.2.1.  Eligibility Criteria  
Eligibility criteria were selected to guard the safety of patients in this study. Results from the 
nonclinical toxicology studies and clinical data with ociperlimab and tislelizumab , as well as the 
nonclinical/clinical data from other TIGIT and PD-L1/PD -[ADDRESS_731260] received a live vaccine ≤ [ADDRESS_731261] of medical interviews, recording of AEs (see Table  8), physical 
examinations, laboratory measurements (hematology, chemistry, etc) and other assessments , 
including those listed in Appendix  1. In addition, patients will be closely monitored for the 
development of any signs or symptoms of infections or autoimmune conditions.  
At the start of each cycle, study drug(s) will be administered only after clinical laboratory results 
have been reviewed. Administration of study drug(s) will be performed in a setting where 
emergency medical equipment and staff who are trained to respond to medical emergencies are 
available (see  Section  5.2). 
Serum samples will be drawn for determination of ADAs to ociperlimab and tislelizumab in 
patients randomized to Arms A and B.  
Investigators are instructed to report all AEs (including pregnancy -related AEs).  
The potential safety issues anticipated in this study, as well as measures intended to avoid or 
minimize such toxicities, are outlined in Section  8.7. 
8.3. Adverse Events  
8.3.1.  Definitions and Reporting  
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated w ith the use of a study 
drug, whether considered related to study drug or not.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 86 Examples of AEs include  the following : 
• Worsening of a chronic or intermittent preexisting condition, including an increase in 
severity, frequency, duration, and/or has an associa tion with a significantly worse 
outcome  
• Detection or diagnosis of a new condition after study drug administration, even 
though the condition may have been present before the start of the study  
• Signs, symptoms, or the clinical sequelae of a suspected intera ction  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study drug 
or a concurrent medication (overdose per se should not be reported as an AE or SAE)  
When an AE or SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory results, and diagnostics reports) relative to 
the AE or SAE. The investigator will then record all relevant informat ion regarding an AE or 
SAE in the eCRF. However, there may be instances when copi[INVESTIGATOR_69780]. In this instance, all patient identifiers will be blinded on the 
copi[INVESTIGATOR_340722].  
8.3.2.  Assessment of Severity  
The investigator will assess the severity of each AE and SAE reported during the study. AEs and 
SAEs should be assessed and graded based upon the NCI-CTCAE v5.0 . 
Toxicities that are not specified in the NCI -CTCAE will be defined as follows:  
• Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated  
• Grade 2: Moderate; minimal, local or noninvasive intervention i ndicated; limiting 
age-appropriate instrumental activities of daily living  
• Grade 3: Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting 
self-care activities  of daily living   
• Grade 4: Life -threatening consequences; urgent intervention indicated  
• Grade 5: Death related to AE  
Note: The terms “severe” and “serious” are not synonymous. Severity is a measure of intensity 
(eg, grade of a specific AE, mild [Grade 1], moderate [Grade 2], severe [Grade 3], or life -
threatening [Grade 4]), whereas seriousness is classified by [CONTACT_556801]. Seriousness serves as the guide for defining regulatory reporting obligations from the 
sponsor to a pplicable regulatory authorities as described in  Section  8.6.[ADDRESS_731262] clinical judgment. Alternative causes,  such as natural history of 
the underlying diseases, concomitant therapy, other risk factors, and the temporal relationship of 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 87 the AE or SAE to the study drug should be considered and investigated. The investigator should 
consult the Tislelizumab Investigator’s Brochure , Ociperlimab (BGB -A1217) Investigator’s 
Brochure , chemotherapy prescribing information, or radiation manual  in the determination of 
his/her assessme nt. 
There may be situations when an SAE has occurred, and the investigator has only limited 
information to include in the initial report to the sponsor. However, it is very important that the 
investigator always assesses causality for every SAE before  transmission of the SAE report to 
the sponsor, because the causality assessment is one of the criteria used when determining 
regulatory reporting requirements. The investigator may subsequently change his/her opi[INVESTIGATOR_508951] -up informat ion and may amend the SAE report accordingly.  
The causality of each AE should be assessed and classified by [CONTACT_1694] “related” or 
“not related” based on all information available at the time of reporting. An AE is considered 
related if there is “a reasonable possibility” that the AE may have been caused by [CONTACT_5257] 
(ie, there are facts, evidence, or arguments to suggest possible causation). A number of factors 
should be considered in making this assessment, including  the following : 
• Temporal  relationship of the AE to the administration of study treatment/study 
procedure  
• Whether an alternative etiology has been identified  
• Mechanism of action of the study drug  
• Biological plausibility  
• An AE should be considered “related” to study drug if any of the following criteria 
are met ; otherwise , the event should be assessed as “not related”:  
− There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out  
− There is evidence to suggest a causal relationship,  and the influence of other 
factors is unlikely  
− There is some evidence to suggest a causal relationship (eg, the AE occurred 
within a reasonable time after administration of the study drug).  However, the 
influence of other factors may have contributed to the AE (eg, the patient’s 
clinical condition or other concomitant AEs).  
8.3.4.  Follow -up of Adverse Events  
After the initial AE or SAE report, the investigator is required to proactively follow each patient 
and provide further information to the sponsor on the pa tient’s condition.  
All AEs and SAEs documented at a previous visit/contact [CONTACT_69846]/contacts.  
All AEs and SAEs will be followed until resolution, the condition stabilizes or is considered 
chronic, the  AE or SAE is otherwise explained, the patient is lost to follow -up or the patient 
withdraws consent. The investigator will ensure that follow -up includes any supplemental 
investigations as may be indicated to elucidate the nature and/or causality of the A E or SAE. 
Version .[ADDRESS_731263] of supplemental 
measurements and/or evaluations to elucidate as fully as possible the nature and/or causality of 
the AE or SAE. The investigator is obligated to assist. If a patient dies during participation in the 
study or during a recognized foll ow-up period, the sponsor will be provided with a copy of any 
postmortem findings, including histopathology.  
New or updated information should be reported to the sponsor according to the SAE instructions 
provided by [CONTACT_556802]  8.6.[ADDRESS_731264] Abnormalities  
Abnormal laboratory findings (eg, clinical chemistry, complete blood count, coagulation, or 
urinaly sis) or other abnormal assessments (eg, ECGs, x-rays, or vital signs) that are judged by 
[CONTACT_397795]. This includes clinically 
significant abnormal laboratory findings or other abnormal assessm ents that are present at 
baseline and significantly worsen during the study. The definition of clinically significant is left 
to the judgment of the investigator. In general, these are the laboratory test abnormalities or other 
abnormal assessments  that: 
• are associated with clinical signs or symptoms, or  
• require active medical intervention, or  
• lead to dose interruption or discontinuation, or  
• require close observation, more frequent follow -up assessments, or further diagnostic 
investigation.  
If a clinically significant laboratory abnormality is a sign of a disease or syndrome (eg, alkaline 
phosphatase and bilirubin [ADDRESS_731265] associated with cholestasis), only the diagnosis (ie, 
cholestasis) should be recorded on the Adverse Event eCRF.  
If the laboratory abnorma lity can be characterized by a precise clinical term per standard 
definitions, the clinical term should be recorded as the AE. For example, an elevated serum 
potassium level of 7.0  mEq/L should be recorded as “hyperkalemia.”  
Observations of the same clinic ally significant laboratory abnormality from visit to visit should 
not be repeatedly recorded on the Adverse Event eCR F unless the etiology changes. The initial 
severity of the event should be recorded,  and the severity or seriousness should be updated any  
time the event worsens.  
8.4. Definition of a Serious Adverse Event  
An SAE is any untoward medical occurrence that, at any dose:  
• Results in death . 
• Is life -threatening . 
Note: The term “life -threatening” in the definition of “serious” refers to an AE from  
Version .[ADDRESS_731266] caused death if it were more severe.  
• Requires hospi[INVESTIGATOR_1081] . 
Note: In general, hospi[INVESTIGATOR_556707] (usually 
involving at least an overnight stay) to the hospi[INVESTIGATOR_1083]/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting.  
• Results in disabil ity/incapacity . 
Note: The term “disability” means a substantial disruption of a person’s ability to 
conduct normal life functions. This definition is not intended to include experiences 
of relatively minor medical significance, such as uncomplicated headac he, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle), which may 
interfere with or prevent everyday life functions but do not constitute a substantial 
disruption.  
• Is a congenital anomaly/birth defect . 
• Is considered a signifi cant medical AE by [CONTACT_509026] (eg, may jeopardize the patient or may require medical/surgical 
intervention to prevent one of the outcomes listed above) . 
The following are NOT  considered to be SAEs:  
• Hospi[INVESTIGATOR_17048] a preexisting condition that did not worsen 
from baseline  
• Hospi[INVESTIGATOR_16739]/convenience considerations  
• Scheduled therapy for the target disease of the study, including admissions for 
transfusion support or convenience  
8.5. Suspected Un expected Serious Adverse Reaction  
A suspected unexpected serious adverse reaction (S[LOCATION_003]R) is a serious adverse reaction that is 
both unexpected (ie, not present in the product’s Reference Safety Information) and meets the 
definition of a serious adverse dr ug reaction, the specificity or severity of which is not consistent 
with those noted in the Tislelizumab Investigator’s Brochure , Ociperlimab (BGB -A1217) 
Investigator’s Brochure , chemotherapy prescribing information, or radiation manual . 
8.6. Timing, Frequency, and Method of Capturing Adverse Events and 
Serious Adverse Events  
8.6.1.  Adverse Event Recording Period  
After informed consent has been signed but before  the administration of study drug, only SAEs 
should be reported.  
Version .[ADDRESS_731267].  
For patients in Arm A and Arm B, i mmune -mediated  AEs (serious or nonserious) should be 
reported until [ADDRESS_731268] dose of ociperlimab plus tislelizumab or tislelizumab alone , 
regardless of whe ther or not the patient starts a new anticancer therapy.  
All SAEs considered related to the study drug(s) that are brought to the attention of the 
investigator should be reported regardless of time since the last dose of treatment.  
All AEs ongoing at the time of treatment discontinuation which worsen in severity to Grade 5 
should be reported regardless of time from treatment stop.  
AEs and SAEs should be recorded according to the details in  Table  8. For the follow -up period 
for AEs, see Section  8.3.4 . For the definition of TEAEs, see Section  9.3.2 . 
Table  8: Guidance for Duration of Recording New or Worsening Adverse Events in 
All Treatment Arms  
Event type  Record ne w or worsening events that occur during this period  
Begin  End 
SAEs a Signing of informed 
consent  Up to [ADDRESS_731269] (see Section  8.6.4 ) 
All nonserious AEs, except 
those due to PD  First dose of study 
treatment  Up to [ADDRESS_731270]  
Immune -related AEs (serious 
or nonserious)  First dose of study 
treatment  Up to [ADDRESS_731271] dose 
(regardless of initiation of new 
anticancer therapy), death, withdrawal 
of consent, or loss to follow -up, 
whichever occurs first 
Abbreviations: AE, adverse event; PD, disease progression; SAE, serious adverse event.  
a All SAEs considered related to the study drug(s) that are brought to the attention of the investigator should be 
reported regardless of time since the last dose o f treatment.  
8.6.2.  Reporting Serious Adverse Events  
[IP_ADDRESS].  Prompt Reporting of Serious Adverse Events  
As soon as the investigator determines that an AE meets the protocol definition of an SAE, the 
event must be reported promptly (within 24  hours) to the sponsor or desi gnee as described in 
Table  9. 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 91 Table  9: Timeframes and Documentation Methods for Reporting Serious Adverse 
Events to the Sponsor or Designee  
 Timeframe for sending 
initial/follow -up a report  Documentation 
method  Reporting method  
All SAEs  Within [ADDRESS_731272] 
knowledge of the SAE  SAE Report  Electronic submission of 
SAE form to safety portal  b 
Abbreviations: EDC, electronic data capture; IMP, investigational medicinal product;  SAE, serious adverse event.  
a Report follow -up information that is clinically relevant and pertain s to the SAE ; this  includes , but is not limited  to, 
the following: Update to the SAE, new additional SAE, outcome, seriousness criteria, investigator causality, event  
start date/date of onset, date of death, relationship to each IMP. Follow -up information will also be reported a t the 
discretion of the inve stigator if the new or updated information changes the medical assessment of the case.  
b SAE reports should be submitted to the sponsor ’s safety database electronically from within the EDC. If the  
electronic submission is not available for any reason, a pa per SAE form should be submitted by [CONTACT_71345] . 
[IP_ADDRESS].  Completion and Transmission of the Serious Adverse Event Report  
Once an investigator becomes aware that an SAE has occurred in a patient, he/she is to report the 
information to the sponsor within 24  hours a s outlined above in Section  [IP_ADDRESS] . The SAE Report 
will always be completed as thoroughly as possible with all available details of the event , and 
forwarded to the sponsor or designee within the designated timeframes.  
If the investigator does not have all information regarding an SAE, he/she is not to wait to 
receive additional information before notifying the sponsor or designee of the SAE and 
comple ting the form. The form will be updated when additional information is received.  
The investigator must always provide an assessment of causality for each SAE as described in 
Section  8.3.[ADDRESS_731273] information for SAE receipt.  
[IP_ADDRESS].  Regulatory Reporting Requirements for Serious Adverse Events  
The investigator will report all SAEs to the sponsor in accordance with the procedures detail ed in 
Section  [IP_ADDRESS] . The sponsor has a legal responsibility to notify, as appropriate, both the local 
regulatory authority and other regulatory agencies about the safety of a product under clinical 
investigation.  
The investigator, or responsible person according to local requirements, will comply with the 
applicable local regulatory requirements related to the reporting of SAEs to regulatory autho rities 
and the IRB/IEC.  
All S[LOCATION_003]Rs (as defined in Section  8.5) will be submitted to all applicable regulatory authorities 
and investigators for ocipe rlimab  and tislelizumab studies.  
When a study center receives an initial or follow -up safety report or other safety information (eg, 
revised Investigator’s Brochure) from the sponsor, the investigator or designated responsible 
person is required to promptl y notify his/her IRB or IEC. The investigator should place copi[INVESTIGATOR_556708].  
Version .[ADDRESS_731274] 
questions : 
• How are you feeling?  
• Have you had any medical problems since your last visit?  
• Have you taken any new medicines since your last visit?  
8.6.4.  Disease Progression  
Disease progression, which is expected in this study population and is measured as an efficacy 
endpoint, should not be recorded as an AE term. Similarly, nonserious AEs that are clearly 
consistent with the pattern of progression of the underlying disease and are considered 
unequivocally due to disease progression should not be recorded. However, if there is any 
uncertainty as to whether a nonserious AE is due to disease progression, it should be recorded as 
an AE. All SAEs and deaths regardless of relatedness to disease progression should be recorded 
and reported (see  Section  8.6.2 ). 
8.6.5.  Deaths  
Death is an outcome and not usually considered an event. If the only information available is 
death and the cause of death is unknown, then the death is reported as an AE, eg, “death,” “death 
of unknown cause,” or “death unexplained.”  
8.6.6.  Pregnancies  
If a female patient or the partner of a male patient becomes pregnant while receiving 
investigational therapy , or within [ADDRESS_731275] dose of radiotherapy or 
chemotherapy  (except for cisplatin) , or within [ADDRESS_731276] dose of cisplatin  (for the 
female patient) , or within [ADDRESS_731277] dose of cisplatin (for the partner of the male 
patient ), a pregnancy report form is required to be completed and expeditiously submitted to the 
sponsor to facilitate outcome follow -up. Information on the status of the mot her and child will be 
forwarded to the sponsor. Generally, follow -up will be no longer than 6 to 8  weeks after the 
estimated delivery date. Any premature termination of the pregnancy will be reported.  
While pregnancy itself is not considered to be an AE, a ny pregnancy complication or elective 
termination of a pregnancy for medical reasons will be recorded as an AE or SAE.  
An abortion, whether accidental, therapeutic, or spontaneous, should be always reported as an 
SAE. Similarly, any congenital anomaly/birt h defect in a child born to a patient exposed to the 
study drug should be recorded and reported as an SAE.  
8.6.7.  Expedited Reporting to Health Authorities, Investigators, Institutional Review 
Boards, and Independent Ethics Committees  
The sponsor will promptly as sess all SAEs against cumulative study drug experience to identify 
and expeditiously communicate new safety findings to regulatory authorities, investigators, 
IRBs, and IECs based on applicable legislation.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 93 To determine the reporting requirements for indiv idual SAEs, the sponsor will assess the 
expectedness of the SAEs using the following Reference Safety Information documents:  
• Tislelizumab Investigator’s Brochure  
• Ociperlimab (BGB -A1217) Investigator’s Brochure  
• Cisplatin prescribing information  
• Carboplatin prescribing information  
• Etoposide prescribing information  
8.6.8.  Assessing and Recording Immune -Mediated  Adverse Events  
Because  treatment with anti -PD-1 therapy  or immune checkpoint inhibitors  can cause 
autoimmune disorders, AEs considered by [CONTACT_556803] -mediated  (see 
Section  8.7.3 ) should  be classified as i mAEs and identified as such on the eCRF AE page until 
[ADDRESS_731278] of potential i mAEs appears in Table  11. All conditions similar to those listed 
should be evaluated to determine whether they are i mAEs, based on a similar diagnostic process 
to those reactions that are presented in more detail in Appendix  7. 
8.6.9.  Recording Infusion -Related Reactions  
The symptoms of infusion -related reactions may include, but are not limited to, fever, 
chills/rigor, n ausea, pruritus, angioedema, hypotension, headache, bronchospasm, urticaria, rash, 
vomiting, myalgia, dizziness, or hypertension. Severe reactions may include acute respi[INVESTIGATOR_1421], myocardial infarction, ventricular fibrillation, or cardioge nic shock. Each 
individual sign and symptom of an infusion -related  reaction should be recorded as a separate AE 
in the eCRF and identified as an infusion -related reaction. Refer to the eCRF completion 
guidelines for details.  
8.7. Management of A dverse Events  of Special Interest  
As a routine precaution, after infusion of ociperlimab and tislelizumab (Arm A) and tislelizumab 
(Arm B) on Day [ADDRESS_731279] be monitored for ≥ [ADDRESS_731280], a 
≥ 60-minute monitoring period is required in an area with resuscitation equipment and 
emergency agents.  
The management of infusion -related reactions, severe hypersensitivity reactions, and i mAEs 
according to the NCI-CTCAE criteria are outlined below.  
8.7.1.  Managing Infusion -Related Reactions  
Patients should be closely monitored for infusion -related reactions. Immediate access to an 
Intensive Care Unit (ICU) or equivalent environment and appropriate medical therapy (incl uding 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 94 epi[INVESTIGATOR_238], corticosteroids, intravenous antihistamines, bronchodilators, and oxygen) must be 
available to treat infusion -related reactions.  
Treatment modifications for symptoms of infusion -related reactions due to study drug(s) are 
provided in Table  10. 
Table  10: Treatment Modifications for Symptoms of Infusion -Related Reactions Due to 
Study Drug(s)  
NCI-CTCAE grade Treatment modification for ociperlimab and 
tislelizumab  
Grade  1 - mild  
Mild transient reaction; infusion interruption not 
indicated; intervention not indicated.  Decrease infusion rate by 50%. Any worsening is 
closely monitored. Medical management as 
needed.  
Subsequent infusions should be given after 
premedication and at the reduced infusion rate.  
Grade  2 - moderate  
Therapy or infusion interruption indicated but 
responds promptly to symptomatic treatment (eg, 
antihistamines, NSAIDS, narcotics, intrave nous 
fluids); prophylactic medications indicated for 
≤ 24 hours.  Stop infusion. Infusion may be resumed at 50% of 
previous rate once infusion -related reaction has 
resolved or decreased to Grade  1 in severity. Any 
worsening is closely monitored. Proper medi cal 
management should be instituted as described 
below.  
Subsequent infusions should be given after 
premedication and at the reduced infusion rate.  
Grade  3 - severe  
Prolonged (eg, not rapi[INVESTIGATOR_86025]/or brief interruption 
of infusion); recurrence of symptoms following 
initial improvement; hospi[INVESTIGATOR_50402].  Immediately stop the infusion. Proper medical 
management should be instituted as described 
below.  
The patient should be withdrawn from study  
drug(s) treatment.  
Grade  4 - life-threatening  
Life-threatening consequences; urgent 
intervention indicated.  Immediately stop the infusion. Proper medical 
management should be instituted as described 
below.  
The patient should be withdrawn from study 
drug(s) treatment.  
Hospi[INVESTIGATOR_44960].  
Abbreviations: NCI -CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Event; NSAIDs, 
nonsteroidal anti -inflammatory drugs.  
Once the ociperlimab or tislelizumab  infusion rate has been  decreased by 50% or suspended due 
to an infusion -related reaction, it must remain decreased for all subsequent infusions and be 
administered with premedication. If the patient has a second infusion -related reaction 
(≥ Grade  2) on the slower infusion rate,  infusion should be discontinued, and the patient should 
be withdrawn from  treatment with  ociperlimab plus tislelizumab or tislelizumab alone . 
NCI-CTCAE Grade  1 or 2 infusion -related  reaction: Proper medical management should be 
instituted as indicated per  the type of reaction. This includes, but is not limited to, an 
antihistamine (eg, diphenhydramine or equivalent), antipyretic (eg, paracetamol or equivalent), 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 95 and if considered indicated, oral or intravenous glucocorticoids, epi[INVESTIGATOR_238], bronchodilators, 
and oxygen. In the next cycle, patients should receive oral premedication with an antihistamine 
(eg, diphenhydramine or equivalent) and an antipyretic (eg, paracetamol or equivalent), and they 
should be closely monitored for clinical signs and symptoms of an infusion -related  reaction.  
NCI-CTCAE Grade  3 or 4 infusion -related  reaction: Proper medical management should be 
instituted immediately, as indicated per type and severity of the reaction. This includes, but is not 
limited to, oral or intravenous antihi stamines, antipyretics, glucocorticoids, epi[INVESTIGATOR_238], 
bronchodilators, and oxygen.  
8.7.2.  Severe Hypersensitivity Reactions and Flu -Like Symptoms  
If a hypersensitivity reaction occurs, the patient must be treated according to the best available 
medical practice a s described in the complete guideline for emergency treatment of anaphylactic 
reactions according to the Working Group of the Resuscitation Council ([LOCATION_006]) ( Soar et al 2008 ). 
Patients should be instructed to report any del ayed reactions to the investigator immediately.  
In the event of a systemic anaphylactic/anaphylactoid reaction the infusion must be immediately 
stopped and the patient discontinued from the study. Systemic anaphylactic/anaphylactoid 
reactions typi[INVESTIGATOR_556709]/antigen and are 
characterized by [CONTACT_15206][INVESTIGATOR_1506]; laryngeal edema; and/or intense bronchospasm; and often 
followed by [CONTACT_556804][INVESTIGATOR_60319]; cutaneous  
manifestations such as pruritus and urticaria with/without edema; and gastrointestinal 
manifestations such as nausea, vomiting, crampy abdominal pain, and diarrhea.  
The patient will be administered epi[INVESTIGATOR_556710] a 
hypersensitivity reaction is observed. The patient should then be placed on monitor immediately, 
and the ICU should be alerted for possible transfer if needed.  
For prophylaxis of flu -like symptoms, a dose of 25  mg indomethacin or a comparable dose of 
nonstero idal anti -inflammatory drugs (ie, 600  mg ibuprofen, 500  mg naproxen sodium) may be 
administered 2  hours before and 8  hours after the start of each dose of study drug infusion. 
Alternative treatments for fever (ie, paracetamol) may be given to patients at t he discretion of the 
investigator.  
8.7.3.  Immune -Mediated  Adverse Events  
Immune -mediated  AEs are of special interest in this study. If the events listed below or similar 
events occur, the investigator should exclude alternative explanations (eg, combination drugs, 
infectious disease, metabolic, toxin, disease progression, or other neoplastic causes) with 
appropriate diagnostic tests that may include, but are not limited to, serologic, immunologic, and 
histologic (biopsy) data. If alternative causes have been ruled out; the AE required the use of 
systemic steroids, other immunosuppressants, or endocrine therapy; and is consistent with an 
immune -mediated mechanism of action, the i mAE indicator on the eCRF AE page should be 
checked.  
A list of potential i mAEs is shown below in Table  11. All conditions similar to those listed 
should be evaluated in patients receiving ociperlimab or tislelizumab to determine whether they 
are immune  mediated . 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 96 Recommendation for diagnostic evalu ation and management of i mAEs is based on European 
Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) 
guidelines ( Haanen et al 2017 ; Brah mer et al 2018 ), and common immune -related toxicities are 
detailed in Appendix  7. For any AEs not included in Appendix  7, please refer to the ASCO 
Clinical Practice Guideline ( Brahmer et al 2018 ) for further guidance on diagnostic evaluation 
and management of  immune -related toxicities.  
Table  11: Examples of Immune -Mediated  Adverse Events  
Body system affected  Events  
Skin (mild -common)  pruritus or maculopapular rash; vitiligo  
Skin (moderate)  follicular or urticarial dermatitis; erythematous/lichenoid rash; Sweet 
syndrome  
Skin (severe -rare)  full-thickness necrolysis/Stevens -Johnson syndrome  
Gastrointestinal  colitis (includes diarrhea with abdominal pain or 
endoscopic/radiographic evidence of inflammation); pancreatit is; 
hepatitis; aminotransferase (ALT/AST) elevation; bowel perforation  
Endocrine  thyroiditis, hypothyroidism, hyperthyroidism; hypophysitis with features 
of hypopi[INVESTIGATOR_297], eg, fatigue, weakness, weight gain; insulin -
dependent diabetes mellitus; diabetic  ketoacidosis; adrenal insufficiency  
Respi[INVESTIGATOR_397692]/diffuse alveolitis  
Eye epi[INVESTIGATOR_227]; conjunctivitis; iritis/uveitis  
Neuromuscular  arthritis; arthralgia; myalgia; neuropathy; Guillain -Barre syndrome; 
aseptic meningitis; myasthenic syndrome/m yasthenia gravis, myositis  
Blood  anemia; leukopenia; thrombocytopenia  
Renal  interstitial nephritis; glomerulonephritis; acute renal failure  
Cardiac  pericarditis; myocarditis; heart failure  
Neurologic  encephalitis, meningitis, meningoradiculitis, meningoencephalitis  
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.  
Recommendations for managing i mAEs are detailed in Appendix  7. 
If a toxicity does not resolve to ≤  Grade  1 within 12  weeks, study drug(s) should be discontinued 
after consultation with the sponsor. Patients who experience a recurrence of any event at the 
same or higher severity grade after restart of stud y drug should permanently discontinue 
treatment.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 97 9. STATISTICAL METHODS AND SAMPLE SIZE 
DETERMINATION  
The statistical analyses will be performed by [CONTACT_556805]. Details  of the statistical analyses will be 
included in a separate Statistical Analysis Plan.  
9.1. Statistical Analysis  
9.1.1.  Randomization Methods  
As discussed in Section  7.2.2 , patients will be randomized using the IRT system for this study by 
[CONTACT_556806] a stratification factor of disease stage 
(stage I/II versus  stage III). 
9.1.2.  Analys is Sets  
The ITT Analysis Set includes all randomized patients. Patients will be analyzed according to 
their randomized treatment arm. This will be the primary analysis set for all efficacy analysis.  
The Safety Analysis Set includes all patients who have received ≥ 1 dose of any component of 
study drug; it will be the analysis set for the safety analyses.  
The PK Analysis Set includes all patients who receive ≥ 1 dose of tislelizumab/ ociperlimab  per 
the protocol  and for whom any quantifiable postbaseline  PK data are available.  
The ADA Analysis Set, which includes all patients who receive ≥  1 dose of 
tislelizumab/ ociperlimab  and for whom both baseline and ≥  [ADDRESS_731281] ≥ 1 evaluable biomarker 
measurement; it will be used for biomarker analysis.  
9.1.3.  Patient Disposition  
The number of patients randomized, treated, or discontinued from study drug and/or study, and 
those w ith important protocol deviations will be counted. The primary reason for study drug 
and/or study discontinuation will be summarized according to the categories in the eCRF. The 
end-of-study status (alive, dead, withdrew consent, or lost to follow -up) at t he data cutoff date 
will be summarized using the data from the eCRF.  
Important protocol deviations will be summarized and listed by [CONTACT_338546].  
9.1.4.  Demographic and Other Baseline Characteristics  
Demographic and other baseline characteristics of the ITT population will be summarized using 
descriptive statistics. Continuous variables include age, weight, vital signs, and time since initial 
cancer diagnosis. Categorical variables include gender, ECOG Performance Status, geographical 
region, country, race, disea se stage , smo king history, and PET-CT done or not done . 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 98 9.1.5.  Prior and Concomitant Medications  
Concomitant medications will be coded using the WHO Drug Dictionary drug codes.  
Concomitant medications will be further coded to the appropriate Anatomical Therapeut ic 
Chemical (ATC) code indicating therapeutic classification. Prior and concomitant medications 
will be summarized and listed by [CONTACT_556807] (CSR) for this 
protocol. Prior medications will be defined as medications that  were stopped before the day of 
the first dose of study drug. Concomitant medications will be defined as medications that 1) were 
started before the first dose of study drug and were continuing at the time of the first dose of 
study drug, or 2) were starte d on or after the date of the first dose of study drug up to 30 days 
after the patient’s last dose (as of the Safety Follow -up Visit). In addition, telephone contacts 
with patients should be conducted to assess i mAEs and concomitant medications (if appropriate, 
ie, associated with an i mAE or is a new anticancer therapy) at 60 and 90  days (±  7 days) after the 
last dose of study drugs regardless of whether or not the patient starts a new anticancer therapy.  
9.2. Efficacy Analyses  
The efficacy endpoints inc luding PFS, CR rate, ORR, DOR, and OS will be summarized by [CONTACT_556808]. The efficacy endpoints will be compared in Arm A versus Arm C and 
Arm B versus Arm C. These analyses are descriptive and exploratory; no formal testing was 
designed fo r this study.  
9.2.1.  Primary Efficacy Analysis  
The primary endpoint is PFS as assessed by [CONTACT_431]. PFS per investigator is defined as the 
time from randomization to the first documented disease progression as assessed by [CONTACT_109823]  v1.1, or death from any cause, whichever occurs first. 
Kaplan -Meier methodology will be used to estimate median or other quartiles of PFS along with 
its 95% confidence interval ( CI; constructed using the Brookmeyer and Crowley method). 
Kaplan -Meier curves  will be constructed to provide a visual description of PFS distribution. 
Event -free rate at selected timepoints will be estimated with 95% CI using Greenwood formula. 
The hazard ratio (HR) for PFS for each comparison (ie, Arm A versus Arm C, Arm B versus 
Arm C) will be estimated using a stratified Cox regression model. The 95% CI for the HR will 
be provided. Unstratified analysis will also be presented.  
Subgroup analysis of primary endpoint of PFS per investigator will be conducted to determine 
whether the  treatment effect is consistent across various subgroups. Subgroup factors include but 
are not limited to PD -L1 expression in tumor cells (clinical meaningful cutoffs), TIGIT 
expression level (clinical meaningful cutoffs), region, race, disease stage, gend er, and age.  
9.2.2.  Secondary Efficacy Analysis  
Complete Response Rate  
CR rate is the proportion of patients who had a CR as assessed by [CONTACT_440277] v1.1 
in all randomized patients with measurable disease at baseline. Patients without any postbaseline  
assessment will be considered nonresponders. CR rate and its Clopper -Pearson 95% CI will be 
calculated for each arm. The comparison in CR rate between arms will be evaluated using the 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 99 Cochran -Mantel -Haenszel (CMH) Χ2 test with the actual stratification fa ctors as strata. Odds 
ratio and the difference in CR rate, as well as their 2-sided 95% CIs , will be calculated.  
Overall Response Rate  
ORR is the proportion of patients who had a CR or PR as assessed by [CONTACT_556749]  v1.[ADDRESS_731282] . Similar methodology used to evaluate PFS will be applied to the analysis 
of DMFS . 
The distant metastasis includes separate tumor nodule(s) in a contralateral lobe, tumor with 
pleural or pericardial nodules or malignant pleural or effusion pericardial, single extrathoracic 
metastasis in a single organ (including involvement of a single nonregional node), and multiple 
extrathoracic metastases i n a single organ or in multiple organs.  
ORR, PFS , and OS in PD -L1 and TIGIT Subgroups  
Clinical ly meaningful cutoffs of PD -L1 and TIGIT expression level will be selected  to divide  the 
biomarker -evaluable patients into subgroups.  ORR, PFS , and OS analysis by [CONTACT_4002] -L1 and TIGIT 
expression subgroups will be performed to investigate the predictive value of these  biomarkers . 
9.2.3.  Exploratory Efficacy Analysis  
Biomarker Analysis  
Raw b iomarker data will be normalized to adjust for batch effect , if applicable,  for exploratory 
statistical analyses. Receiver operating characteristics curves will be generated and AUC will be 
calculated based on a logistic regression model to evaluate the association between continuous 
biomarkers and ORR. Biomarker cutof fs (PD-L1 and TIGIT expression level s) used in subgroup 
analys es will be explored in this study using the Youden method. The cutoffs from the Youden 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 100 method or/and clinically meaningful cutoffs will be used in subgroup analys es. Logistic 
regression and Cox regression will be used to evaluate the prognostic and predictive effects of 
the biomarker s on response and survival endpoints with treatment, biomarker status , and their 
interaction as the main factors.  
The potential utility of ctDNA level change as a su rrogate predictor of efficacy and the 
mechanisms of resistance will also be assessed.  
Health -Related Quality of Life  
Summary statistics (mean, standard deviation, median, and range) of the postbaseline scores and 
changes from baseline will be reported for the EORTC QLQ -C30 and QLQ -LC13 
questionnaires. Line charts depi[INVESTIGATOR_235241] (and standard errors) over time from the 
baseline assessment will be provided for each treatment arm. The clinically meaningful changes 
postbaseline and a mixed model ana lysis will be performed  using the global health status , 
physical function and fatigue domains of QLQ -C30, and dyspnoea, coughing, haemotysis and 
pain in chest, pain in arms and shoulders and peripheral neuropathy domains of QLQ -LC13. 
Completion and complia nce rates will be summarized at each timepoint by [CONTACT_2939]. Only 
patients in the ITT Analysis Set with a nonmissing baseline assessment and ≥  1 in-study 
nonmissing postbaseline assessment will be included in the analyses.  
9.3. Safety Analyses  
Safety will b e assessed by [CONTACT_556759]-CTCAE v5.0 . 
Laboratory values (eg, hematology, clinical chemistry, coagulation, urinalysis), vital signs, 
ECGs, and physical examinations will also be used to assess safety. Descriptive statistics will be 
used to analyze all safety data overall and by [CONTACT_556809] . 
9.3.1.  Extent of Exposure  
Extent of exposure to each study drug will be summarized descriptively as the number of cycles 
received (number and percentage of patients), duration of exposure (days), cumulative total dose 
received per patient (mg), dose intensity, and relative dose intensity.  
The number (percentage) o f patients requiring dose reduction, interruption, dose delay, and drug 
discontinuation due to AEs will be summarized for each study drug. Frequency of the above dose 
adjustments and discontinuation will be summarized by [CONTACT_17203].  
Patient data listings wil l be provided for all dosing records and for calculated summary statistics.  
9.3.2.  Adverse Events  
The AE verbatim descriptions (investigator’s description from the eCRF) will be classified into 
standardized medical terminology using MedDRA. AEs will be coded  according  to MedDRA 
(Version  22.0 or higher) lowest level term closest to the verbatim term, Preferred Term (PT), and 
primary System Organ Class (SOC).  
A TEAE is defined as an AE that had an onset date or a worsening in severity from baseline 
(pretreatment) on  or after the first dose of study drug and up to [ADDRESS_731283]. The TEAE 
classification also applies to i mAEs that are recorded up to 90  days after discontinuat ion of 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 101 ociperlimab or tislelizumab , regardless of whether the patient starts a new anticancer therapy. 
Only those AEs that were treatment -emergent will be included in summary tables. All AEs, 
treatment -emergent or otherwise, will be presented in patient data listings.  
The incidence of TEAEs will be reported as the number (percentage) of patients with TEAEs by 
[CONTACT_3592]. A patient will be counted only once by [CONTACT_397806]-CTCAE  v5.0 withi n an SOC and PT, even if the patient experienced more than 1 TEAE 
within a specific SOC and PT.  
The number (percentage) of patients with TEAEs will also be summarized by [CONTACT_556810]. Treatment -related AEs include those events considered  by [CONTACT_319492] a study drug or with missing assessment of the causal relationship.  
SAEs, deaths, TEAEs ≥  Grade  3 severity, i mAEs, treatment -related TEAEs, and TEAEs that led 
to treatment discontinuation, dose interruption, dose redu ction, or dose delay will be 
summarized.  
9.3.3.  Laboratory Analyses  
Clinical laboratory (eg, hematology, serum chemistry, and urinalysis) values will be evaluated 
for each laboratory parameter as appropriate. Abnormal laboratory values will be flagged and 
identif ied as those outside (above or below) the normal range. Reference (normal) ranges for 
laboratory parameters will be provided. Descriptive summary statistics (eg, n, mean, standard 
deviation, median, minimum, maximum for continuous variables; n [%] for cate gorical 
variables) for laboratory parameters and their changes from baseline will be calculated. 
Laboratory values will be summarized by [CONTACT_3595].  
Laboratory parameters that are graded by [CONTACT_12134]-CTCAE v5.0  will be summarized by 
[CONTACT_12134]-CTCAE grade. In the summary of laboratory parameters by [CONTACT_12134] -CTCAE grade, parameters 
with NCI -CTCAE grading in both high and low directions (eg, glucose, potassium, sodium) will 
be summarized separately.  
9.3.4.  Vital  Signs  
Descriptive statistics for vital sign s parameters (body temperature, pulse rate, and systolic and 
diastolic blood pressure) and changes from baseline will be presented by [CONTACT_3597]. Vital 
signs will be listed by [CONTACT_69867].  
9.3.5.  Pulmonary Function Test  
Pulmonary function test results will be listed by [CONTACT_556811].  
9.4. Pharmacokinetic Analysis  
Ociperlimab and tislelizumab serum concentration data will be tabulated and summarized by [CONTACT_556761]/cycle at which these concentrations  are collected. Descriptive statistics will include means, 
medians, ranges, and standard deviations, as appropriate.  Additional PK analyses may be 
conducted as appropriate.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 102 Additional PK analyses, including population PK analyses and exposure -response anal yses 
(efficacy or safety endpoints) may be conducted as appropriate and the results of such analysis 
may be reported separately from the clinical study report.  
9.5. Immunogenicity Analys is 
The anti-ociperlimab antibody and anti-tislelizumab antibody results wil l be summarized using 
descriptive statistics by [CONTACT_556762]. 
The incidence of positive ADAs and neutralizing ADAs will be reported for evaluable patients. 
The effect of immunogenicity on PK, efficacy, a nd safety may be evaluated if data allow and 
will be reported separately from the main study report.  
9.6. Sample Size Consideration  
This study is not designed to make explicit power and type I error consideration s but rather to 
obtain preliminary efficacy and s afety data for ociperlimab plus tislelizumab and tislelizumab 
monotherapy for patients with untreated LS -SCLC. This study will enroll approximately 120 
subjects into 3 arms with approximately 40 patients in each arm. The contribution of tislelizumab 
to the  efficacy results will be demonstrated by [CONTACT_556763], ORR , and DOR in the 
comparison of Arm B versus  Arm C. The contribution of adding ociperlimab  will be 
demonstrated by [CONTACT_556812] A versus  Arm B. With 
a sample size of 40 patients in each arm, the binomial probabilities of detecting 1 or more 
TEAEs with a frequency of 5% and 1% are approximately 0.[ADDRESS_731284] safety 
assessments at the following timepoints:  
• After approximately 6 patients (≥  2 patients per arm) have completed 2 cycles of 
study treatment   
• After approximately 18 patie nts (≥ 6 patients per arm) have completed [ADDRESS_731285]  
• After the scheduled SMC assessments, the SMC will review data approximately 
every [ADDRESS_731286] 18 months of the study and yearly thereafter  
The SMC could review data more frequently if indicated or requested by [CONTACT_556813]. The SMC may recommend 
study modification s including early termination of the study due to safety concerns. Full details 
of the SMC procedures and processes can be found in the SMC Charter.  
Enrollment may continue during these SMC safety reviews.  
10.1.1.  Study Safety Stoppi[INVESTIGATOR_556711], early stoppi[INVESTIGATOR_556712] a prespecified 
stoppi[INVESTIGATOR_1877]. The early stoppi[INVESTIGATOR_556713] 
≥ Grade [ADDRESS_731287] more than one AEs as defined above, the patients will be counted only once. 
If the early stoppi[INVESTIGATOR_556714], enrollment will be suspended to wait for the 
recommendation of the SMC. Based on the SMC recommendation, the sponsor may choose to:  
1. terminate the treatment arm  or arms meeting  the stoppi[INVESTIGATOR_1877]; 
2. amend the protocol to improve the benefit/risk for patients ; 
3. continue without any changes.  
The stoppi[INVESTIGATOR_556715], Simon, and 
Estey ( Thall et al 1995 ). The sponsor may consider terminating the treatment arm if the posterior 
probability of the AE rate of greater than 30% is at least 80% for that treatment arm. 
Noninformative prior of Beta  (1,1) is used to calculate the Bayesian posterior probability. Two 
evaluations of early stoppi[INVESTIGATOR_556716].  
1. The first one is planned when approximately 18 patients (≥ 6 patients per arm) have 
completed 2 cycles of study treatment. Based on the prespecified early stoppi[INVESTIGATOR_1877], the  
early stoppi[INVESTIGATOR_556717] ≥ [ADDRESS_731288] early stoppi[INVESTIGATOR_556718] 60 patients (≥ 20 patients per arm)  have completed 2 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 104 cycles of study treatment, whichever is earlier. Based on the prespecified early stoppi[INVESTIGATOR_10035], the early stoppi[INVESTIGATOR_556717] ≥ 8 patients with the above AEs among 20 
patients in Arm A or Arm B.  
The s toppi[INVESTIGATOR_556719] A or 
Arm B at the analysis timing of early stoppi[INVESTIGATOR_556720].  
Besides the stoppi[INVESTIGATOR_556721], the sponsor will further evaluate the trend of 
the AE rates between experimental arm ( Arm A  or Arm B) and control arm (Arm C). The safety 
evaluation will be continued by [CONTACT_556814][INVESTIGATOR_556722]. An 
ad-hoc SMC review will be triggered for further safety evaluation if necessary to address 
emerging safety concerns .  
 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 105 11. SOURCE DOCUMENTS AND  ACCESS TO SOURCE 
DATA/DOCUMENTS  
The investigator must maintain adequate and accurate records to ensure that the conduct of the 
study may be fully documented. Such records include, but are not limited to, the protocol, 
protocol amen dments, ICFs, and documentation of IRB/IEC and governmental approvals. In 
addition, at the end of the study, the investigator will receive patient data, which will include an 
audit trail containing a complete record of all changes to such data.  
11.1. Access to I nformation for Monitoring  
In accordance with International Council for Harmonisation ( ICH) GCP guidelines, the study 
monitor must have direct access to the investigator’s source documentation in order to verify the 
data recorded in the eCRFs for consistenc y. 
The monitor is responsible for routine review of the eCRFs at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy of the 
data being entered on them. The monitor should have access to  any patient records needed to 
verify the entries on the eCRFs. The investigator agrees to cooperate with the monitor to ensure 
that any problems detected during these monitoring visits are resolved.  
11.2. Access to Information for Auditing or Inspections  
Repres entatives of regulatory authorities or of the sponsor  may conduct inspections or audits any 
time during or after completion of this clinical study. If the investigator is notified of an 
inspection by a regulatory authority, the investigator agrees to notif y the sponsor or its designee 
immediately. The investigator agrees to provide access to records, facilities, and personnel to 
representatives of a regulatory agency or the sponsor  for the effective conduct of any inspection 
or audit.  
Version .[ADDRESS_731289] a regulatory inspection 
of this study. Such audits/inspections can occur at any time during or after completion of the 
study. If an audit or inspection occurs, the investigator and institution agree to allow the 
auditor/inspector direct access to all relevant documents and to allocate his/her time and the time 
of his/her personnel to the auditor/inspector to discuss findings and any relevant issues.  
12.3. Study Site Inspections  
This study will be organized, performed, and reported in compliance with the prot ocol, standard 
operating procedures, working practice documents, and applicable regulations and guidelines. 
Site audits may be performed periodically by [CONTACT_456]’s or the contract research 
organization’s qualified compliance auditing team, which is an i ndependent function from the 
study team responsible for conduct of the study.  
Site visits will be conducted by [CONTACT_338560], 
patients’ medical records, and eCRFs. The investigator is to permit national a nd local health 
authorities; sponsor study monitors, representatives, and collaborators; and IRB/IEC members to 
inspect all facilities and records relevant to this study.  
12.4. Drug Accountability  
The investigator or designee (ie, pharmacist) is responsible for  ensuring adequate accountability 
of all used and unused study drug. This includes acknowledgment of receipt of each shipment of 
study product (quantity and condition), patient drug dispensation records, and returned or 
destroyed study product. Dispensatio n records will document quantities received from the 
sponsor ’s designated depot or its designee and quantities dispensed to patients, including 
batch/lot number, date dispensed, patient identifier number, and the initials of the person 
dispensing the medic ation.  
At study initiation, the monitor will evaluate the site’s standard operating procedure for study 
drug disposal/destruction to ensure that it complies with the sponsor’s  requirements specified in 
the Pharmacy Manual. At appropriate times during the conduct of the study or at the end of the 
study following final drug inventory reconciliation by [CONTACT_2037], the study site will dispose of 
and/or destroy all unused study dru g supplies, including empty containers, according to these 
procedures. If the site cannot meet the sponsor ’s requirements specified in the Pharmacy Manual 
for disposal, arrangements will be made between the site and the sponsor  or its representative for 
destruction or return of unused study drug supplies.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 107 All drug supplies and associated documentation will be periodically reviewed and verified by [CONTACT_69878].  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 108 13. ETHICS/PROTECTION OF  HUMAN PATIENTS  
13.1. Ethical Standard  
This study will be conducted by [CONTACT_458] [INVESTIGATOR_556723] E6 guideline for GCP  and the principles of the Declaration of 
Helsinki or the laws and regulations of the country in which the research is conducted, whic hever 
affords the greater protection to the patient. The study will also comply with the requirements of 
the ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards for 
Expedited Reporting).  
13.2. Institutional Review Board/Independent Ethi cs Committee  
This protocol, the ICFs, any information to be given to the patient, and relevant supporting 
information must be submitted, reviewed, and approved by [CONTACT_1201]/IEC before the study is 
initiated. In addition, any patient recruitment materials mus t be approved by [CONTACT_1201]/IEC.  
Copi[INVESTIGATOR_5196]/IRB correspondence and approval of the amended ICF/other information and 
the approved amended ICF/other information must be forwarded to the sponsor promptly.  
The principal investigator [INVESTIGATOR_556724]/IEC annually or more frequently in accordance with the requirements, policies, 
and procedures established by [CONTACT_1201]/IEC. Investigators are also responsible for promptly 
informing the IRB/IEC of any protocol amendments. In addition to the requirements for 
reporting all AEs to the sponsor, investigators must comply with requirements for reporting 
SAEs to the local health authority and IRB/IEC. Investigators may receive written 
investigational ne w drug  (IND) safety reports or other safety -related communications from the 
sponsor. Investigators are responsible for ensuring that such reports are reviewed and processed 
in accordance with health authority requirements and the policies and procedures es tablished by 
[CONTACT_11577]/IEC and archived in the site’s study file.  
13.2.1.  Protocol Amendments  
Any protocol amendments will be prepared by [CONTACT_456]. All protocol modifications must be 
submitted to competent authorities according to local requirements and to the IRB/IEC  together 
with, if applicable, a revised model ICF  in accordance with local requirements. Written 
documentation from competent authorities (according to local requirements) and from the 
IRB/IEC and required site approval must be obtained by [CONTACT_556815], except for changes necessary to eliminate an immediate hazard to patients or 
changes that involve logistical or administrative aspects only (eg, change in medical monitor or 
contact [CONTACT_3031]).  
Information on any ch ange in risk and/or change in scope must be provided to patients already 
actively participating in the study, and they must read, understand, and sign each revised ICF 
confirming their willingness to remain in the study.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 109 13.3. Informed Consent  
The sponsor’s sam ple ICF will be provided to each site. If applicable, it will be provided in a 
certified translation of the local language. The final IRB/IEC -approved ICFs must be provided to 
the sponsor for health authority submission purposes according to local requirem ents. 
The ICFs must be signed and dated by [CONTACT_12718]’s legally authorized 
representative before his or her participation in the study. The case history or clinical records for 
each patient shall document the informed consent process and th at written informed consent was 
obtained before  participation in the study.  
The ICFs will be revised whenever there are changes to study procedures or when new 
information becomes available that may affect the willingness of the patient to participate. The  
final revised IRB -/IEC -approved consent forms must be provided to the sponsor for health 
authority submission purposes.  
Patients must reconsent to the most current version of the ICFs (or to a significant new 
information/findings addendum in accordance wi th applicable laws and IRB/IEC policy) during 
their participation in the study. For any updated or revised ICFs, the case history or clinical 
records for each patient shall document the informed consent process and that written informed 
consent was obtaine d using the updated/revised ICFs for continued participation in the study.  
A copy of each signed ICF must be provided to the patient or the patient’s legally authorized 
representative. All signed and dated ICFs must remain in each patient’s study file or in the site 
file and must be available for verification by [CONTACT_9534].  
13.4. Patient and Data Confidentiality  
The principal investigator [INVESTIGATOR_556725], storage, transmission, and 
processing of patients’ personal and medical information.  
The principal investigator [INVESTIGATOR_338491] a 
unique patient identification number assigned to each patient enrolled in the study. This approach 
ensures that patients’ names are not included in any dataset transmitted to any sponsor location.  
Patient medical information obtained during this study is confidential and may be disclosed only 
to third parties  as permitted by [CONTACT_69874] (or a separate authorization for the use and 
disclosure of personal health information that has been signed by [CONTACT_102]), unless permitted or 
required by [CONTACT_2371].  
In the event of a breach of the confidentiality of a patient’s  personal and medical information, the 
principal investigator [INVESTIGATOR_38107], as appropriate, shall fulfill all mediation steps and reporting 
obligations under applicable data privacy laws.  
Medical information may be given to a patient’s personal physician or  other appropriate medical 
personnel responsible for the patient’s welfare for treatment purposes.  
Data generated during this study must be available for inspection upon request by [CONTACT_556816] , the China NMPA, and all other national and l ocal health authorities; by [CONTACT_556817], representatives, and collaborators; and by [CONTACT_1026]/IECs for each study site, as 
appropriate.  
Version .[ADDRESS_731290] ensure that patients’ anonymity will be strictly maintained and that their 
identities are prot ected from unauthorized parties. The investigator agrees that all information 
received from the sponsor, including but not limited to, the Investigator's Brochure, this protocol, 
eCRFs, the IND, and any other study information, remain the sole and exclusiv e property of the 
sponsor during the conduct of the study and thereafter. This information is not to be disclosed to 
any third party (except employees or agents directly involved in the conduct of the study or as 
required by [CONTACT_2371]) without prior written cons ent from the sponsor. The investigator further agrees 
to take all reasonable precautions to prevent the disclosure by [CONTACT_509043].  
If a written contract for the conduct of t he study is executed, and that contract includes 
confidentiality provisions inconsistent with this section, that contract’s provisions shall apply to 
the extent they are inconsistent with this section.  
13.5. Financial Disclosure  
Investigators are required to provide the sponsor with sufficient accurate financial information in 
accordance with regulations to allow the sponsor to submit complete disclosure or certification to 
the absence of certain financial interest s of the clinical investigators, and/or disclo se those 
financial interests, as required, to the appropriate health authorities. This is intended to ensure 
that financial interests and arrangements of the clinical investigators with the sponsor  that could 
affect reliability of data submitted to health authorities are identified and disclosed by [CONTACT_103]. Investigators are responsible for providing information about their financial interests 
before participation in the study and for updating this information if any relevant changes occur 
during the st udy and for 1 year after completion of the study (ie, last patient, last visit).  
Version .[ADDRESS_731291] after the data is collected or received by [CONTACT_556818].  
14.1.2.  Data Collection  
Data required by [CONTACT_397825] (EDC) system.  
Data collection in the eCRF should follow the instructions described in the eCRF  Completion 
Guidelines. The investigator has ultimate responsibility for the collection and reporting of all 
clinical data entered in the eCRF. The e -signature [CONTACT_556833], au thenticity, and completeness.  
Data contained in the eCRFs are the sole property of the sponsor  and should not be made 
available in any form to third parties without written permission from the sponsor , except for 
authorized representatives of the sponsor  or appropriate regulatory authorities.  
14.1.3.  Data Management/Coding  
All final patient data, both eCRF and external data (eg, laboratory data), collected according to 
the protocol will be stored by [CONTACT_556819].  
Standard procedures (includin g following data review guidelines, computerized validation to 
produce queries, and maintenance of an audit file that includes all database modifications) will 
be followed to support accurate data collection. Data will be reviewed for outliers, logic, data  
inconsistencies, and completeness.  
During the study, a study monitor (clinical research associate) will make site visits to review 
protocol compliance, compare eCRFs against individual patient’s medical records, and ensure 
that the study is being conducte d according to pertinent regulatory requirements.  
The eCRF entries will be verified with source documentation. The review of medical records 
will be performed in a manner to ensure that patient confidentiality is maintained. Checking the 
eCRFs for complete ness, clarity, and cross -checking with source documents is required to 
monitor the progress of the study. Direct access to source data is also required for inspections 
and audits and will be carried out with due consideration given to data protection and m edical 
confidentiality.  
The AE verbatim descriptions (the investigator’s description from the eCRF) will be coded using 
MedDRA. AEs will be coded to MedDRA by [CONTACT_556820], PT, and primary SOC. 
Concomitant medications will be coded using the World Health Organization (WHO) Drug 
Dictionary. Concomitant diseases/medical history will be coded using MedDRA.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 112 14.2. Data Integrity and In -house Blinding  
Functions/persons with access to the EDC system shall be prohibited from using the EDC system 
to generate unnec essary listings/summaries that may introduce unwanted bias or to share such 
outputs from the EDC system with other functions/persons who do not have access to the EDC  
system . In addition, the central imaging vendor will perform the central imaging review w ithout 
knowledge of treatment arm assignment. Although the study is open -label, analyses or 
summaries generated by [CONTACT_556821].  
14.3. Study Records Retention  
The investigator must m aintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents should 
be classified into at least 1 of the following 2  categories: 1) investigator’s study file , and/or 2) 
patient clinical source documents.  
The investigator’s study file will contain the protocol/amendments, eCRF and query forms, 
IRB/IEC and governmental approval with correspondence, informed consent forms, drug 
records, staff curriculum vitae and  authorization forms, and other appropriate documents and 
correspondence.  
Patient clinical source documents (usually defined by [CONTACT_5280]/safety parameters independent of the eCRFs) would include documents such as 
(altho ugh not be limited to) the following: patient hospi[INVESTIGATOR_307]/clinic records, physician’s and nurse’s 
notes, appointment book, original laboratory reports, ECG, electroencephalogram, x-ray, 
pathology and special assessment reports, consultant letters, screening a nd enrollment logs, etc.  
After  closure of the study, the investigator must maintain all study records in a safe and secure 
location. The records must be maintained to allow easy and timely retrieval when needed (eg, 
audit or inspection) and, whenever feasi ble, to allow any subsequent review of data in 
conjunction with assessment of the facility, supporting systems, and personnel. Where permitted 
by [CONTACT_1207]/regulations or institutional policy, some or all of these records can be maintained in 
a format oth er than hard copy (eg, microfiche, scanned, electronic); however, caution needs to be 
exercised before such action is taken. The investigator must ensure that all reproductions are 
legible, are a true and accurate copy of the original, and meet accessibili ty and retrieval 
standards, including regenerating a hard copy, if required. Furthermore, the investigator must 
ensure there is an acceptable backup of these reproductions and that an acceptable quality control 
process exists for making these reproductions . 
The sponsor will inform the investigator of the time period for retaining these records to comply 
with all applicable regulatory requirements. The minimum retention time will meet the strictest 
standard applicable to that study center for the study, as d ictated by [CONTACT_251216], local laws or regulations, or the sponsor’s standards/procedures; otherwise, the 
retention period will default to [ADDRESS_731292] notify the sponsor of any changes in the archival arrangements, inc luding 
but not limited to the following: archival at an off -site facility, or transfer of ownership of or 
responsibility for the records in the event the investigator leaves the study center.  
Version .[ADDRESS_731293] be made between the investigator and the sponsor  to 
store these in sealed containers outside of the site so that they can be returned sealed to the 
investigator in case of a regul atory audit. When source documents are required for the continued 
care of the patient, appropriate copi[INVESTIGATOR_69786].  
Biological samples at the conclusion of this study may be retained as outlined in the agreement 
with t he CRO managing the biological samples, for the shorter of a period of up to 10  years or as 
allowed by [CONTACT_5282]/IEC.  
14.4. Protocol Deviations  
The investigator is responsible for ensuring that the study is conducted in accordance with the 
procedures and evaluations described in this protocol. Investigators assert they will apply due 
diligence to avoid protocol deviations and shall report all protocol deviations to sponsor.  
The investigator is to document and explain any deviations from the approved protoc ol. The 
investigator must promptly report any major deviations that might impact patient safety and/or 
data integrity to the sponsor and to the IRB/IEC, in accordance with established IRB/IEC 
policies and procedures.  
14.5. Study Report and Publications  
A clinica l study report will be prepared and provided to the regulatory agency(ies). The sponsor  
will ensure that the report meets the standards set out in the ICH Guideline for Structure and 
Content of Clinical Study Reports (ICH E3). Note that an abbreviated repo rt may be prepared in 
certain cases.  
The results of this study will be published or presented at scientific meetings in a timely, 
objective, and clinically meaningful manner that is consistent with good science, industry and 
regulatory guidance and the nee d to protect the intellectual property of the sponsor, regardless of 
the outcome of the study. The data generated in this clinical study are the exclusive property of 
the sponsor and are confidential. As this is a multicenter study, the first publication o r disclosure 
of study results shall be a complete, joint multicenter publication or disclosure coordinated by 
[CONTACT_456]. Thereafter, any secondary publications will reference the original publication(s). 
Authorship will be determined by [CONTACT_556822] ( International Commit tee of Medical 
Journal Editors 2018 ). 
Each investigator agrees to submit all manuscripts, abstracts, posters, publications, and 
presentations (both oral and written) to the sponsor for review before submission or presentation 
in accordance with the clinica l study agreement. This allows the sponsor to protect proprietary 
information, provide comments based on information from other studies that may not yet be 
available to the investigator, and ensure scientific and clinical accuracy. The details of the 
proce sses of producing and reviewing reports, manuscripts, and presentations based on the data 
from this trial will be presented in the investigator’s clinical study agreement. Each investigator 
agrees that, in accordance with the terms of the clinical study ag reement, a further delay of the 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 114 publication/presentation may be requested by [CONTACT_69881]/presentation.  
14.6. Study and Study Center Closure  
Upon completion of the study, the monitor will conduct the follo wing activities in conjunction 
with the investigator or study center personnel, as appropriate:  
• Return of all study data to the sponsor  
• Resolution and closure of all data queries  
• Accountability, reconciliation, and arrangements for unused study drug(s)  
• Review of study records for completeness  
• Collection of all study documents for the trial master file filing according to GCP and 
local regulation  
• Shipment of samples (including, but not limited to, those for PK, ADA, and 
biomarkers) to the assay lab for centr al lab analysis according to protocol and lab 
manual requirements  
In addition, the sponsor reserves the right to suspend the enrollment or prematurely discontinue 
this study either at a single study center or at all study centers at any time for any reason. 
Potential reasons for suspension or discontinuation include but are not limited to safety or ethical 
issues or noncompliance with this protocol, GCP, the sponsor’s written instructions, the clinical 
study agreement, or applicable laws and regulatio ns. If the sponsor determines such action is 
needed, the sponsor will discuss this with the investigator (including the reasons for taking such 
action) at that time. When feasible, the sponsor will provide advance notification to the 
investigator of the im pending action before it takes effect.  
The sponsor will promptly inform all other investigators and/or institutions conducting the study 
if the study is suspended or terminated for safety reasons. The sponsor will also inform the 
regulatory authorities of the suspension or termination of the study and the reason(s) for the 
action. If required by [CONTACT_5279], the investigator must inform the IEC/IRB promptly 
and provide the reason for the suspension or termination.  
If the study is prematurely disc ontinued, all study data must still be provided to the sponsor. In 
addition, arrangements will be made for the return of all unused study drug(s) in accordance with 
the applicable sponsor procedures for the study.  
Financial compensation to the investigato rs and/or institutions will be in accordance with the 
clinical study agreement established between the investigator and/or institutions and the sponsor.  
14.7. Information Disclosure and Inventions  
All rights, title, and interests in any inventions, know -how, or other intellectual or industrial 
property rights that are conceived or reduced to practice by [CONTACT_556823] a result of the study are the sole property of the sponsor and are hereby [CONTACT_556824].  
Version .[ADDRESS_731294]’s ownership provisions shall apply rather than this statement.  
All informat ion provided by [CONTACT_397829] (other than a patient’s medical records) are the sole property of the 
sponsor and will be kept confidential by [CONTACT_556825].  
This information and data will not be used by [CONTACT_556826].  
These restrictions do not apply to  the following : 
• Information that becomes publicly available through no fault of the investigator or 
study center personnel  
• Information that is necessary to disclose in confidence to an IEC/IRB solely for the 
evaluation of the study  
• Information that is necessary to disclo se to provide appropriate medical care to a 
patient  
• Study results that may be published as described in Section  14.[ADDRESS_731295]’s provisions shall apply rather than this statement.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 116 15. REFERENCES  
AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD -IDSA recommendations 
for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 
2015;62(3):932 -54. 
Acheampong E, Abed A, Morici M, et al. Tumour PD -L1 expression in small -cell lung cancer: a 
systematic review and meta -analysis. Cells . 2020;9(11):2393.  
Antonia SJ, Lopez -Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipi[INVESTIGATOR_556726] -cell lung cancer (CheckMate  032): a multicentre, open -label, Phase 1/2 trial. 
Lancet Oncol. 2016;17(7):P883 -95. 
Antonia SJ, Villegas A, Daniel D , et al. Durvalumab after chemoradiotherapy in stage III 
non-small -cell lung cancer. N Engl J Med. 2017;377:1919 -29. 
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after 
chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;37 9:2342 -50. 
Aupérin A, Arriagada R, Pi[INVESTIGATOR_286978], et al. Prophylactic cranial irradiation for patients with 
small -cell lung cancer in complete remission. Prophylactic cranial irradiation overview 
collaborative group . N Engl J Med. 1999;341:476 -84. 
Baker S, Fai rchild A. Radiation -induced esophagitis in lung cancer . Lung Cancer (Auckl). 
2016;7:119 -27. 
BeiGene Investigator’s Brochure, BGB -A1217. Edition 2. 1, November  2020.  
BeiGene Investigator’s Brochure, Tislelizumab (BGB -A317). Edition 8.0, September 2020.  
Bogar t JA, Herndon JE, 2nd, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent 
with chemotherapy for limited -stage small -cell lung cancer: analysis of cancer and leukemia 
Group B Study [ZIP_CODE]. Int J Radiat Oncol Biol Phys. 2004;59:460 -8. 
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune -related adverse events in 
patients treated with immune checkpoint inhibitor therapy: American Society of Clinical 
Oncology Clinical Practice Guideline . J Clin Oncol. 2018 ;36(17):1714 -68. 
Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates 
of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 
2018;68(6):394 -424. 
Chen W, Zheng R, Baade P, et al. Cancer statistics in Ch ina, 2015. CA Cancer J Clin. 
2016;66(2):115 -32. 
Chung HC, Lopez -Martin JA, Kao SC -H, et al. Phase 2 study of pembrolizumab in advanced 
small -cell lung cancer (SCLC): KEYNOTE -158. J Clin Oncol. 2018;36 (suppl  15):8506.  
Chung HC, Ros W, Delord J, et al. Effic acy and safety of pembrolizumab in previously treated 
advanced cervical cancer: results from the Phase II KEYNOTE -158 Study. J Clin Oncol. 
2019;37:1470 -8.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 117 Clinical Trials Facilitation Group (CTFG). Recommendations related to contraception and 
pregnancy te sting in clinical trials. September 15, 2014. 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/01 -
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf . 
Deng L, Liang H, Burnette B, et al. Radiation and anti-PD-L1 antibody combinatorial therapy 
induces T cell mediated depletion of myeloid -derived suppressor cells and tumor regression. 
Oncoimmunology . 2014;3:e28499.  
Deng R, Jin F, Prabhu S, et al. Monoclonal antibodies: What are the pharmacokinetic and 
pharmacodynami c considerations for drug development? Expert Opin Drug Metab Toxicol. 
2012;8(2):141 -60. 
Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin 
Pharmacokinet. 2010;49(10):633 -59. 
Dolgin M, Fox AC, Gorlin R, et al ; New Y ork Heart Association . Nomenclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels . 9th ed. Lippi[INVESTIGATOR_4603];  
[ADDRESS_731296] AL, Lipowska -Bhalla G, et al. Acquired resistance to fractionated 
radiotherapy can b e overcome by [CONTACT_276279]-L1 blockade. Cancer Res. 2014;74:5458 -68. 
Dovedi SJ, Cheadle EJ, Popple AL, et al. Fractionated  radiation therapy stimulates antitumor 
immunity mediated by [CONTACT_556827] T-cell populations when 
combined with PD-1 blockade. Clin Cancer Res . 2017;23:5514 -26. 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: 
revised RECIST Guideline ( Version 1.1). Eur J Cancer. 2009;45(2):228 -47. 
Faivre -Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice -daily 
chemoradiotherapy in patients with limited -stage small-cell lung cancer ( CONVERT ): an 
open-label, Phase 3, randomised, superiority trial. Lancet Oncol . 2017;18:1116 -25. 
Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic 
radiation therapy in combined modality therapy for limited -stage small -cell lung cancer . J Clin 
Oncol. 2004 ;22:4785 -93. 
Gandhi L, Rodriguez -Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in 
metastatic non -small -cell lung cancer. N Engl J Med. 2018;378:[ADDRESS_731297] subtypes of 
small cell lung cancer with unique therapeutic vulnerabilities (Abstract OA03.06). J Thorac 
Oncol. 2019;14(10):S213.  
Goldman  JW, Dowlati A, Antonia SJ, et al. Safety and antitumor activity of durvalumab 
monotherapy in patients with pretreated extensive disease small -cell lung cancer (ED-SCLC). J 
Clin Oncol. 2018;36 (suppl  15):8518.  
Grapin M, Richard C, Limagne E, et al. Optimized fractionated radiotherapy with anti -PD-L1 
and anti-TIGIT: a promising new combination . J Immunother Cancer . 2019;7:160 -71. 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 118 Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: 
ESMO clinical practice guidelines for diagnosis, treatment, and follow -up. Ann Oncol. 
2017:28(suppl 4):iv119 -42. 
Hellmann MD, Ott PA, Zugazagoitia J, et al. Nivolumab (nivo) ± ipi[INVESTIGATOR_125] (ipi) in advanced 
small -cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 
032 (Abstract 8503) . J Clin Oncol. 2017;35 (suppl  15). 
Horn L, Mansfield AS, Szczesna A, et al. First -line atezolizumab plus chemotherapy in 
extensive -stage small -cell lung cancer . N Engl J Med. 2 018;379:2220 -9. 
Hu F, Wang W, Fang C, et al. TIGIT presents earlier expression dynamic than PD -1 in activated 
CD8+  T cells and is upregulated in non -small cell lung cancer patients. Exp Cell Res. 
2020;396(1):112260.  
Human Protein Atlas. https://www.protein atlas.org/ENSG00000181847 -TIGIT/tissue . Accessed 
[ADDRESS_731298], 
reporting, editing, and publication of scholarly work in medical journals . 2018. 
http://www.icmje.org/icmje -recommendations.pdf. Accessed 10 September 2019.  
Johnston RJ, Comps -Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor 
and antiviral CD8+ T cell effector function.  Cancer Cell . 2014;26:823 -37. 
Keizer RJ, Huit ema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic 
monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493 -507. 
Kordbacheh T, Honeychurch J, Blackhall F, et al. Radiotherapy and anti-PD-1/PD -L1 
combinations in lung cancer: building bet ter translational research platforms . Ann Oncol. 
2018;29:[ADDRESS_731299] biotechnology products . J Immunol Methods. 
2008;333(1 -2):1-9. 
Labrijn AF, Buijsse AO, van den Bremer ET, et al. Therapeutic IgG4 antibodies engage in 
Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27(8):767 -71. 
Lally BE, Urbanic JJ, Blackstock AW, et al. Small cell lung cancer: have we  made any progress 
over the last 25 years? Oncologist . 2007;12(9):1096 -104. 
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. 
Ann Intern Med. 2009;150(9):604 -12. 
Lin SH, Lin Y, Yao L, et al. Phase II trial of co ncurrent atezolizumab with chemoradiation for 
unresectable NSCLC. J Thorac Oncol. 2020;15(2):248 -57. 
Miller KL, Marks LB, Sibley GS, et al. Routine use of approximately 60 Gy once -daily thoracic 
irradiation for patients with limited -stage small -cell lung cancer . Int J Radiat Oncol Biol Phys. 
2003;56:355 -9. 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 119 Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined 
modality treatment of limited -stage small-cell lung cancer. The National Cancer Institute of 
Canada Clinica l Trials Group. J Clin Oncol. 1993;11(2):336 -44. 
National Cancer Institute Common Toxicity Criteria for Adverse Events Version 5.0. 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_R
eference_5x7.pdf. Accessed 27  Novem ber 2017 . 
National Comprehensive Cancer Network [Internet]. NCCN Guidelines for treatment of cancer: 
non-small cell lung cancer, version 2, 2021. Available from: 
https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf . Accessed 0 4 September  2021.   
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649 -55. 
Ott P, Felip E, Hiret S, et al. OA05.01 Pembrolizumab in patients with extensive -stage small cell 
lung cancer: updated survival results from KEYNOTE -028. J Thorac Oncol. 
2017;12(suppl  1):S259.  
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy . Nat Rev Cancer . 
2012;12:252 -64. 
Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum –etoposide versus 
platinum -etoposide in first -line treatment of extensive -stage small -cell lung cancer (CASPI[INVESTIGATOR_204681]): 
a randomised, controlled, open -label , Phase 3 trial. Lancet . 2019;394([ZIP_CODE]):[ADDRESS_731300]. Non -Small Cell Lung Cancer Treatment (PDQ®): Health 
Professional Version. 2020 May 20. In: PDQ Cancer Information Summaries [Internet]. National 
Cancer Institute (US); 2002. https://www.ncbi.nlm.nih.gov/books/NBK6 5917/. Accessed 01 
September 2020.  
Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests . Eur 
Respir J. 2005;25(5):[ADDRESS_731301] line chemo -radiotherapy regimen in stage III non-small cell lung 
cancer -the ETOP NICOLAS trial . Lung Cancer 2019;133:83 -87. 
Peters S, Felip E, Dafni U, et al. LBA84 - Consolidation ipi[INVESTIGATOR_556727] d stage SCLC after chemo -radiotherapy: results from the ETOP/IFCT 4 -12 
STIMULI trial. Annals Oncol. 2020;31(suppl  4):S1142 -S1215.  
Pi[INVESTIGATOR_286978], Arriagada R, Ihde DC, et al. A meta -analysis of thoracic radiotherapy for small -cell 
lung cancer . N Engl J Med. 199 2;327:1618 -24. 
Pujol J -L, Greillier L, Audigier -Valette C, et al. A randomized non -comparative Phase II study 
of anti -programmed cell death -ligand 1 atezolizumab or chemotherapy as second -line therapy in 
patients with small cell lung cancer: results from the IFCT -1603 trial. J Thorac Oncol. 
2019;14(5):903 -13. 
Rodriguez -Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, 
double -blind, Phase  II study of the anti -TIGIT antibody tiragolumab (tira) plus atezolizumab 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 120 (atezo) versus placebo p lus atezo as first -line treatment in patients with PD-L1-selected NSCLC 
(CITYSCAPE). J Clin Oncol. 2020;38(suppl; abstr 9503).  
Roof KS, Fidias P, Lynch TJ, et al. Radiation dose escalation in limited -stage small -cell lung 
cancer. Int J Radiat Oncol Biol Phys. 2003;57:[ADDRESS_731302]-line 
treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin 
Oncol. 2012;30:[ADDRESS_731303] -line therapy for extensive -stage small -cell lung cancer: randomized, double -blind, 
Phase  III KEYNOTE -604 study. J Clin Oncol. 2020;38(21):[ADDRESS_731304] 
Pharmacol. 2017;6(9):576 -88. 
Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions --guidelines 
for healthcare providers. Resuscitation. 2008;77(2):157 -69. 
Tassi E, Graz ia G, Vegetti C, et al. Early effector T lymphocytes coexpress multiple inhibitory 
receptors in primary non -small cell lung cancer . Cancer Res. 2017;77(4):851 -61. 
Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic 
hepatitis  B. Hepatology. 2016;63(1):261 -83. 
Thall, P,  Simon  R, Estey  E, Bayesian sequential monitoring designs for single -arm clinical trials 
with multiple outcomes. Stat Med.  1995;14(4): [ADDRESS_731305], Kim K, Blum R, et al. Twice -daily compared with once-daily thoracic 
radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide . 
N Engl J Med. 1999;340:265 -71. 
Vanneman M and Dranoff G. Combining immunotherapy and targeted therapi[INVESTIGATOR_556728]. Nat Rev Cancer. 201 2;12(4):237 -51. 
Verma V, Simone CB, Allen PK, et al. Multi -institutional experience of stereotactic ablative 
radiation therapy for stage I small cell lung cancer . Int J Radiat Oncol. 2017;97:[ADDRESS_731306] -line (1L) treatment for advanced squamous non -small cell lung cancer (SQ 
NSCLC)  [ASCO Abstract 9554 ]. Clin Oncol. 2020; 38(suppl  15). 
Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited -stage 
small -cell carcinoma of the lung? A meta -analysis . J Clin Oncol. 1992;10:890 -5. 
Wei X, Liu HH, Tucker SL, et al. Risk factors for acute esophagitis in non -small -cell lung cancer 
patients treated with concurrent chemothera py and three -dimensional conformal radiotherapy . Int 
J Radiat Oncol Biol Phys. 2006;66(1):100 -7. 
Welsh  JW, Heymach  JV, Guo C , et al. Phase 1/2 trial of pembrolizumab and concurrent 
chemoradiation therapy for limited -stage SCLC. J Thor Oncol. 2020;15(12):19 19–27. 
Werner -Wasik M. Treatment -related esophagitis. Semin Oncol. 2005;32(Suppl  3):60 -6. 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 121 Worobec AS , Rosenberg AS. A risk-based approach to immunogenicity concerns of therapeutic 
protein products, Part 1: considering consequences of the immune response to a protein. 
BioPharm Intl. 2004a;17(11 ). 
Worobec AS , Rosenberg AS. A risk-based approach to immunogenicity concerns of therapeutic 
protein products, Part 2: considering host -specific and product -specific factors impacting 
immunogenicity . BioPharm Intl. 2004b;17(12).  
Wu CY, Budha N, Gao Y, et al. Tislelizumab exposure -respo nse analyses of efficacy and safety 
in patients with advanced tumors [ESMO Abstract 482P]. Ann Oncol. 
2019a;30(suppl  5):mdz244.044.  
Wu CY, Tang Z, Liu L, et al.  Population pharmacokinetics of tislelizumab in patients with 
advanced tumors [ESMO  Abstract 483P]. Ann Oncol. 2019 b;30(suppl 5):mdz244.045.  
Yang Z. Expression and function of TIGIT in B -cell non-Hodgkin lymphoma. Blood. 
2016;128:4138.  
Yu H, Koczara C, Badzio A, et al. Expression of an immune checkpoint - poliovirus receptor 
(PVR) in small cell lung c ancer . [AACR Abstract 3637]. Cancer Res. 2018; 78(suppl  13). 
Zhang M, Li G, Wang Y, et al. PD -L1 Expression  in lung cancer and its correlation with driver 
mutations: a meta -analysis. Sci Rep. 2017;7:[ADDRESS_731307] on its biological functions . Cancer Immunol Immunother. 2018;67(7):1079 -90. 
 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 122 APPENDIX  1. SCHEDULE OF ASSESSME NTS  
 
Assessment  Screening  
a Treatment Cycles  
 
EOT  Visit  b Safety Follow -up 
Visit  60-Day and 90 -Day 
Follow -up c Survival Follow -up 
d Cycles 1 to 2 ≥ Cycle  3 and up to 
Cycle 17 (approximately 
12 months ) 
Days ( Window ) -28 to -1 1 (+ 3) e 8 (±3) 15 (± 3) 1 (±3) [ADDRESS_731308] 
dose  30 (±7) days  after 
last dose  60 and 90 (±7) days 
after last dose  Every 3  months  
(±14  days) after  
Safety Follow -up 
STUDY ENTRY AND GENERAL ASSESSMENTS  
Informed consent a X         
Inclusion/exclusion  
criteria   X         
Randomization  f X         
Medical history 
(including cancer 
history)  g  X         
Demographics  g X         
Prior /concomitant 
medication evaluation  g Continuous from ≤ [ADDRESS_731309] dose of study treatment for AEs; [ADDRESS_731310] dose of ociperlimab plus 
tislelizumab or tislelizumab alone for imAEs. All SAEs considered related to the study drug(s) that are brought to the attention of the investigator 
should be reported regardless of time since the last dose of treatment.  
Physical examination  i X X X X X X X   
Vital signs/weight j X X X X X X X   
ECOG Performance 
Status  w X X   X X X   
Height  X         
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 123 Assessment  Screening  
a Treatment Cycles  
 
EOT  Visit  b Safety Follow -up 
Visit  60-Day and 90 -Day 
Follow -up c Survival Follow -up 
d Cycles 1 to 2 ≥ Cycle  3 and up to 
Cycle 17 (approximately 
12 months ) 
Days ( Window ) -28 to -1 1 (+ 3) e 8 (±3) 15 (± 3) 1 (±3) [ADDRESS_731311] 
dose  30 (±7) days  after 
last dose  60 and 90 (±7) days 
after last dose  Every 3  months  
(±14  days) after  
Safety Follow -up 
Pulmonary function  
test k Only if clinically indicated      
12-lead ECG l X Only if clinically indicated  X X   
Hematology m X X X X X (also Day 8 [±  3 days] 
in Cycles 3 and 4) m X X   
Chemistry m X X X  
X (also Day 8 [±  3 days] 
in Cycles 3 and 4) m X X   
Coagulation  
laboratory (PT, PTT, 
INR) m X X   
X X X   
Thyroid function  n X    
Cycles 4, 7, 10, 13, and 
16  
X   
HBV/HCV test o X As clinically indicated    
Urinalysis m X As clinically indicated    
Serum β-hCG  
pregnancy test p X         
Urine β-hCG  
pregnancy test p  X X   
X X X   
EFFICACY ASSESSMENTS  
Tumor assessment  
CT/MRI  X Tumor imaging will be performed at approximately 12  weeks (±  7 days) from the date of randomization (an additional tumor assessment is 
allowed if clinically indicated), then every 6  weeks (±  7 days) for the next 54  weeks, and then every 12  weeks (±  7 days) thereafter based 
on RECIST v1.1. (Section  7.5). 
Brain MRI with contrast 
or CT scan, with contrast, 
of the head  X Only if clinically indicated  
PRO q   
X   
X X    
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 124 Assessment  Screening  
a Treatment Cycles  
 
EOT  Visit  b Safety Follow -up 
Visit  60-Day and 90 -Day 
Follow -up c Survival Follow -up 
d Cycles 1 to 2 ≥ Cycle  3 and up to 
Cycle 17 (approximately 
12 months ) 
Days ( Window ) -28 to -1 1 (+ 3) e 8 (±3) 15 (± 3) 1 (±3) [ADDRESS_731312] 
dose  30 (±7) days  after 
last dose  60 and 90 (±7) days 
after last dose  Every 3  months  
(±14  days) after  
Safety Follow -up 
PHARMACOKINETIC ASSESSEMENTS  
Pharmacokinetics r  X   
Cycles 5, 9, and 17   
X   
Anti-ociperlimab and 
anti-tislelizumab 
antibody blood samples  s  
X   
Cycles 5, 9, and 17   
X   
BIOMARKER ASSESSMENTS  
Archived tumor t X         
Fresh tumor biopsy t X At the time of disease progression or  at EOT Visit (optional)     
Blood  u  
X 
(C1D1 
predose)    
C3D1, C5D1, disease progression or 
EOT Visit     
Investigational Product (s)  
Arm A:  
ociperlimab + 
tislelizumab 
administration  v  
X   
X     
Arm B:  
tislelizumab 
administration  v  
X   
X  
   
Concurrent CRT (chemotherapy every 3 weeks for 4 cycles)  
Radiation therapy 
administration  v   
Given once daily for a total dose of 60 to 70 Gy  
over 6 to 7 weeks       
Chemotherapy  v  
X   
X (through Cycle 4)      
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 125 Assessment  Screening  
a Treatment Cycles  
 
EOT  Visit  b Safety Follow -up 
Visit  60-Day and 90 -Day 
Follow -up c Survival Follow -up 
d Cycles 1 to 2 ≥ Cycle  3 and up to 
Cycle 17 (approximately 
12 months ) 
Days ( Window ) -28 to -1 1 (+ 3) e 8 (±3) 15 (± 3) 1 (±3) [ADDRESS_731313] 
dose  30 (±7) days  after 
last dose  60 and 90 (±7) days 
after last dose  Every 3  months  
(±14  days) after  
Safety Follow -up 
FOLLOW -UP 
Survival status        
X X X 
Disease therapy since IP 
discontinuation        
X X X 
Abbreviations: ADA, antidrug antibody; AE, adverse event; β -hCG, beta human chorionic gonadotropin; C xDy, Cycle x Day y; cCRT, concurrent 
chemoradiotherapy; CT, computed tomography; D, day; DLCO, diffusing capacity of the lungs for carbon monoxide; ECOG, Eastern Cooperative Oncology 
Group; EORTC QLQ -C30, European Organization for Research and Treatment of Cancer -Quality of Life C30 questionnaire; EOT, End of Treatment; FEV, 
forced expi[INVESTIGATOR_12194] ; HBcAb, hepatitis B core antibody; HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B  virus; 
HCV, hepatitis C virus; imAE, immune -mediated adverse event; INR, international normalized ratio; IEC, Independent Ethics C ommittee; IP, investigational 
product; IRB, Institutional Review Board; IRC, Independent Review Committee; IRT, integrated response technology; QLQ -LC13, Lung Cancer Module of 
EORTC QLQ -C30; MRI, magnetic resonance imaging; NCI, National Cancer Institute; PK, pharmacokinetics; PR, partial response; PRO, Patient -Reported 
Outcome; PT, prothrombin time; PTT, partial thromboplastin time; RT, radiation therapy; SAE, serious adverse event ; T3, triiodothyronine; T4, thyroxine . 
 
a Written informed consent is requir ed before performing any study -specific tests or procedures. Screening evaluations must be completed within [ADDRESS_731314] -of-care tests or examinations performed before obtaining informed consent and within 28 days before ra ndomization may 
be used for screening assessments rather than repeating such tests.  
b The EOT Visit (Section  3.4) is to be completed within 7 days after the decision to discontinue study treatment  or upon completion of study treatment . If routine 
laboratory tests (eg, hematology, serum chemistry) are com pleted within 7 days before the EOT Visit, these tests need not be repeated. Tumor assessment is not 
speci fically required at the EOT Visit. Patients who discontinue study treatment before disease progression confirmed by [CONTACT_556828]  7.5; however , in some cases , the time window of tumor assessment might overlap with the EOT and/or Safety 
Follow -up Visit. 
c The 60 -day and 90 -day follow -up visits may be completed at the site or by [CONTACT_756].  
d Survival follow -up information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 3 months after the Safety 
Follow -up Visit until death, loss to follow -up, withdrawal of consent, or end of study by [CONTACT_3211]. All patients will be followed up for survival and subsequent 
anticancer therapy information unless a patient requests to be withdrawn  from follow -up. 
e Cycle 1 Day 1 (C1D1) dosing should be initiated within [ADDRESS_731315] receive study treatment within 3 business days of randomization . 
g Includes age or year of birth, sex, and self -reported race/ethnicity; medical history includes any history of clinically significant disease, surgery, or cancer ; 
cancer history will include an assessment of prior surgery, prior RT, and prior drug thera py including start and stop dates, best response, and reason for 
discontinuation . Information on radiographic studies performed before study entry may be collected for review by [CONTACT_093]. Preexisting  AEs at baseline 
should be recorded as medical hi story. Refer to Section  7.1.[ADDRESS_731316]. For patients in Arm A and Arm B, immune -mediated AEs  (serious or nonserious) should be reported until [ADDRESS_731317] dose of 
ociperlimab plus tislelizumab or tislelizumab alone regardless of whether or not the patient starts a new anticancer therapy. All SAEs considered related to the 
study drug(s) that are brought to the attention of the investigator should be reported regardless of time since the last dose of treatment.  Refer to Section  8.6 for 
additional information.  
i A complete physical examination will be performed at the Screening Visit . At subsequent visits  and as clinically indicated , limited , symptom -directed physical 
examinations will be performed . Refer to Section  7.4.2  for additional information.  
j Vital signs collected on study include temperature, pulse rate, and blood pressure (systolic and diastolic). Vital signs will be assessed in Arms A, B, and C at 
screening, before study drug administration on Day s 1, 8, and [ADDRESS_731318] 2 cycles for all patients , at the beginning of each subsequent cycle , at the EOT 
Visit, and at the Safety Follow -up Visit  (Section  7.4.1 ). The patient’s vital signs should be recorded within [ADDRESS_731319] infusion of ociperlimab plus tislelizumab  (as a whole infusion ) in Arm A or tislelizumab alone  in Arm B  at each cycle visit for [ADDRESS_731320] results indicative of significantly impaired pulmonary function, eg, resting pulse oximetry 
< 90% on r oom air and further desaturation upon exercise, FEV1 < 60% or DLCO (if performed) < 60% of age - and sex-adjusted predicted performance levels 
(Pellegrino et al 2005 ), the medical monitor needs to be consulted to conf irm eligibility. Tests m ay be repeated as clinically indicated while on study.  
l The ECG recordings will be obtained during screening, as clinically indicated during the treatment period, at the EOT Visit, and at the Safety Follow -up Visit . 
Patients should rest in semirecumbent supi[INVESTIGATOR_19636] ≥  10 minutes before ECG collection . 
m Local laboratory assessments o f serum chemistry, hematology, coagulation, and urinalysis will be conducted  as outlined  in Appendix  2. If laboratory tests at 
screening are not performed within 7  days before the administration of study drug(s) on Day  1 of Cycle 1, these tests should be repeated and reviewed b efore 
administration of study drug(s). Hematology and serum chemistry  assessments  (including liver function tests) a re specified in Appendix  2. Hematology 
assessments should be performed at Day 1 (±  3 days), Day 8 (±  3 days), and Day 15 (±  3 days) of the first 2  cycles, at Day 1 (±  3 days) and Day 8 (±  3 days) of 
the third and the f ourth cycles, on Day 1 (± 3 days) of each subsequent cycle, at the EOT Visit, and at the Safety Follow -up Visit.  Serum chemistry  assessments  
(including liver function tests) should be performed on Day 1  (± 3 days) and Day 8 (±  3 days) of the first 4 cycles, on Day 1 (±  3 days) of each subsequent 
cycle , at the EOT Visit, and at the Safety Follow -up Visit. Coagulation ass essments  should be performed at screening, on Day 1 (±  3 days) of each cycle , at the 
EOT Visit, and at the Safety Follow -up Visit.  Urinalysis is to be conducted during the treatment period only if clinically warranted. Refer to Section  8.3.5  for 
additional information regarding clini cal assessment and management of clinical laboratory abnormalities.  
n Analysis of free T3 or total T3, free T4 or total T4, and thyroid -stimulating hormone will be performed by [CONTACT_79428]. Thyroid function tests 
will be performed at screening and every 3 cycles (ie, Cycles 4, 7, 10 , etc. ), and at the Safety Follow -up Visit.  
o Testing will be performed by [CONTACT_556829]/HCV serology (HBsAg, HBsAb, HBc Ab, and HCV antibody). 
After screenin g, viral load assessment (HBV DNA and HCV RNA) may be performed if clinically indicated. Patients who have detectable HBV DNA  at 
screening or upon repeat testing will undergo the respective viral load test every 4 cycles (, Cycles 4, 8, and 12).  
 
Version .[ADDRESS_731321] (for women of childbearing potential, including women who have had a tubal ligation) must be performe d and documented as 
negative within [ADDRESS_731322] is positive or equivocal.  
q To be completed before  any clinical activities during on -study site visits. EORTC QLQ -C30 and QLQ -LC13  questionnaires will be completed at predose on 
Day 1 of every cycle from Cycle 1 (baseline) through Cycle 4, and then to coincide with scheduled tumor assessments (every 6 weeks [±  7 days]) until the EOT 
Visit  (Arms A, B, and C) .  
r PK blood samples will be collected from patients who randomized to receive ociperlimab plus tislelizumab or tislelizumab alone  (Arms A and B). Procedures 
for collection of ociperlimab  and tislelizumab PK and ADA samples are described in the Laboratory Manu al. Predose (within [ADDRESS_731323] study drug infusion )PK samples  (Arm A: 2 samples  collected at the same time  [1 for ociperlimab , another for tislelizumab ]; Arm B: 1 sample for 
tislelizumab)  will be collected on Day 1 of Cycles 1, 2, 5, 9 and 17. Postdose (within [ADDRESS_731324] study drug infusion) PK sample s 
(2 samples collected at the same time [1 sample for ociperlimab; another for tislelizumab] in Arm A; 1  sample for tislelizumab in Arm  B) will be collected on 
Day 1 of Cycles 1 and 5 . An additional PK sample is required to be collected at the Safety Follow -up Visit  (Arm A: 2  samples collected at the same time [1 for 
ociperlimab, another for tislelizumab]; Arm B: 1  sample for tislelizumab) . Should a patient present with any ≥  Grade 3 imAE, an additional blood PK sample  
may be taken to determine the serum concentration of ociperlimab and tislelizumab  (Arm A: 2  samples collected at the same time [1 for ociperlimab, another 
for tislelizumab]; Arm B: 1  sample for tislelizumab) . These tests are required when it is allowed by [CONTACT_427]/IRBs/IECs.  
s ADA blood samples will be collected from patients who randomized to receive ociperlimab plus tislelizumab or tislelizumab alone  (Arms A and B).  Blood 
samples will be collected at predose (within 60 minutes before dose) on Day 1 of Cycles 1, 2, 5, 9, 17, and at the Safety Follow -up Visit for ociperlimab and 
tislelizumab  (Arm A: 2  samples collected at the same time [1 for ociperlimab, another for t islelizumab]; Arm B: 1  sample for tislelizumab) . All samples should 
be drawn at the same time as blood collection for predose PK analysis. These tests are required when it is allowed by [CONTACT_5737] r egulations/IRBs/IECs.  
t Patient s must agree to provide an archival tumor tissue with an associated pathology report or agree to perform a fresh biopsy during  screen ing (formalin -fixed 
paraffin -embedded block or approximately 15 unstained slides [8 slides  minimum ]). Note: If < 8 unstained slides are available, a di scussion with the sponsor is 
required . If the baseline archival tumor tissues are not collected during the screening period due to unspecified reasons, archival tissue collection after screening 
period is applicable. If baseline archival tumor tissue is not available, a fresh biopsy of a tumor lesion at baseline (within 28 days before randomization) is 
required . Optional biopsies will also be taken for the patients at confirmed disease progression or EOT fo r the assessment of mechanism of resistance. Written 
informed consent is required before collecting fresh tumor biopsies. If at any time during the study a patient undergoes a medically indicated procedure that has 
the likelihood of yielding tumor tissue, any remaining sample or a portion of the sample not necessary for medical diagnosis (leftover tumor tissue) may be 
obtained for exploratory analysis.  
u For Arm A and Arm B: Blood samples (about 10 mL at each timepoint) will be collected predose at C1D1, C 3D1, C5D1, EOT visit or at the time of confirmed 
disease progression  (whichever occurs first).  For Arm C: Blood samples (about 10 mL at each timepoint) will be collected predose at C1D1, C3D1, EOT visit 
or at the time of confirmed disease progression  (whichever occurs first) . 
v The schedule of RT and chemotherapy administrations is detailed in the specific section. The r ecommend ation is  to start RT on C1D1  of chemotherapy.  
Ociperlimab plus tislelizumab or tislelizumab alone should be given intravenously once every 3 weeks. The initial 2 infusion s (Cycl es 1 and 2 ) will be 
delivered over 60 (± 5) minutes, and administration can then occur over 30 (± 5)  minutes for subsequent infusions if well-tolerated. Patients must be monitor ed 
for 2 hours after infusion of tislelizumab followed by [CONTACT_556753] (Arm A)  and tislelizumab (Arm B)  on Day 1 of Cycle s 1 and 2; from Cycle [ADDRESS_731325] 4 cycles. On Day  1 of Cycles 1 to 4, chemotherapy drugs will be 
administered in a sequential manner  separately after the infusion of ociperlimab plus tislelizumab or tislelizumab alone ; cisplatin 75 mg/m2 will be administered 
on Day 1  of each cycle . If the patient is unable to tolerate the 1-day administration of cisplatin 75 mg/m2, at the investigator’s discretion  (eg, patients had 
concurrent superior vena cava syndrome)  cisplatin 25  mg/m2 dosed on Days 1, 2 and 3 is allowed ; carboplatin will be administered on Day 1 of each cycle ; 
etoposide will be administered on Days 1, [ADDRESS_731326] bilirubin  Platelet count   Blood  
Blood urea nitrogen or urea    24-hour protein a 
Potassium     
Sodium     
Calcium b    
Creatinine     
Glucose     
Lactate dehydrogenase     
Total protein     
Magnesium     
Phosphorus     
Chloride     
Creatine kinase/  
CK-MB c    
Abbreviations: CK -MB, creatine kinase cardiac muscle isoenzyme.  
a On routine urinalysis, if urine protein is ≥ 2+ by [CONTACT_5230] , then obtain a 24 -hour urine sample for total protein or a 
random urine sample for total protein and creatinine to determine a protein -to-creatinine ratio.  
b Calcium values will be corrected for pa tients with hypoalbuminemia.  
 c Cardiac enzyme testing has been added to monitor for potential event of immune -related myocarditis. If CK-MB 
fractionation is not available, assess troponin I and/ or troponin T instead. Investigators should make every effort to 
test either CK -MB, troponin I , and/or troponin T consistently at screening and at follow -up visits . 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 130 APPENDIX  3. EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG ) 
PERFORMANCE STATUS  
Grade  Description  
0 Fully active, able to carry on all predisease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light housework , office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities; up and 
about more than 50% of waking hours  
3 Capable of only limited self -care; confined to bed or chair more than 50% of waking hours  
4 Completely disabled; cannot carry on any self -care; totally confined to bed or chair  
5 Dead  
Source: Oken et al 1982 . Eastern Cooperative Oncology Group, Robert Comis MD, Group Chair.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 131 APPENDIX  4. THE RESPONSE EVALUAT ION CRITERIA IN SOLI D 
TUMORS (RECIST) GUID ELINES, VERSION 1.1  
Sourc e: Eisenhauer et al 2009 . 
Definitions  
Response and progression will be evaluated in this trial using the international criteria proposed 
by [CONTACT_8225] (RECIST) Committee (v1.1). Changes in 
only the largest diameter (uni -dimensional measurement) of the tumor lesions are used in the 
RECIST criteria.  
Note: Lesions are either measurable or nonmeasurable using the criteria provided below. The 
term “evaluable” in reference to me asurability will not be used because it does not provide 
additional meaning or accuracy.  
Measurable Disease  
Tumor lesions: Must be accurately measured in at least 1 dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum s ize of:  
• 10 mm by [CONTACT_20420] (CT) and magnetic resonance imaging (MRI) (no 
less than double the slice thickness and a minimum of 10  mm). Assumes a scan slice 
thickness no greater than 5 mm.  
• 10 mm caliper measurement by [CONTACT_461] (when superfici al) 
• [ADDRESS_731327] X -ray (if clearly defined and surrounded by [CONTACT_6776])  
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be ≥  [ADDRESS_731328] scan (CT scan slice thickness 
recomm ended to be no greater than 5  mm). At baseline and in follow -up, only the short axis will 
be measured and followed.  
Nonmeasurable Disease  
All other lesions (or sites of disease), including small lesions (longest diameter < 10 mm or 
pathological lymph nodes  with ≥ 10 to < 15  mm short axis), are considered nonmeasurable 
disease. Leptomeningeal disease, ascites, pleural, or pericardial effusion, inflammatory breast 
disease, lymphangitic involvement of skin or lung, and abdominal masses/abdominal 
organomegaly identified by [CONTACT_556830].  
Bone lesions:  
• Bone scan, positron -emission tomography (PET) scan, or plain films are not 
considered adequate imaging techniques to measure b one lesions. However, these 
techniques can be used to confirm the presence or disappearance of bone lesions.  
• Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue 
components, that can be evaluated by [CONTACT_12783] -sectional imaging techn iques such as CT 
or MRI can be considered as measurable lesions if the soft tissue component meets 
the definition of measurability described above.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 132 • Blastic bone lesions are nonmeasurable.  
Cystic lesions:  
• Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor nonmeasurable) since they 
are, by [CONTACT_108], simple cysts.  
• Cystic lesions thought to represent cystic metastases can be considered as measurable 
lesions if they mee t the definition of measurability described above. However, if 
noncystic lesions are present in the same patient, these are preferred for selection as 
target lesions.  
Lesions with prior local treatment:  
• Tumor lesions situated in a previously irradiated are a or in an area subjected to other 
locoregional therapy are usually not considered measurable unless there has been 
demonstrated progression in the lesion. Trial protocols should detail the conditions 
under which such lesions would be considered measurable . 
Target Lesions  
All measurable lesions up to a maximum of 2  lesions per organ and 5  lesions in total should be 
identified as target lesions and recorded and measured at baseline. Target lesions should be 
selected on the basis of their size (lesions with t he longest diameter), be representative of all 
involved organs, add lend themselves to reproducible repeated measurements.  
Lymph nodes merit special mention since they are normal anatomical structures that may be 
visible by [CONTACT_33490]. Pathological nodes that are defined as 
measurable and may be identified as target lesions must meet the criterion of a short axis of 
≥ [ADDRESS_731329] in which the image 
is obtained (for CT scan, this is almost always the axial plane; for MRI , the pl ane of acquisition 
may be axial, sagittal, or coronal). The smaller of these measures is the short axis. For example, 
an abdominal node that is reported as being 20  mm by 30  mm has a short axis of 20  mm and 
qualifies as a malignant, measurable node. In thi s example, 20  mm should be recorded as the 
node measurement. All other pathological nodes (those with short axis ≥  10 mm but < 15  mm) 
should be considered nontarget lesions. Nodes that have a short axis < 10  mm are considered 
nonpathological and should not  be recorded or followed.  
A sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted  above, only the short axis is added into the sum. The baseline 
sum diameters will be used as reference to further characterize any objective tumor regression in 
the measurable dimension of the disease.  
Nontarget Lesions  
All other lesions (or sites of dise ase) including pathological lymph nodes should be identified as 
nontarget lesions and should also be recorded at baseline. Measurements are not required and 
these lesions should be followed as “present,” “absent,” or in rare cases “unequivocal 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 133 progression”  (more details to follow). In addition, it is possible to record multiple nontarget 
lesions involving the same organ as a single item on the case record form (eg, “multiple enlarged 
pelvic lymph nodes” or “multiple liver metastases”).  
Guidelines for Evalua tion of Measurable Disease  
All measurements should be recorded in metric notation, using calipers if clinically assessed. All 
baseline evaluations should be performed as close as possible to the treatment start and never 
more than 4  weeks before the beginn ing of the treatment.  
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow -up. Imaging -based evaluation should 
always be done rather than clinical examination unless the lesion(s) being followed cannot be 
imaged but are assessable by [CONTACT_12148].  
• Clinical lesions: Clinical lesions will only be considered measurable when they are 
superficial and ≥ 10  mm diameter as assessed using calipers (eg, skin nodules). For 
the case of skin lesions, documentation by [CONTACT_3606] a ruler to 
estimate the size of the lesion is suggested. As noted above, when lesions can be 
evaluated by [CONTACT_197302], imaging evaluation should be 
undertaken since it is more objective and may also be reviewed at the end of the trial.  
• Chest X -ray: Chest CT is preferred over chest X -ray, particularly when progression is 
an important endpoint, since CT is more sensitive than X -ray, particularly in 
identifying new lesions. However, lesions on chest X -ray may be considered 
measurable if they are clearly defined and surrounded by [CONTACT_6776].  
• CT, MRI: CT is the best currently available and reproducible method to measure 
lesions selected for response as sessment. This guideline has defined measurability of 
lesions on CT scan based on the assumption that CT slice thickness is [ADDRESS_731330] slice thickness greater than 5  mm, the minimum size for a 
measurable lesion should be twice the sli ce thickness. MRI is also acceptable in 
certain situations (eg, for body scans).  
• Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be 
used as a method of measurement. Ultrasound examinations cannot be reproduced in 
their enti rety for independent review at a later date, and because they are operator 
dependent, it cannot be guaranteed that the same technique and measurements will be 
taken from one assessment to the next. If new lesions are identified by [CONTACT_397838], confirmation by [CONTACT_12154]. If there is concern 
about radiation exposure at CT, MRI may be used instead of CT in selected instances.  
• Endoscopy, laparoscopy: The utilization of these techniques for objective tumor 
evaluation is not a dvised. However, they can be useful to confirm complete 
pathological response when biopsies are obtained or to determine relapse in trials 
where recurrence following complete response (CR) or surgical resection is an 
endpoint.  
• Tumor markers: Tumor markers alone cannot be used to assess objective tumor 
response. If markers are initially above the upper normal limit, they must normalize 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 134 for a patient to be considered in CR. Because tumor markers are disease specific, 
instructions for their measurement should be incorporated into protocols on a disease -
specific basis. Specific guidelines for both CA -125 response (in recurrent ovarian 
cancer) and prostate -specific antigen response (in recurrent prostate cancer), have 
been published. In addition, the Gynecologic Cancer Intergroup has developed 
CA-[ADDRESS_731331] -line trials in ovarian cancer.  
• Cytology, histology: These techniques can be used to differentiate between partial 
respons e (PR) and CR in rare cases if required by [CONTACT_990] (for example, residual 
lesions in tumor types such as germ cell tumors, where known residual benign tumors 
can remain). When effusions are known to be a potential adverse effect of treatment 
(eg, with cer tain taxane compounds or angiogenesis inhibitors), the cytological 
confirmation of the neoplastic origin of any effusion that appears or worsens during 
treatment can be considered if the measurable tumor has met criteria for response or 
stable disease in o rder to differentiate between response (or stable disease) and 
progressive disease.  
Response Criteria  
Evaluation of Target Lesions  
• Complete response: Disappearance of all target lesions. Any pathological lymph 
nodes (whether target or nontarget) must have reduction in short axis to <  10 mm. 
• Partial response: At least a 30% decrease in the sum of diameters of target lesions, 
taking as reference the baseline sum diameters  
• Progressive disease: At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is 
the smallest on study). In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5  mm. (Note: The appearance of one or 
more new lesions is also considered progression).  
• Stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for progressive disease , taking as reference the smallest sum diameters while 
on study  
• Lymph nodes: Lymph  nodes identified as target lesions should always have the actual 
short axis measurement recorded (measured in the same anatomical plane as the 
baseline examination), even if the nodes regress to below 10  mm on study. This 
means that when lymph nodes are i ncluded as target lesions, the “sum” of lesions 
may not be zero even if CR criteria are met, since a normal lymph node is defined as 
having a short axis of <  [ADDRESS_731332] achieve a short axis <  10 mm. For PR, stable disease,  and progressive 
disease , the actual short axis measurement of the nodes is to be included in the sum of 
target lesions.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 135 • Target lesions that become “to o small to measure.” While on study, all lesions (nodal 
and non -nodal) recorded at baseline should have their actual measurements recorded 
at each subsequent evaluation, even when very small (eg, 2  mm). However, 
sometimes lesions or lymph nodes that are re corded as target lesions at baseline 
become so faint on CT scan that the radiologist may not feel comfortable assigning an 
exact measure and may report them as being “too small to measure.”  
When this occurs, it is important that a value be recorded on the electronic case report 
form (eCRF). If it is the opi[INVESTIGATOR_130990], the measurement should be recorded as 0  mm. If the lesion is believed to 
be present and is faintly seen but too small to measure, a default value of 5  mm 
should be assigned. (Note: It is less likely that this rule will be used for lymph nodes 
since they usually have a definable size when normal and are frequently surrounded 
by [CONTACT_108160], such as in the retroperitoneum; however, if a lymph node is be lieved to be 
present and is faintly seen but too small to measure, a default value of 5  mm should 
be assigned in this circumstance as well). This default value is derived from the [ADDRESS_731333] slice thickness (but should not be changed with varying CT slice thi ckness). The 
measurement of these lesions is potentially nonreproducible; therefore, providing this 
default value will prevent false responses or progressions based upon measurement 
error. To reiterate, however, if the radiologist is able to provide an act ual measure, 
that measurement should be recorded, even if it is below 5  mm. 
• Lesions that split or coalesce on treatment : When non -nodal lesions “fragment,” the 
longest diameters of the fragmented portions should be added together to calculate the 
target le sion sum. Similarly, as lesions coalesce, a plane between them may be 
maintained that would aid in obtaining maximal diameter measurements of each 
individual lesion. If the lesions have truly coalesced such that they are no longer 
separable, the vector of the longest diameter in this instance should be the maximal 
longest diameter for the “coalesced lesion.”  
Evaluation of Nontarget Lesions  
While some nontarget lesions may actually be measurable, they need not be measured and 
instead should be assessed only qualitatively at the time points specified in the protocol.  
• CR: Disappearance of all nontarget lesions and normalization of tumor marker level. 
All lymph nodes must be nonpathological in size (<  10 mm short axis).  
• Non-CR/Non -PD: Persistence of one or more nontarget lesion(s) and/or maintenance 
of tumor marker level above the normal limits  
• PD: Unequivocal progression (as detailed below) of existing nontarget lesions. (Note: 
The appearance of one or more new lesions is also considered progression.)  
• When the p atient also has measurable disease : In this setting, to achieve “unequivocal 
progression” on the basis of the nontarget disease, there must be an overall level of 
substantial worsening in nontarget disease such that, even in presence of stable 
disease  or PR in target disease, the overall tumor burden has increased sufficiently to 
merit discontinuation of therapy. A modest “increase” in the size of one or more 
nontarget lesions is usually not sufficient to qualify for unequivocal progression 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 136 status. The desi gnation of overall progression solely on the basis of change in 
nontarget disease in the face of stable disease  or PR of target disease will therefore be 
extremely rare.  
• When the patient has only nonmeasurable disease:  This circumstance arises in some 
Phase [ADDRESS_731334] measurable disease. The 
same general concept applies here as noted above; however, in this instance there is 
no measurable disease assessment to factor into the interpretation of an increase in 
nonmeasurable disease burden. Because worsening in nontarget disease cannot be 
easily quantified (by [CONTACT_108]: if all lesions are truly nonmeasurable) a useful test 
that can be applied when assessing patients for unequivocal progression is to consider 
if the increase in overall disease burden based on the change in nonmeasurable 
disease is comparable in magnitude to the increase that would be required to declare 
progressive disease  for measurable disease: ie, an increase in tumor burden 
representing an add itional 73% increase in “volume” (which is equivalent to a 20% 
increase diameter in a measurable lesion).  
• Examples include an increase in a pleural effusion from “trace” to “large,” an 
increase in lymphangitic disease from localized to widespread, or may b e described in 
protocols as “sufficient to require a change in therapy.” If “unequivocal progression” 
is seen, the patient should be considered to have had overall progressive disease  at 
that point. While it would be ideal to have objective criteria to app ly to 
nonmeasurable disease, the very nature of that disease makes it impossible to do so; 
therefore, the increase must be substantial.  
New Lesions  
The appearance of new malignant lesions denotes disease progression; therefore, some 
comments on detection o f new lesions are important. There are no specific criteria for the 
identification of new radiographic lesions; however, the finding of a new lesion should be 
unequivocal: ie, not attributable to differences in scanning technique, change in imaging 
modalit y or findings thought to represent something other than tumor (for example, some “new” 
bone lesions may be simply healing or flare of preexisting lesions). This is particularly important 
when the patient’s baseline lesions show partial or complete response . For example, necrosis of a 
liver lesion may be reported on a CT scan report as a “new” cystic lesion, which it is not.  
A lesion identified on a follow -up trial in an anatomical location that was not scanned at baseline 
is considered a new lesion and will  indicate disease progression. An example of this is a patient 
who has visceral disease at baseline and while on study has a CT or MRI brain scan ordered that 
reveals metastases. The patient’s brain metastases are considered to be evidence of progressive 
disease  even if he/she did not have brain imaging at baseline.  
If a new lesion is equivocal, for example because of its small size, continued therapy and 
follow -up evaluation will clarify if it represents truly new disease. If repeat scans confirm there 
is definitely a new lesion, then progression should be declared using the date of the initial scan.  
While fluorodeoxyglucose (FDG) -PET response assessments need additional study, it is 
sometimes reasonable to incorporate the use of FDG -PET scanning to complement CT scanning 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 137 in assessment of progression (particularly possible “new” disease). New lesions on the basis of 
FDG -PET imaging can be identified according to the following algorithm:  
• Negative FDG -PET at baseline, with a positive FDG -PET at follow -up, is a sign of 
progressive disease  based on a new lesion.  
• No FDG -PET at baseline and a positive FDG -PET at follow -up: If the positive 
FDG -PET at follow -up corresponds to a new site of disease confirmed by [CONTACT_4654], this is 
progressive disease . If the positive FDG -PET at follow -up is not confirmed as a new 
site of disease on CT, additional follow -up CT scans are needed to determine if there 
is truly progression occurring at that site (if so, the date of progressive disease  will be 
the date of the initial abnormal FDG -PET scan). If the positive FDG -PET at 
follow -up corresponds to a preexisting site of disease on CT that is not progressing on 
the basis of the anatomic images, this is not progressive disease . 
• Timepoint Response  
• It is assumed that at e ach protocol -specified time point, a response assessment occurs. 
The following table provides a summary of the overall response status calculation at 
each time point for patients who have measurable disease at baseline:  
Target Lesions  Nontarget Lesions  New  Lesions  Overall Response  
CR CR No CR 
CR Non-CR/non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD or not all evaluated  No PR 
Stable disease  Non-PD or not all evaluated  No Stable disease  
Not all evaluated  Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No PD 
Any Any Yes PD 
Abbreviations: CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response . 
When patients have nonmeasurable (therefore nontarget) disease only, the following table is to 
be used:  
Nontarget Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Stable disease   
(Non -CR/non -PD) 
Not all evaluated  No NE 
Unequivocal PD  Yes or No  PD 
Any Yes PD 
Abbreviations: CR, complete response; NE, not evaluable; PD, progressive disease.  
Version .[ADDRESS_731335] 
response designation. T he patient’s best overall response assignment will depend on the findings 
of both target and nontarget disease and will also take into consideration the appearance of new 
lesions. Furthermore, depending on the nature of the trial and the protocol requireme nts, it may 
also require confirmatory measurement. Specifically, in nonrandomized trials where response is 
the primary endpoint, confirmation of PR or CR is needed to deem either one the “best overall 
response.”  
The best overall response is determined once  all the data for the patient is known.  
Best response determination in trials where confirmation of CR or PR IS NOT required : Best 
response in these trials is defined as the best response across all time points (for example, a 
patient who has stable disease  at first assessment, PR at second assessment, and progressive 
disease  on last assessment has a best overall response of PR). When stable disease  is believed to 
be best response, it must also meet the protocol -specified minimum time from baseline. I f the 
minimum time is not met when stable disease  is otherwise the best time point response, the 
patient’s best response depends on the subsequent assessments. For example, a patient who has 
stable disease  at first assessment, progressive disease  at second  and does not meet minimum 
duration for stable disease , will have a best response of progressive disease . The same patient 
lost to follow -up after the first stable disease  assessment would be considered inevaluable . 
Best response determination in trials wh ere confirmation of CR or PR IS required : CR or PR 
may be claimed only if the criteria for each are met at a subsequent time point as specified in the 
protocol (generally 4 weeks later).  
When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” 
size (<  10 mm), they may still have a measurement reported on scans. This measurement should 
be recorded even though the nodes are normal in order not to overstate progression should it be 
based on increase in size of the nodes. As noted earlier, this means that patients with CR may not 
have a total sum of “zero.”  
In trials where confirmation of response is required, repeated "NE" (not evaluable) time point 
assessments may complicate best response determination. The analysis plan for the trial must 
address how missing data/assessments will be addressed in determination of response and 
progression. For example, in most trials it is reasonable to consider a patient with time point 
responses of PR -NE-PR as having a confirmed response.  
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
“symptomatic deterioration”. Every effort should be made to document objectiv e progression 
even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an 
objective response: it is a reason for stoppi[INVESTIGATOR_397699].  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 139 Conditions that define “early progression, early death, and inevaluability” are trial specific and 
should be clearly described in each protocol (depending on treatment duration, treatment 
periodicity).  
In some circumstances , it may be difficult to distinguish residual disease from normal tissue.  
When the evaluation of CR depends upon this d etermination, it is recommended that the residual 
lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy) before assigning a status of CR. FDG -PET 
may be used to upgrade a response to a CR in a manner similar to a biopsy in cases where a 
residual radiographic  abnormality is thought to represent fibrosis or scarring. The use of 
FDG -PET in this circumstance should be prospectively described in the protocol and supported 
by [CONTACT_4623] -specific medical literature for the indication. However, it must be acknowledged t hat 
both approaches may lead to false positive CR due to limitations of FDG -PET and biopsy 
resolution/sensitivity.  
For equivocal findings of progression (eg, very small and uncertain new lesions; cystic changes, 
or necrosis in existing lesions), treatment may continue until the next scheduled assessment. If 
progression is confirmed at the next scheduled assessment, the date of progression should be the 
earlier date when progression was suspected.  
Confirmation of Measurement/Duration of Response  
Confirmation  
In nonrandomized trials where response is the primary endpoint, confirmation of PR and CR is 
required to ensure that responses identified are not the result of measurement error. This will also 
permit appropriate interpretation of results in the context o f historical data where response has 
traditionally required confirmation in such trials. However, in all other circumstances, ie, in 
randomized trials ( Phase 2 or 3) or trials where stable disease or progression are the primary 
endpoints, confirmation of r esponse is not required since it will not add value to the 
interpretation of trial results. However, elimination of the requirement for response confirmation 
may increase the importance of central review to protect against bias, in particular in trials that 
are not blinded.  
In the case of stable disease , measurements must have met the stable disease  criteria at least once 
after trial entry at a minimum interval (in general not less than 6 weeks).  
Duration of Overall Response  
The duration of overall response  is measured from the time the measurement criteria are first met 
for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is 
objectively documented (taking as reference for progressive disease the smallest measure ments 
recorded on study).  
The duration of overall CR is measured from the time the measurement criteria are first met for 
CR until the first date that recurrent disease is objectively documented.  
Duration of Stable Disease  
Stable disease is measured from t he start of the treatment (in randomized trials, from date of 
randomization) until the criteria for progression are met, taking as reference the smallest sum on 
study (if the baseline sum is the smallest, this is the reference for calculation of PD).  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 140 The c linical relevance of the duration of stable disease varies in different studies and diseases. If 
the proportion of patients achieving stable disease for a minimum period of time is an endpoint 
of importance in a particular trial, the protocol should specif y the minimal time interval required 
between 2 measurements for determination of stable disease.  
Note: The duration of response and stable disease as well as the progression -free survival are 
influenced by [CONTACT_150065] -up after baseline evaluati on. It is not in the scope of this 
guideline to define a standard follow -up frequency. The frequency should take into account 
many parameters including disease types and stages, treatment periodicity, and standard practice. 
However, these limitations of th e precision of the measured endpoint should be taken into 
account if comparisons between trials are to be made.  
Version .[ADDRESS_731336] the medical monitor regarding any uncertainty about immune 
deficiency/autoimmune disease exclusions.  
Acute disseminated encephalomyelitis  Addison disease  
Ankylosing spondylitis  Antiphospholipid antibody syndrome  
Aplastic anemia  Autoimmune hemolytic anemia  
Autoimmune hepatitis  Autoimmune hypoparathyroidism  
Autoimmune hypophysitis  Autoimmune myocarditis  
Autoimmune oophoritis  Autoimmune orchitis  
Autoimmune thrombocytopenic purpura  Behcet ’s disease  
Bullous pemphigoid  Chronic inflammatory demyelinating polyneuropathy  
Chung -Strauss syndrome  Crohn disease  
Dermatomyositis  Dysautonomia  
Epi[INVESTIGATOR_556729]’  disease  
Guillain -Barré syndrome  Hashimoto disease  
Immunoglobulin A (IgA) neuropathy  Inflammatory bowel disease  
Interstitial cystitis  Kawasaki disease  
Lambert -Eaton myasthenic syndrome  Lupus erythematosus  
Lyme disease (chronic)  Mooren ulcer  
Morphea  Multiple sclerosis  
Myasthenia gravis  Neuromyotonia  
Opsoclonus myoclonus syndrome  Optic neuritis  
Ord thyroiditis  Pemphigus  
Pernicious anemia  Polyarteritis nodosa  
Polyarthritis  Polyglandular autoimmune syndrome  
Primary biliary cirrhosis  Psoriasis  
Reiter syndrome  Rheumatoid arthritis  
Sarcoidosis  Sjögren syndrome  
Stiff person syndrome  Takayasu arteritis  
Ulcerative colitis  Vogt -Kovangai -Harada disease  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 142 APPENDIX  6. NEW YORK HEART ASSOCIATION FUNCTION AL 
CLASSIFICATION  
Class  Symptoms  
I No limitation of physical activity.  Ordinary physical activity does not cause undue 
fatigue, palpi[INVESTIGATOR_332], dyspnea (shortness of breath).  
II Slight limitation of physical activity.  Comfortable at rest, but ordinary physical activity 
results in fatigue, palpi[INVESTIGATOR_332], dyspnea (shortness of breath).  
III Marked limitation of physical activity.  Comfortable at rest, but less than ordinary 
activity causes fatigue, palpi[INVESTIGATOR_332], or dyspnea.  
IV Unable to c arry on any physical activity without discomfort.  Symptoms of heart failure 
at rest.  If any physical activity is undertaken, discomfort increases.  
Adapted from Dolgin et al 1994 . 
Original source: Criteria Commit tee, [LOCATION_001] Heart Association, Inc. Diseases of the Heart and Blood Vessels. 
Nomenclature and Criteria for diagnosis, 6th edition [LOCATION_011], Little, Brown and Co. 1964, p114.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 143 APPENDIX  7. IMMUNE -MEDIATED  ADVERSE EVENT EVALU ATION 
AND MANAGEMENT  
The recommendations below for the diagnosis and management of any immune -mediated  AEs 
(imAEs) are intended as a guidance.  This document should be used in conjunction with expert 
clinical judgement (by [CONTACT_556831]), and individual institutional guidelines or policies.  
Criteria used to diagnose i mAEs include blood tests, diagnostic imaging, histopathology, and 
microbiology assessments to exclude alternative causes such as infection, disease progression, 
and a dverse effects of concomitant drugs. In addition to the results of these tests, the following 
factors should be considered when making an i mAE diagnosis:  
• What was the temporal relationship between initiation of tislelizumab  or tislelizumab 
plus ociperlimab  and the AE?  
• How did the patient respond to withdrawal of tislelizumab  or tislelizumab plus 
ociperlimab ? 
• Did the event recur when tislelizumab  or tislelizumab plus ociperlimab  was 
reintroduced?  
• Was there a clinical response to corticosteroids?  
• Is the event  an autoimmune endocrinopathy?  
• Is disease progression or an alternative diagnosis a more likely explanation?  
When alternative explanations to autoimmune toxicity have been excluded, the i mAE field 
associated with the AE in the eCRF should be checked. If fu rther diagnostic evaluations change 
the assessment, the eCRF should be updated accordingly.  
Recommended Diagnostic Tests in the Management of  
Possible Immune -related Adverse Events  
Immune -related Toxicity  Diagnostic Evaluation Guideline  
Thyroid Disorders  Scheduled and repeated thyroid function tests (TSH and T4).  
Hypophysitis  Check visual fields and consider pi[INVESTIGATOR_397701].  Perform 
pi[INVESTIGATOR_397702], visual disturbance, 
unexplained fatigue, asthenia, weight loss, and unexplained constitutional 
symptoms.  
Consider consultation with an endocrinologist if an abnormality is detected.  
Pneumonitis  All patients presenting with new or worsened pulmonary symptoms or signs, such 
as an upper respi[INVESTIGATOR_23739], new cough, shortness of breath, or hypoxia 
should be assessed by [CONTACT_5019] -resolution CT.  Consider pulmonary function test 
including DLCO . 
Radiographic appearance is often nonspecific.  Depending on the location of the 
abnormality, bronchoscopy and  bronchoalveolar lavage or lung biopsy may be 
considered. Consult with a respi[INVESTIGATOR_556730].  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 144 Recommended Diagnostic Tests in the Management of  
Possible Immune -related Adverse Events  
Immune -related Toxicity  Diagnostic Evaluation Guideline  
Neurological Toxicity  Perform a comprehensive neurological examination and brain MRI for all CNS 
symptoms; review alcoho l history and other medications. Conduct a diabetic 
screen and assess blood B12/folate, HIV status, TFTs, and consider autoimmune 
serology. Consider the need for brain/spi[INVESTIGATOR_25342]/MRA and nerve conduction study 
for peripheral neuropathy. Consult with a neuro logist if there are abnormal 
findings.  
Colitis  Review dietary intake and exclude steatorrhea. Consider comprehensive testing, 
including the following: FBC, UEC, LFTs, CRP, TFTs, stool microscopy and 
culture, viral PCR, Clostridium difficile  toxin, and cry ptosporidia (drug -resistant 
organism).  
In case of abdominal discomfort, consider imaging, eg, X -ray, CT scan. If a 
patient experiences bleeding, pain, or distension, consider colonoscopy with 
biopsy and surgical intervention as appropriate.  
Eye Disorders  If a patient experiences acute, new onset, or worsening of eye inflammation; 
blurred vision; or other visual disturbances, refer the patient urgently to an 
ophthalmologist for evaluation and management.  
Hepatitis  Check ALT/AST/total bilirubin, INR/albumin; the frequency will depend on 
severity of the AE (eg, daily if Grade  3 to 4; every 2  to 3 days if Grade  2, until 
recovering). Review medications (eg, statins, antibiotics) and alcohol history. 
Perform liver screen  including hepatitis A/B/C serology, hepatitis E PCR and 
assess anti -ANA/SMA/LKM/SLA/LP/LCI, iron studies. Consider imaging (eg, 
ultrasound scan for metastases or thromboembolism). Consult with a hepatologist 
and consider liver biopsy.  
Renal toxicity  Review hydration status and medication history. Test and culture urine. Consider 
renal ultrasound scan, protein assessment (dipstick/24 -hour urine collection), or 
phase -contrast microscopy. Refer to a nephrologist for further management 
assistance.  
Dermat ology  Consider other causes by [CONTACT_14664] a physical examination. Consider 
dermatology referral for skin biopsy.  
Joint or muscle 
inflammation  Conduct musculoskeletal history and perform complete musculoskeletal 
examination. Consider joint X -ray and other imaging as required to exclude 
metastatic disease. Perform autoimmune serology and refer to rheumatology for 
further management assistance.  
For suspected myositis/rhabdomyolysis/myasthenia , include CK, ESR, CRP, 
troponin, and consider a muscle biopsy.  
Myo carditis  Perform ECG, echocardiogram, CK/CK -MB, troponin (I and/or T), and refer to a 
cardiologist.  
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; ANA, antinuclear antibody; AST, aspartate 
aminotransferase; CK, creatine kinase; CK -MB, cr eatine kinase cardiac isoenzyme; CNS, central nervous system; 
CRP, C -reactive protein; CT, computed tomography; DLCO , diffusing capacity for carbon monoxide; ECG, 
electrocardiogram; ESR, erythrocyte sedimentation rate; FBC, full blood count; HIV, human imm unodeficiency 
virus; INR, international normalized ratio; LCI, liver cytosolic antigen; LFT, liver function test; LKM, liver kidney 
microsomal antibody; LP, liver pancreas antigen; MRA, magnetic resonance angiogram; MRI, magnetic resonance 
imaging; PCR, po lymerase chain reaction; SLA, soluble liver antigen; SMA, smooth muscle antibody; T4, 
thyroxine; TFT, thyroid function tests; TSH, thyroid -stimulating hormone; UEC, urea electrolytes and creatinine.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 145 Treatment of Immune -Related Adverse Events  
• Immune -related  AEs can escalate quickly. Study treatment interruption, close 
monitoring, timely diagnostic work -up, and treatment intervention as appropriate is 
required.  
• Immune -related AEs should improve promptly after introduction of 
immunosuppressive therapy. If this  does not occur, review the diagnosis, seek further 
specialist advice, and contact [CONTACT_138830].  
• For some Grade 3 toxicities that resolve quickly, rechallenge with study drug may be 
considered if there is evidence of a clinical response to stu dy treatment, after 
consultation with the study medical monitor.  
• Steroid dosages in the table below are for oral or intravenous (methyl)prednisolone. 
Equivalent dosages of other corticosteroids can be substituted. For steroid -refractory 
imAEs, consider use  of steroid -sparing agents (eg, mycophenolate mofetil [MMF]).  
• Consider prophylactic antibiotics for opportunistic infections if the patient is 
receiving long -term immunosuppressive therapy.  
 
Autoimmune 
Toxicity  Grade  Treatment Guidelines 
(Subject to Clinic al 
Judgement)  Study Drug 
Management  
Thyroid 
Disorders  1-[ADDRESS_731337] thyroxine if 
hypothyroid until TSH/T4 
levels return to normal 
range.  
Thyrotoxic patients should 
be referred to an 
endocrinologist. In cases 
with systemic symptoms: 
withhold study treatment, 
treat with a beta blocker, 
and consider oral 
prednisolone 0.5  mg/kg/day 
for thyroid pain.  
Taper corticosteroids over 
2-4 weeks. Monitor thyroid 
function regarding the need 
for hormone replacement.  Continue study 
treatment or withhold 
treatment in cases with 
systemic symptoms.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 146 Autoimmune 
Toxicity  Grade  Treatment Guidelines 
(Subject to Clinic al 
Judgement)  Study Drug 
Management  
3-[ADDRESS_731338] with 
thyroxine 0.5 -1.6 µg/kg/day 
(for the elderly or those with 
comorbiditie s, the suggested 
starting dose is 
0.5 µg/kg/day). Add oral 
prednisolone 0.5  mg/kg/day 
for thyroid pain.  
Thyrotoxic patients require 
treatment with a beta 
blocker and may require 
carbimazole until thyroiditis 
resolves.  Hold study treatment; 
resume when 
resolved/improved to 
Grade [ADDRESS_731339] for hormone 
replacement.  
Add oral prednisolone 
0.5-1 mg/kg/day for patients 
with pi[INVESTIGATOR_397705].  
Taper corticosteroids over at 
least [ADDRESS_731340] for 
assessment and treatment.  
Initiate pulse intravenous 
methylprednisolone 
1 mg/kg for patients with 
headache/visual disturbance 
due to pi[INVESTIGATOR_508969]. Convert to 
oral prednisolone and taper 
over at least [ADDRESS_731341]’s advice.  Hold study treatment 
for patients with 
headache/visua l 
disturbance due to 
pi[INVESTIGATOR_397706]/improved 
to ≤ Grade  2. 
Discontinuation is 
usually not necessary.  
Pneumonitis  1 
Radiographic changes only  Monitor symptoms every 2 -
3 days.  
If appearance worsens, treat 
as Grade 2.  Consider holding study 
treatment until 
appearance improves 
and cause is 
determined.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 147 Autoimmune 
Toxicity  Grade  Treatment Guidelines 
(Subject to Clinic al 
Judgement)  Study Drug 
Management  
2 
Symptomatic: exertional 
breathlessness  Commence antibiotics if 
infection suspected. Add 
oral prednisolone 
1 mg/kg/day if 
symptoms/appearance 
persist for [ADDRESS_731342] 6  weeks.  
Consider prophylaxis for 
adverse steroid effects: eg, 
blood glucose monitoring, 
vitamin D/calcium 
supplement.  Hold study treatment.  
Retreatment is 
acceptable if symptoms 
resolve completely or 
are controlled on 
prednisolone 
≤ 10 mg/day. 
Discontinue study 
treatment if symptoms 
persist with 
corticosteroid 
treatment.  
3-4 
Severe or life -threatening 
symptoms: breathless at rest  Admit to a hospi[INVESTIGATOR_556731] 
2-4 mg/kg/day. If there is no 
improvement, or worsening 
after 48  hours, add 
infliximab 5  mg/kg (if no 
hepatic involvement).  
Convert to oral prednisolone 
and taper over at least 
2 months.  
Cover with empi[INVESTIGATOR_556732], eg, blood glucose 
monitoring, vitamin 
D/calcium supplement.  Discontinue study 
treatment.  
Neurological 
Toxicity  1 
Mild symptoms  – Continue study 
treatment.  
2 
Moderate symptoms  Treat with oral prednisolone 
0.5-1 mg/kg/day.  Taper 
over at least 4  weeks.  
Obtain neurology 
consultation.  Hold study treatment; 
resume when 
resolved/improved to 
Grade 0 -1. 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 148 Autoimmune 
Toxicity  Grade  Treatment Guidelines 
(Subject to Clinic al 
Judgement)  Study Drug 
Management  
3-4 
Severe/life -threatening symptoms  Initiate treatment with oral 
prednisolone or intravenous 
methylprednisolone 
1-2 mg/kg/day, depending 
on symptoms. Taper 
corticosteroids over at least 
4 weeks.  
Consider azathioprine, 
MMF, cyclosporine if no 
response within 
72-96 hours.  Discontinue study 
treatment.  
Colitis/Diarrhea  1 
Mild symptoms: ≤  3 liquid stools 
per day over baseline and feeling 
well Symptomatic management: 
fluids, loperamide, avoid 
high fiber/lactose diet.  
If Grade 1 persists 
for >  14 days, manage as a 
Grade 2 event.  Continue study 
treatment.  
2 
Moderate symptoms:  4-6 liquid 
stools per day over baseline, or 
abdominal pain, or blood in stool, 
or nausea, or nocturnal epi[INVESTIGATOR_397709] 
0.5 mg/kg/day (nonenteric 
coated).  
Do not wait for any 
diagnostic tests to start 
treatment. Taper steroids 
over 2 -4 weeks.  
Consider endoscopy if 
symptoms are recurring.  Hold study treatment; 
resume when 
resolved/improved to 
baseline grade.  
3 
Severe symptoms: >  6 liquid stools 
per day over baseline, or if 
epi[INVESTIGATOR_556733] 1  hour of eating  Initiate intravenous 
methylprednisolone 
1-2 mg/kg/day.  
Convert to oral prednisolone 
and taper over at least 
4 weeks. Consider 
prophylaxis for adverse 
steroid effects, eg, blood 
glucose monitoring, vitamin 
D/calcium supplement.  
If no improvement in 
72 hours or symptoms 
worsen, consider infliximab  
5 mg/kg if no perforation, 
sepsis, TB, hepatitis, NYHA 
Class III/IV CHF or other 
immunosuppressive 
treatment: MMF or 
tacrolimus.  
Consult gastroenterologist 
to conduct colonoscopy/ 
sigmoidoscopy.  Hold study treatment; 
retreatment may be 
considered when 
resolved/improved to 
baseline grade and after 
discussion with the 
study medical monitor.  
 
4 
Life-threatening symptoms  Discontinue study 
treatment.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 149 Autoimmune 
Toxicity  Grade  Treatment Guidelines 
(Subject to Clinic al 
Judgement)  Study Drug 
Management  
Skin reactions  1 
Skin rash, with or without 
symptoms, <  10% BSA  Avoid skin irritants and sun 
exposure; topi[INVESTIGATOR_397711].  Continue study 
treatment.  
2 
Rash covers 10% -30% of BSA  Avoid skin irritants and sun 
exposure; topi[INVESTIGATOR_397711].  
Topi[INVESTIGATOR_8826] ( moderate -
strength cream once a day 
or potent cream twice a day) 
± oral or topi[INVESTIGATOR_397712].  
Consider a short course of 
oral steroids.  Continue study 
treatment.  
3 
Rash covers >  30% BSA or Grade 
2 with substantial symptoms  Avoid skin irritants and sun 
exposure; topi[INVESTIGATOR_397711].  
Initiate steroids as  follows 
based on clinical judgement:  
For moderate symptoms: 
oral prednisolone 
0.5-1 mg/kg/day for 
3 days then taper over 
2-4 weeks.  
For severe symptoms: 
intravenous 
methylprednisolone 0.5 -
1 mg/kg/day; convert to 
oral prednisolone and 
taper over at least 
4 weeks.  Hold study treatment.  
Re-treat when AE is 
resolved or improved to 
mild rash (Grade 1 -2) 
after discussion with 
the study medical 
monitor.  
 
4 
Skin sloughing >  30% BSA with 
associated symptoms (eg, 
erythema, purpura, epi[INVESTIGATOR_499909]),  Initiate  intravenous 
methylprednisolone 
1-2 mg/kg/day. Convert to 
oral prednisolone and taper 
over at least [ADDRESS_731343] >  ULN to [ADDRESS_731344]  Check LFTs with in 1 week 
and before the next dose; 
check LFTs to verify that 
there has been no 
worsening.  
If LFTs are worsening, 
recheck every 48 -72 hours 
until improvement is seen.  Continue study 
treatment if LFTs are 
unchanged or 
improving.  
Hold study treatment if 
LFTs  are worsening 
until improvement is 
seen.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 150 Autoimmune 
Toxicity  Grade  Treatment Guidelines 
(Subject to Clinic al 
Judgement)  Study Drug 
Management  
[ADDRESS_731345]  Recheck LFTs every 48 -
72 hours.  
For persistent ALT/AST 
elevation: consider oral 
prednisolone 
0.5-1 mg/kg/day for 3  days, 
then taper over 2 -4 weeks.  
For rising ALT/AST: start 
oral prednisolone 
1 mg/kg/day and taper over 
2-4 weeks; re -escalate dose 
if LFTs worsen, depending 
on clinical judgement.  Hold study treatment; 
treatment may be 
resumed when 
resolved/improved to 
baseline grade and 
prednisolone tapered to 
≤ [ADDRESS_731346]  ALT/AST <  400 IU/L and 
normal 
bilirubin/INR/albumin: 
Initiate oral prednisolone 
1 mg/kg and taper over at 
least 4  weeks.  
ALT/AST >  400 IU/L or 
raised bilirubin/INR/low 
albumin: Initiate 
intravenous 
(methyl)prednisolone 
2 mg/kg/day.  
When LFTs im prove to 
Grade  [ADDRESS_731347] 4  weeks.  Hold study treatment 
until improved to 
baseline grade; 
reintroduce only after 
discussion with the 
study medical monitor.  
 
[ADDRESS_731348] >  [ADDRESS_731349]  Initiate intravenou s 
methylprednisolone 
2 mg/kg/day. Convert to 
oral prednisolone and taper 
over at least 6  weeks.  Discontinue study 
treatment.  
Worsening LFTs despi[INVESTIGATOR_397713]:  
• If on oral prednisolone, change to pulsed intravenous methylprednisolone.  
• If on intravenous methylprednisolone, add mycophenolate mofetil (MMF) 
500 to 1000  mg twice a day.  
• If worsen ing on MMF, consider addition of tacrolimus.  
Duration and dose of steroid required will depend on severity of event.  
Nephritis  1 
Creatinine 1.5  x baseline  
or > ULN to  1.[ADDRESS_731350]  Repeat creatinine weekly.  
If symptoms worsen, 
manage as per criteria 
below.  Continue study 
treatment.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 151 Autoimmune 
Toxicity  Grade  Treatment Guidelines 
(Subject to Clinic al 
Judgement)  Study Drug 
Management  
2 
Creatinine >  1.5-3 x baseline 
or > 1.5-[ADDRESS_731351]  Ensure hydration and 
review creatinine in 
48-72 hours; if not 
improving, consider 
creatinine  clearance 
measurement by [ADDRESS_731352] 
the need for kidney biopsy.  
If attributed to study drug, 
initiate oral prednisolone 
0.5-1 mg/kg and taper over 
at least 2  weeks.  
Repeat creatinine/U&E 
every 48 -72 hours.  Hold stu dy treatment.  
If not attributed to drug 
toxicity, restart 
treatment.  
If attributed to study 
drug and 
resolved/improved to 
baseline grade: Restart 
study drug if tapered to 
< 10 mg prednisolone.  
3 
Creatinine >  3 x baseline 
or > 3-[ADDRESS_731353]  Hospi[INVESTIGATOR_556734]; repeat creatinine 
every 24  hours; refer to a 
nephrologist and discuss 
need for biopsy.  
If worsening, initiate 
intravenous 
(methyl)prednisolone 
1-2 mg/kg. Taper 
corticosteroids over at least 
4 weeks.  Hold study trea tment 
until the cause is 
investigated.  
If study drug suspected: 
Discontinue study 
treatment.  
 
4 
Creatinine >  [ADDRESS_731354]  As per Grade  3, patient 
should be managed in a 
hospi[INVESTIGATOR_556735].  Discontinue study 
treatment.  
Diabetes/  
Hyperglycemia  [ADDRESS_731355] to 
160 mg/dL; ULN to 8.9  mmol/L  Monitor closely and treat 
according to local guideline. 
Check for C -peptide and 
antibodies against glutamic 
acid decarboxylase and islet 
cells are recommended.  Continue study 
treatment.  
2 
Fasting glucose value 
160-250 mg/dL; 8.9 -13.9 mmol/L  Obtain a repeat blood 
glucose level at least every 
week. Manage according to 
local guideline.  Continue study 
treatment or hold 
treatment if 
hyperglycemia is 
worsening.  Resume 
treatm ent when blood 
glucose is stabilized at 
baseline or Grade  0-1. 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 152 Autoimmune 
Toxicity  Grade  Treatment Guidelines 
(Subject to Clinic al 
Judgement)  Study Drug 
Management  
3 
Fasting glucose value 
250-500 mg/dL; 13.9 -27.8 mmol/L  Admit patient to hospi[INVESTIGATOR_556736] a diabetologist 
for hyperglycemia 
management. 
Corticosteroids may 
exacerbate hyperglycemia 
and should be avoided.  Hold study treatment 
until patient is 
hyperglycemia 
symptom -free, and 
blood glucose has been 
stabilized at baseline or 
Grade  0-1. 
 
4 
Fasting glucose 
value >  500 mg/dL; >  27.8 mmol/L  Admit patient to hospi[INVESTIGATOR_556737].  
Refer the patient to a 
diabetologist for insulin 
maintenance and 
monitoring.  Hold study treatment 
until patient is 
hyperglycemia 
symptom -free, and 
blood glucose has been 
stabilized at baseline or 
Grade  0-1. 
 
Ocular Toxicity  1 
Asymptomatic eye 
examination/test abnormality  Consider alternative causes 
and prescribe topi[INVESTIGATOR_556738].  Continue study 
treatment.  
[ADDRESS_731356] for 
assessment and topi[INVESTIGATOR_397720].  
Consider a course of oral 
steroids.  Continue study 
treatment or hold 
treatment if symptoms 
worsen or if there are 
symptoms of visual 
disturbance.  
3 
Posterior uveitis/panuveitis or 
significant symptoms  Refer patient urgently to an 
ophthalmologist.  Initiate 
oral prednisolone 1 -2 mg/kg 
and taper over at least 
4 weeks.  Hold study treatment 
until improved to 
Grade  0-1; reintroduce 
only after discussion 
with the study medical 
monitor.  
 
4 
Blindness (at least 20/200) in the 
affected eyes Initiate intravenous 
(methyl)prednisolone 
2 mg/kg/day. Convert to 
oral prednisolone and taper 
over at least [ADDRESS_731357] 
abnormalities  Monitor pancreatic 
enzymes.  Continue study 
treatment.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 153 Autoimmune 
Toxicity  Grade  Treatment Guidelines 
(Subject to Clinic al 
Judgement)  Study Drug 
Management  
3 
Abdominal pain, nausea and 
vomiting  Admit to hospi[INVESTIGATOR_397721].  Initiate 
intravenous 
(methyl)prednisolone 
1-2 mg/kg/day. Convert to 
oral prednisolone when 
amylase/lipase improved to 
Grade  [ADDRESS_731358] 4  weeks.  Hold  study treatment; 
reintroduce only after 
discussion with the 
study medical monitor.  
 
4 
Acute abdominal pain, surgical 
emergency  Admit to hospi[INVESTIGATOR_556739].  Discontinue study 
treatment.  
Arthritis  1 
Mild pain with inflammation, 
swelling  Management per local 
guideline.  Continue study 
treatment.  
2 
Moderate pain with inflammation, 
swelling, limited instrumental (fine 
motor) activities  Management as per local 
guideline.  Consider 
referring patient to a 
rheumatologist.  
If symptoms worsen on 
treatment, manage as a 
Grade  [ADDRESS_731359] for 
assessment and 
management.  
Initiate oral prednisolone 
0.5-1 mg/kg and taper over 
at least 4  weeks.  Hold study treatment 
unless improved to 
Grade  0-1; reintroduce 
only after discussion 
with the study medical 
monitor.  
 
Mucositis/  
stomatitis  [ADDRESS_731360] findings only or minimal 
symptoms  Consider topi[INVESTIGATOR_556740].  Continue study 
treatment.  
2 
Moderate pain, reduced oral 
intake, limited instrumental 
activities  As per local guidelines, treat 
with analgesics, topi[INVESTIGATOR_73211], and oral hygiene 
care.  
Ensure adequate hydration.  
If symptoms worsen or 
there is sepsis or bleeding, 
manage as a Grade  3 event.  Continue study 
treatment.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 154 Autoimmune 
Toxicity  Grade  Treatment Guidelines 
(Subject to Clinic al 
Judgement)  Study Drug 
Management  
3 
Severe pain, limited food and fluid 
intake, daily living activity limited  Admit to hospi[INVESTIGATOR_508983].  
Initiate intravenous 
(methyl)prednisolone 
1-2 mg/kg/day.  
Convert to oral prednisolone 
when symptoms improve to 
Grade  [ADDRESS_731361] 4  week s. Hold study treatment 
until improved to 
Grade  0-1. 
 
4 
Life-threatening complications or 
dehydration  Admit to hospi[INVESTIGATOR_508984]. Consider 
intravenous corticosteroids 
if not contraindicated by 
[CONTACT_80601].  Discontinue study 
treatment.  
Myositis/  
Rhabdomyolysis  1 
Mild weakness with/without pain  Prescribe analgesics.  
If CK is significantly 
elevated and patient has 
symptoms, consider oral 
steroids and treat as 
Grade  2. Continue study 
treatment.  
2 
Moderate weakness with/without 
pain If CK is [ADDRESS_731362]  or worse, 
initiate oral prednisolone 
0.5-1 mg/kg and taper over 
at least 4  weeks.  Hold study treatment 
until improved to 
Grade  0-1. 
3-4 
Severe weakness, limiting self -care Admit to hospi[INVESTIGATOR_556741] 
1 mg/kg. Consider bolus 
intravenous 
(methyl)prednisolone and 1 -
2 mg/kg/day maintenance 
for severe activity 
restriction or dysphagia.  
If symptoms do not 
improve, add 
immunosuppressant 
therapy.  
Taper oral steroids over at 
least 4  weeks.  For Grade  3: Hold 
study treatment until 
impro ved to Grade  0-1. 
Discontinue upon any 
evidence of myocardial 
involvement.  
 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 155 Autoimmune 
Toxicity  Grade  Treatment Guidelines 
(Subject to Clinic al 
Judgement)  Study Drug 
Management  
Myocarditis  a < 2 
Asymptomatic but significantly 
increased CK -MB or increased 
troponin OR clinically significant 
intraventricular conduction delay  Initiate cardiac evaluation 
under close monitoring with 
repeat serum testing and 
including ECG, cardiac 
echo/MUGA, and/or other 
interventions per 
institutional guidelines; 
consider referral to a 
cardiologist.  
If diagnosis of myocarditis 
is confirmed, treat as 
Grade  2. Hold study trea tment.  
If a diagnosis of 
myocarditis is 
confirmed and 
considered immune  
related, permanently 
discontinue study 
treatment in patients 
with moderate or severe 
symptoms.  
Patients with no 
symptoms or mild 
symptoms may not 
restart tislelizumab 
unless cardiac 
parameters have 
returned to baseline and 
after discussion with 
the study medical 
monitor.  2 
Symptoms on mild -moderate 
exertion  Admit to hospi[INVESTIGATOR_556742] 
(methyl)prednisolone at 
1-2 mg/kg/day. Consult 
with a cardiologist and 
manage symptoms of 
cardiac failure according to 
local guidelines.  
If no immediate response, 
change to pulsed doses of 
(methyl)prednisolone 
1 g/day and add MMF, 
infliximab, or antithymocyte 
globulin.  [ADDRESS_731363] 
returned to baseline and 
after discussion with 
the study medical 
monitor.  
 4 
Life-threatening  
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSA, body 
surface area; CHF, congestive heart failure; CK, creatine kinase; CK -MB, creatine kinase cardiac isoenzyme; ECG, 
electrocardiogram; INR, internation al normalized ratio; LFT, liver function test; MMF, mycophenolate mofetil; 
MUGA, multigated acquisition scan;  NYHA, [LOCATION_001] Heart Association; T4, thyroxine; TB, tuberculosis; TFT, 
thyroid function test; TSH, thyroid -stimulating hormone; U&E, urea and ele ctrolytes; ULN, upper limit of normal.  
a If clinically significant cardiac enzyme abnormalities are detected during laboratory assessment and serial cardiac 
enzyme assessments pose logistical hardship for the patient, then patient hospi[INVESTIGATOR_556743] -related myocarditis has been ruled out.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 156 APPENDIX  8. CHRONIC KIDNEY DISEA SE EPI[INVESTIGATOR_397664] (CKD -EPI) EQUATION  
In adults, the most widely -used equations for estimating glomerular filtration rate (GFR) from 
serum creatinine are the Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD -EPI) 
equation ( Levey et al 2009 ) and the Modification of Diet in Renal Disease (MDRD) Study 
equation. The National Kidney Disease Education Program (NKDEP)  calculators rely on 
creatinine determinations , which are isotope dilution mass spectrometry (IDMS) traceable. All 
laboratories should be using creatinine methods calibrated to be IDMS traceable.  
This CKD -EPI [INVESTIGATOR_556744] (S cr) is reported in 
mg/dL. This equation is recommended when eGFR values above 60 mL/min/1.73 m2 are desired.  
GFR = 141 x min (S cr /κ, 1)α x max(S cr /κ, 1)-1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black]  
where:  
Scr is serum creatinine i n mg/dL,  
κ is 0.7 for females and 0.9 for males,  
α is -0.329 for females and -0.411 for males,  
min indicates the minimum of S cr /κ or 1, and  
max indicates the maximum of S cr /κ or 1.  
The equation does not require weight because the results are reported nor malized to 1.73 m2 
body surface area, which is an accepted average adult surface area.  
The online calculator for CKD -EPI [INVESTIGATOR_397730]:  
https://www.niddk.nih.gov/health -information/communication -programs/nkdep/laboratory -
evaluation/glomerular -filtratio n-rate-calculators  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 157 APPENDIX  9. CONTRACEPTION GUIDEL INES AND DEFINITIONS  OF 
“WOMEN OF CHILDBEARI NG POTENTIAL,” “NO 
CHILDBEARING POTENTI AL”  
Contraception Guidelines  
The Clinical Trials Facilitation Group recommendations related to contraception and pregnancy 
testing in clinical trials include the use of highly effective forms of birth control ( Clinical Trials 
Facilitation Group 2014 ). These methods include the following:  
• Combined (estrogen - and progestogen -containing) ho rmonal contraception associated 
with the inhibition of ovulation  
− Oral, intravaginal, or transdermal  
• Progestogen -only hormonal contraception associated with the inhibition of ovulation  
− Oral, injectable, implantable  
Note: Oral birth control pi[INVESTIGATOR_556745] a highly effective form of birth 
control, and if they are selected, they must be used with a second, barrier method 
of contraception such as condoms with or without spermicide.  
• An intrauterine device  
• Intrau terine hormone -releasing system  
• Bilateral tubal occlusion  
• Vasectomized partner  
Note: This is only considered a highly effective form of birth control when the 
vasectomized partner is the sole partner of the study participant and there has been a 
medical as sessment confirming surgical success.  
− A sterile male is one for whom azoospermia in a  semen sample has been 
demonstrated as definitive evidence of infertility.  
• Sexual abstinence (defined as refraining from heterosexual intercourse during the 
entire period of risk associated with the study treatment)  
Note: Total sexual abstinence should only be used as a contraceptive method if it is in 
line with the patients’ usual and preferred lifestyle. Periodic abstinence (eg, calendar, 
ovulation, symptothermal, postovu lation methods), declaration of abstinence for the 
duration of exposure to study drug, and withdrawal are not acceptable methods of 
contraception.  
Of note, barrier contraception (including male and female condoms with or without spermicide) 
is not considered a highly effective method of contraception, and if used, this method must be 
used in combination with one of the highly effective forms of birth control listed above.  
Definitions of “Women of Childbearing Potential,” “Women of No Childbearing Po tential”  
As defined in this protocol, “women of childbearing potential” are female patients who are 
physiologically capable of becoming pregnant.  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 158 Conversely, “women of no childbearing potential” are defined as female patients meeting any of 
the following c riteria:  
• Surgically sterile (ie, through bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy, or 
hysterectomy)  
• Postmenopausal, defined as:  
− ≥ 55 years of age with no spontaneous menses for ≥ 12 months OR  
− < 55 years of age with no spontaneous menses for ≥ 12 mon ths AND with 
postmenopausal follicle -stimulating hormone (FSH) concentration > 30 IU/mL  
and all alternative medical causes for the lack of spontaneous menses for ≥ [ADDRESS_731364] been ruled out, such as polycystic ovarian syndrome, 
hyperprolactinemia, etc.  
If an FSH measurement is required to confirm postmenopausal state, concomitant use of 
hormonal contraception or hormonal replacement therapy should be excluded.  
Adapted from Clinical Trials Facilitation G roup (CTFG) 2014 . 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 159 APPENDIX  10. EUROPEAN ORGANISATIO N FOR RESEARCH AND 
TREATMENT OF CANCER QUALITY OF LIFE CANC ER 
QUESTIONNAIRE (EORTC -QLQ -C30) 
 
 
 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 160  
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 161 APPENDIX  11. EUROPEAN ORGANISATIO N FOR RESEARCH AND 
TREATMENT OF CANCER QUALITY OF LIFE 
QUESTIONNAIRE LUNG C ANCER (QLQ -LC13 ) 
 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 162 APPENDIX  12. COCKROFT -GAULT FORMULA AND C ALVERT 
FORMULA  
CALVERT FORMULA:  
 
a Age in years and weight in kilograms.  
b Recommend using ideal body weight if the patient is obese (>  30% over ideal body weight) in calculation of 
estimated CL Cr. Calculating by [CONTACT_556832].  
(GFR * + 25) x AUC  = dose (in mg ). 
*GFR calculation formula is same as ClCr formula as shown above.  
 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 163 APPENDIX  13. DOSE MODIFICATION OF  CHEMOTHERAPY  
Dose Reduction Level of Etoposide, Cisplatin and Carboplatin  
Dose Lever  Etoposide  (mg/m2)a Cisplatin  (mg/m2)a Carboplatin  (mg/m2)a 
Full Dose  100 mg/m2, on Days 1, 2, 
and 3 of each cycle for 4 
cycles  75 mg/m2, on Day 1  of 
each cycle for 4 cycles   
If the patient is unable to 
tolerate the 1-day 
administration of cisplatin 
75 mg/m2, at the 
investigator’s discretion , 
cisplatin 25  mg/m2 dosed 
on Days 1, [ADDRESS_731365] Dose 
Reduction  
(-1 dose level)  75% of initial starting 
dose 75% of initial starting 
dose 75% of initial starting 
dose 
Second Dose 
Reduction b 
(-2 dose level)  50% of initial starting 
dose 50% of initial starting 
dose NA c 
Abbreviations: AUC, area under the plasma or serum concentration -time curve; NA, not applicable.  
a Dose reductions may or may not be concomitant, refer to the tables below.  
b Including the second appearance of the toxicity needs 1 dose reduction. A maximum of 2 dose level reductions are 
allowed.  
c Only 1 dose reduction is permitted for carboplatin.  
 
In patients with impaired renal function, the following initial dose modification should be 
considered based on measured creatinine clearance:  
Measured Creatinine Clearance  >50 mL/min  15 to 50 mL/min  
Etoposide  100% of dose  75% of dose  
Subsequent etoposide dosing should be based on patient tolerance and clinical effect. The 
minimum dose of etoposide should be 50% of dose.  
 
Recommended Dose Modifications for Hematologic Toxicity  
Dose adjustments are based on nadir blood counts since the preceding chemotherapy 
administration. Dose level adjustments are relative to those of the preceding administration. 
Recommended dose modifications for hematologic toxicity are provided in the foll owing table .  
 
 
 
 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 164 Chemotherapy Dose Modification for Hematolog ical Toxicity  a 
Adverse event  Treatment  
Febrile neutropenia; documented 
infection  1) The first epi[INVESTIGATOR_556746] 1 dose level 
reduction in the dose of both drugs.  
2) If there is a second epi[INVESTIGATOR_556747], the patient 
must receive prophylactic antibioti cs during the subsequent 
cycle.  
3) If there is a third epi[INVESTIGATOR_1865], the chemotherapy will be 
discontinued.  
Neutropenia  Grade 3 
(0.5-1.0 x 109/L) Chemotherapy delay until ≤ Grade 1  (≥ 1.5 x 109/L); restart with 
the full dose  
Grade 4  
(< 0.5  x 109/L) Chemotherapy delay until recovered to ≤ Grade 1; 1 dose 
reduction of all further doses  
Thrombo -
cytopenia  Grade 1  Chemotherapy delay until recovered to normal; restart with the 
full dose  
Grade 2 or Grade 3 
without bleeding  Chemotherapy delay until recovered to normal; 1 dose reduction 
of all further doses  
Grade 4  Chemotherapy delay until recovered to normal; 2 dose reduction 
of all further doses (the lowest dose level)  
Grade 3 or 4 
associated  
with clinically  
significant bleeding  Discontinue chemotherapy  
Recurrence of Grade 3 or 4 after 2 
dose reductions (with either 
neutropenia or thrombo  cytopenia)  Discontinue chemotherapy  
a If considered in the best interest of the patient and consistent with local practice, investigators may decide to use 
supportive measures/treatment and/or secondary prophylaxis instead of dose reductions for the next cycle. The 
provided triggers for dose m odifications are recommendations only.  
 
Version .[ADDRESS_731366] grade toxicity.  
In general, for ≥ Grade 3 nonhematologic toxicities, chemotherapy should be delayed until 
resolution to less than or equal to the patient ’s baseline value before resuming treatment at a 
reduced dose. However, exceptions may be made for Grade 3 neurotoxicity or esophagitis. In the 
case of neurotoxicity, the investigator and patient  may decide to continue treatment at a reduced 
dose, with no delay required, as neurotoxicity may not res olve to baseline values. Adjustments 
for esophagitis are recommended to follow dose modifications as described in the table below.  
Chemotherapy  Dose Modifications a for Nonhematologic Toxicities  
Toxicity  Grade  Treatment  
Renal toxicity  ≥ Grade 1  Delay chemotherapy until recovered to Grade 0 or baseline, change cisplatin 
to carboplatin, if possible; 1 dose reduction for other drug; if recur, 
discontinue chemotherapy.  
Etoposide dosage should be reduced one dose leve l in patients with a 
creatinine clearance from 15 to 50 mL/min.  
Ototoxicity  Grade 2  1 Reduction of all further doses of cisplatin  
Grade 3 -4 Delay chemotherapy until recovered to ≤ Grade 2, change cisplatin to 
carboplatin  
Sensory 
neuropathy b, c Grade 2 1 Reduction for all further doses of cisplatin  
For carboplatin + paclitaxel regimen, delay paclitaxel  until ≤ Grade 1 while 
continuing carboplatin  
Grade 3  Discontinue cisplatin, change cisplatin to carboplatin; 1 dose reduction for 
etoposide  
For carboplatin + paclitaxel regimen, discontinue paclitaxel while continuing 
carboplatin  
Grade 4  Discontinue cisplatin, carboplatin, paclitaxel, and etoposide  
Hepatic toxicity  
(transaminase 
elevation)  Grade 3 or 4  1 dose reduction for cisplatin and etoposide  
Diarrhea  Grade 4  Discontinue chemotherapy  
Oral mucositis 
or stomatitis  ≥ Grade 3   Reduction for further doses of etoposide  
Discontinue chemotherapy for Grade 4  
Esophagitis d, e ≥ Grade 3  Hold chemotherapy until ≤ Grade 2  
Delay chemotherapy at the discretion of investigator for Grade 3; delay 
chemotherapy for Grade 4  
Other organ 
toxicity  Grade 2  Delay chemotherapy until ≤ Grade 1 or baseline f 
Grade 3 -4 Delay chemotherapy until recovered to ≤ Grade 1 or baseline  e; [ADDRESS_731367] of the patient and consistent with local practice, investigators may decide to use 
supportive measures/treatment and/or secondary prophylaxis instead of dose reductions for the next cycle. The 
provided triggers for dose modifications are recommendations only.  
b Delay until resolution of toxicity to baseline value is not required for Grade [ADDRESS_731368] the end of radiation therapy. For patients 
who experience this  event earlier than anticipated in the course of their treatment, the advice would be to hold 
chemotherapy and assess at weekly intervals. If symptoms do not progress at the time of assessment, chemotherapy 
can be resumed; chemotherapy can be resumed at 80 % of previous dose for both drugs.  
e Grade 4 esophagitis results in holding chemotherapy until toxicity resolves to ≤ Grade 2, and then chemotherapy 
may be resumed; chemotherapy can be resumed at 80% of previous dose for both drugs.  
f Skin reactions, paron ychia, alopecia, fatigue, nausea/vomiting, which may have resolved to Grade 2 or baseline . 
Version .0 VV-CLIN-048167 9
AdvanTIG -204 BeiGene  
Protocol Amendment Version 3.0 08 October 2021  
 
CONFIDENTIAL  Page 167 APPENDIX  14. MANAGEMENT OF RADIAT ION ESOPHAGITIS  
CTCAE Scale: Acute Esophagitis Related to Radiation  
Grade  Clinical state 
1 Asymptomatic; clinical or diagnostic observations only; intervention not indicated  
2 Symptomatic; altered eating/swallowing; oral supplements indicated  
3 Severely altered eating/swallowing; tube feeding, TPN, or hospi[INVESTIGATOR_374]  
4 Life-threatening consequences; urgent operative intervention in dicated  
5 Death  
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; TPN, total parenteral nutrition.  
Dietary and Nutritional Support Recommendations for Acute Radiation Esophagitis  
Supportive measure  Recommendation  
Dietary modification  • Consider dietician referral  
• Avoid potentially irritant foods (tobacco, alcohol, coffee, and 
spi[INVESTIGATOR_84716])  
• Soft, bland diet  
• Small, frequent meals  
Nutritional support  • Liquid meal replacements/supplements  
• Intravenous hydration  
• Electrolyte correction  
• For prolonged symptoms, enteral feeding or total parenteral 
nutrition may be required, although former is preferred  
• Antiemetics may be beneficial  
Modified from Baker and Fairchild 2016  
Recommendations for Medication Management of Radiation Esophagitis  
Treatment 
option  Management of esophagitis  
1 Ketoconazole 200 mg PO QD  
2 Fluconazole 100 mg PO QD until the completion of radiation  
3 Mixture of viscous lidocaine 60 mL + Mylanta (or generic equivalent  
antacid) 30 mL + sucralfate (1 gm/mL) 10 mL. Take 15 to 30 mL PO q3 to 4 h PRN  
4 Ranitidine 150 mg PO BID (or other histamine -2 [H2] receptor blocker or a proton -
pump inhibitor such as omeprazole) until completion of radiation  
5 Grade 4 esophagitis: hold CRT until Grad e 2 or less  
Abbreviations: BID, twice daily; CRT, chemoradiotherapy; h, hour; PO, oral; PRN, when necessary; q, every; QD, 
once daily.  
Version .0 VV-CLIN-048167 9